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Glioblastoma Multiforme (GBM) é o tipo de glioma mais prevalente, possuindo a taxa de 
incidência de tumores malignos do cérebro e Sistema Nervoso Central mais elevada e a 
taxa de sobrevida mais baixa. Tumores de GBM distinguem-se de tumores gliais de 
menor grau pela presença de certas características histológicas únicas tal como a 
presença de necrose central na massa tumoral, proliferação marginal de células 
endoteliais e a presença de células em pseudo-paliçada a circundar a área necrótica. 
Várias características únicas contribuem para a fraca resposta que tumores de GBM têm 
a tratamento incluindo a sua elevada heterogeneidade inter- e intratumoral a nível 
fenotípico, celular, genético e epigenético. Mais importante, a existência de populações 
de células estaminais cancerígenas (CSCs) dentro de tumores de GBM é crucial para 
impulsionar o crescimento invasivo do tumor devido ao seu potencial para proliferar 
em condições vasculares, tornando-se altamente invasivas em condições hipóxicas. 
Além disso, a capacidade de CSCs de GBM de infiltrarem o parênquima cerebral 
circundante significa que mesmo o menor número de tais células que escapem á cirurgia 
irão provocar a recorrência do tumor.  
Invasão a partir do tumor primário para o tecido circundante é uma característica 
importante não de GBM mas também de carcinomas. No caso de carcinomas, o primeiro 
passo para invasão e metastização é a Transição Epitelial-Mesenquimal (EMT), um 
programa genético complexo associado a perda de polaridade celular, extensa 
remodelação da matriz extracelular e a aquisição de um comportamento migratório. 
ZEB1 é um factor de transcrição dedo de zinco conhecido por desencadear a EMT 
através da sua capacidade para reprimir a transcrição de vários gene epiteliais, tais 
como a Caderina-E. Embora a EMT não tinha sido vista como um processo relevante no 
GBM, há cada vez mais provas de que a transição das CSCs de GBM de um fenótipo 
proliferativo em condições vasculares para um fenótipo invasivo no nicho hipóxico 
hipóxicos partilha muitas semelhanças com a EMT. 
ZEB1 emergiu como um regulador crucial de invasão, resistência a quimioterapia e 
tumorigénese em GBM. ZEB1 é altamente expresso tanto em zonas proliferativas 
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hipercelulares e zonas menos celulares da periferia do tumor. A sua expressão 
correlaciona-se com o grau do tumor e invasividade. Apesar da sua expressão 
generalizada em GBM e do papel que desempenha, pouco se sabe sobre a base molecular 
para as suas funções celulares durante cancro e desenvolvimento, incluindo a 
identidade dos seus genes-alvo. Na primeira parte desta tese (Capítulo 2), realizámos a 
primeira caracterização do programa transcricional do ZEB1 á escala genómica num 
contexto maligno, em CSCs de GBM. Surpreendentemente, descobrimos que a ligação de 
ZEB1 ao DNA está associada tanto com activação como com repressão da transcrição de 
genes á escala genómica. A activação de genes ocorre através de um mecanismo de 
recrutamento indirecto, não descrito anteriormente, através de LEF1 para regiões 
reguladoras de genes alvo. O fator de troca de nucleótidos de guanina Prex1 está incluído 
nos genes activados por ZEB1. Estudos de correlação em dados do transcriptoma de um 
grande número de amostras de tumores suportam ainda mais Prex1 como um alvo de 
ZEB1, com um papel importante na biologia de GBM. No geral, o nosso estudo demonstra 
que ZEB1 coordena diretamente a implementação de um programa genético complexo 
com semelhanças com a EMT, ativando e reprimindo genes envolvidos na regulação da 
forma celular, motilidade e proliferação. 
ZEB1 é altamente expresso nas camadas germinativas do cérebro e espinal medula em 
desenvolvimento, com provas funcionais e de desenvolvimento sugerindo que pode 
desempenhar um papel na manutenção do estado progenitor. Na segunda parte da tese 
(Capítulo 3), estendemos a nossa abordagem ao contexto de células estaminais neurais 
(NSCs) através da realização de análise de localização genómica de ZEB1 em duas linhas 
de NSCs. Os resultados sugerem que o paradigma ZEB1 / LEF1 também está presente 
nas células humanas Cb192, encontrando-se este mecanismo num contexto não-
maligno. Além disso, através da combinação de análise de localização genómica com 
perfil de expressão genético após ganho de função de ZEB1 no contexto de Progenitores 
Neuronais Granulares, identificamos genes-alvo de ZEB1 envolvidos na regulação da 
polaridade apical-basal celular. Ao reprimir estes genes, ZEB1 controla a diferenciação 
neuronal do cerebelo através da inibição da saída da zona germinal. 
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No geral, o nosso trabalho fornece novas perspectivas importantes sobre como o ZEB1 
atua ao nível molecular para regular múltiplos componentes de um programa genético 






Glioblastoma Multiforme (GBM) is the most prevalent type of glioma, bearing the 
highest incidence rate of brain and Central Nervous System (CNS) malignant tumors and 
the lowest survival rate. GBMs distinguish themselves from lower grade glial tumors by 
the presence of certain hallmark histological features such as the presence of central 
necrosis in the tumor mass, marginal proliferation of endothelial cells and the presence 
of palisading cells around the area of necrosis. 
Several hallmark features contribute to the poor responsiveness that GBM tumors have 
to treatment including their high inter- and intratumoral heterogeneity at a phenotypic, 
cellular, genetic and epigenetic level. Most importantly, the existence of cancer stem cell 
(CSC) populations within GBM tumors is crucial for driving invasive tumor growth due 
to their potential to proliferate in vascular conditions, while becoming highly invasive 
in hypoxic conditions. Moreover, the ability of GBM CSCs to infiltrate surrounding brain 
parenchyma means that even the smallest number of such cells left after surgery will 
cause tumor recurrence.  
Invasion from the primary tumor into the surrounding tissue is a major trait not only of 
GBMs but also of carcinomas. In the case of carcinomas, the first step towards invasion 
and metastization is the Epithelial-Mesenchymal Transition (EMT), a complex genetic 
program associated with loss of cell polarity, extensive extracellular matrix remodeling 
and acquisition of a migratory behavior. ZEB1 is a zinc-finger transcription factor known 
for triggering EMT through its capacity to transcriptionally repress several epithelial 
genes such as E-cadherin. Although EMT had not been entertained as a relevant process 
in GBM, there is increasing evidence that the GBM CSCs transition from a proliferative 
phenotype in vascular conditions to an invasive phenotype in the hypoxic niche shares 
many similarities to EMT.  
ZEB1 has emerged as a pivotal regulator of invasiveness, chemoresistance and 
tumorigenesis in GBM. ZEB1 is highly expressed both in hypercellular proliferative 
zones and less cellular zones from the periphery of the tumor. Its expression correlates 
with tumor grade and invasiveness. In spite of its role and widespread expression in 
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GBM, little is known of the molecular basis for its cellular functions during cancer and 
development including the identity of its target genes. In the first part of this thesis 
(Chapter 2), we perform the first genome-wide characterization of the ZEB1 
transcriptional program in a malignant context, in GBM CSCs. Strikingly, we found that 
ZEB1 binding is associated with both activation and repression of gene transcription on 
a genome-wide level.  Gene activation occurs through a previously undescribed 
mechanism by indirect recruitment via LEF1 to regulatory regions of target genes. 
Included in the ZEB1 activated genes is the guanine nucleotide exchange factor Prex1.  
Correlation studies in transcriptomic data from a large number of tumor samples 
further support Prex1 as a downstream target of ZEB1, with an important role in GBM 
biology. Overall our study demonstrates that by directly activating and repressing genes 
involved in the regulation of cell shape, motility and proliferation ZEB1 coordinates the 
implementation of a complex genetic program with similarities to EMT. 
ZEB1 is highly expressed in the germinal layers of the developing brain and spinal cord, 
with developmental and functional evidence suggesting that it may play a role as a 
maintainer of the progenitor state. In the second part of the thesis (Chapter 3), we 
extended our approach to a neural stem cell (NSC) context by performing genome-wide 
location analysis of ZEB1 in two NSC lines.  Results suggest the ZEB1/LEF1 paradigm is 
also at play in human Cb192 cells, extending this mechanism to a non-malignant context.   
Moreover, by combining our genomic location analysis with expression profiling after 
ZEB1 Gain of Function in a Granule Neuron Progenitor context, we identified ZEB1 
target genes involved in the regulation of apical-basal cell polarity. By repressing these, 
ZEB1 controls neuronal differentiation in the cerebellum by inhibiting germinal zone 
exit. 
Overall, our work provides important new insights into how ZEB1 functions at the 



















Gliomas and Glioblastoma multiforme 
Gliomas are the most common primary malignant brain tumors in adults accounting for 
80% of malignant tumors and 27% of all brain tumors (Ostrom et al., 2015). Gliomas 
usually arise in the brain parenchyma and while typically malignant, some types do not 
consistently behave in a malignant fashion. The term glioma refers to the presence of 
histological features similar to normal glial cells although the cell of origin remains 
unclear. They are usually divided based on histopathologic appearance and similarity to 
different glial cell types as oligodendrogliomas, astrocytomas and oligoastrocytomas 
(Ostrom et al., 2014). 
Gliomas are classified not only by glial cell type but also by malignancy according to a 
grading guideline defined by the WHO from Grade I to Grade IV (Louis et al., 2007). The 
WHO system is based on the presence of specific characteristics and the four grades are 
defined as the following: 
 Grade I lesions have low proliferative potential and are usually cured after 
surgical resection alone; 
 Grade II lesions are infiltrative in nature and even though they also have low 
proliferative potential, they have infiltrative growth and recur after surgical 
resection. Some type II gliomas tend to progress to high grades of malignancy 
usually transforming to anaplastic astrocytomas or GBM; 
 Grade III classification is reserved to lesions with histological evidence of 
malignancy including nuclear atypia and accelerated mitotic activity. They are 
considered intermediate to high grade lesions and patients with grade III tumors 
receive radiation and/or chemotherapy; 
 Grade IV lesions are associated with rapid pre- and post-operative disease 
evolution and a fatal outcome. They are cytologically malignant, mitotically 
active, necrosis-prone neoplasms. 
Tumor grade is one of the components of a combination of criteria used to predict a 
response to therapy and outcome besides clinical findings, age of the patient, tumor 
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location, etc. Combination of grade with other parameters can provide an overall 
estimate of prognosis. Nevertheless, tumor grade is an indicator of prognosis with 
patients with grade I lesions usually surviving more than 5 years, those with grade II 
usually surviving 2-3 years while patients with grade IV lesions such as GBM usually 
succumbing within a year of diagnosis (Louis et al., 2007). However, the presence of a 
grade I lesion may prove fatal if located in a region of the brain that renders it not totally 
resectable. 
From these, Glioblastoma Multiforme (GBM) or grade IV astrocytomas are the most 
prevalent type of glioma (55.1%) and of brain and CNS malignant tumors (46,1%) 
bearing the highest incidence rate of brain and CNS malignant tumors (3.20 per 100,000 
population) and with a dismal survival rate of 5.1% five years post-diagnosis which is 
even worse for older patients (age 55 and above) (Ostrom et al., 2015). Astrocytomas 
are the most prevalent histological type of gliomas, independently of WHO tumor grade, 
representing approximately 75% of all gliomas (Ostrom et al., 2015). Besides 
astrocytomas, the most common gliomas are oligodendrogliomas and 
oligoastrocytomas of grades II-III (Ostrom et al., 2014). However, the dismal clinical 
outcome makes GBM a focal target of cancer research. 
As grade IV astrocytomas, GBM distinguish themselves from lower grade glial tumors 
by the presence of certain hallmark histological features such as the presence of central 
necrosis in the tumor mass, marginal proliferation of endothelial cells and the presence 
of palisading cells around the area of necrosis (Fig. 1) (Bradshaw et al., 2016) which is 
regarded as a poor prognostic hallmark of GBM. Increased mitotic activity, 
hipercellularity, atypical nuclei and cellular pleomorphism are other characteristics of 
GBM. Combination of these features results in marked histological heterogeneity that 
makes it extremely difficult to treat, with GBM tumors being invariably recurrent after 
tumor resection even with the standard treatment post-resection of radiotherapy and 
chemotherapy with the oral alkylating agent temozolomide (Chakravarti et al., 2002; 




Figure 1. 1 Hematoxylin and eosin staining of a GBM.  
(A) The interface between tumor cells and the area of necrosis. The necrotic area (arrows) 
show greatly reduced nuclear staining. (B) Proliferation of the endothelial cells (arrows) 
within a microvessel. (C) Palisading cells (arrows) around the necrotic area. Original 
magnification: 200X. Figure from (Bradshaw et al., 2016) 
Primary and secondary GBMs 
Historically (H. J. Scherer, 1940), GBMs have been classified into two groups: primary or 
de novo and secondary GBMs. Histologically both types are indistinguishable but 
primary GBMs represent the overwhelming majority of (more than 90%) of diagnosed 
cases, developing very rapidly in elderly patients without clinical or histopathological 
evidence of a less malignant precursor lesion and are also called de novo GBMs. On the 
other hand, secondary GBMs arise through progression of low-grade diffuse or 
anaplastic astrocytoma manifesting predominantly in younger patients and represent 
only 5% of total cases (median age of 45 versus 60 for primary GBM) (Kleihues and 
Ohgaki, 1999; Ohgaki and Kleihues, 2007, 2013; Ohgaki et al., 2004). Interestingly, 
although median survival of patients with secondary GBMs being significantly longer 
than that of patients with primary GBMs the prognoses are equally poor after 
performing age-adjusted analysis since patients with secondary GBMs tend to be 
younger and age is a predictive factor of longer survival of GBM patients (Ohgaki and 
Kleihues, 2005; Ohgaki et al., 2004). 
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Despite being histologically indistinguishable, primary and secondary GBMs differ 
significantly genetically and epigenetically (Fig. 2). EGFR amplification, TP53 and PTEN 
mutation, entire loss of chromosome 10 and p16INK4a deletion are genetic alterations 
characteristic of both primary and secondary GBMs with the loss of heterozygosity 10 
being the most frequent alteration. However, there are significant differences in the 
prevalence of these mutations between primary and secondary GBMs. EGFR 
amplification and PTEN mutation are significantly more prevalent in primary GBMs 
while TP53 mutation is significantly more prevalent on secondary GBMs, being the 
earliest detectable genetic mutation, already present in 60% of the lower-grade 
precursor astrocytomas (Ohgaki and Kleihues, 2007).  
 
Figure 1. 2 Differences between primary and secondary GBMs.  
Note that only secondary GBMs share common origin of cells with oligodendrogliomas. 
Figure from (Ohgaki and Kleihues, 2013) 
Genetic pathways involved in primary and secondary GBMs 
The genesis of GBM involves the concurrent deregulation of components of three core 
pathways: the receptor tyrosine kinases (RTK)/PI3K/PTEN signaling pathways, the p53 
and the Rb tumor suppressor pathways (Fig. 3) (Furnari et al., 2007; Lino and Merlo, 
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2011; McLendon et al., 2008; Westhoff et al., 2014). Hence, amplification or mutational 
activation of receptor tyrosine kinases and the inactivation of genes that activate tumor 
suppressor pathways are crucial genetic events in gliomagenesis. The EGF and PDGF 
pathway play important roles in both CNS development and in gliomagenesis leading to 
the overactivation of mitogenic signaling pathways such as the PI3K and Ras/MAPK 
pathways (Furnari et al., 2007; Lino and Merlo, 2011; Parsons et al., 2008; Westhoff et 
al., 2014). The deregulation of cell cycle through inactivating mutations of the Rb and 
p53 pathways, which regulate the cell cycle primarily by governing the G1/S transition 
renders tumors susceptible to inappropriate cell division led by constitutively active 
mitogenic signaling effectors. 
When two hundred and six GBM samples from the The Cancer Genome Atlas (TCGA) 
were analyzed for copy number, expression and DNA methylation these three pathways 
were singled out, after mapping the somatic nucleotide alterations, genome copy 
number alterations such as homozygous deletions and amplifications onto the major 
pathways implicated in GBM (McLendon et al., 2008). Interestingly, there was a 
statistical tendency towards mutual exclusivity of alterations of components within 
each pathway, hinting at deregulation of one component relieving the selective pressure 
for additional mutations in the same pathway. Moreover, it was also observed that a 
given sample harbors at least one aberrant gene from each of the three pathways. In fact, 
74% harbored aberrations affecting intermediates of all three pathways suggesting that 
deregulation of the three pathways is a core requirement for GBM pathogenesis. The 
study by Parsons (Parsons et al., 2008) corroborates this, when the integration of 
sequencing, copy number and expression analysis identified several alterations of 
critical genes in the p53 pathway (TP53, Mdm2 p53 binding protein homologue (MDM2) 
and MDM4 p53 binding protein homologue (MDM4)), the Rb pathway (RB1, CDK4 and 
CDKN2A) and in the PI3K/PTEN pathway (PIK3CA, PIK3R1, PTEN and IRS1). These 
alterations affected pathways in a majority of tumors (64%, 68% and 50% respectively) 
and in all cases but one, mutations within each tumor affected only a single member of 





Figure 1. 3 Frequent genetic alterations in three critical signaling pathways.  
Primary sequence alterations and copy number changes for components of the 
RTK/Ras/PI3K/PTEN signaling (a), p53 signaling (b) and Rb signaling. Red indicates 
activating genetic alterations while blue indicates inactivating alterations, with darker shades 
corresponding to higher percentage of GBM samples with alterations. Figure from 
(McLendon et al., 2008) 
RTK/PI3K/PTEN signaling pathway 
Tumor cells usually accumulate genetic mutations that activate receptor-driven 
pathways, thus reducing their dependence on exogenous stimulation by growth factor 
binding to transmembrane receptors, cell-cell adhesion or the extracellular matrix 
(ECM). The predominant mechanism of mitogenic signaling activation in gliomas and 
GBMs occurs through receptor tyrosine kinases (RTKs) that bind and transduce the 
signal from cytokines, growth factors and hormones, and integrins that mediate the 
interaction between the ECM and the cytoskeleton. These receptors catalyze the transfer 
of phosphate groups from ATP to hydroxyl groups of tyrosines in target proteins and all 
contain an extracellular ligand binding domain connected to the cytoplasmic domain by 
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a single transmembrane helix. The cytoplasmic domain contains the catalytic domain 
and additional regulatory regions that are subjected to autophosphorylation and 
phosphorylation by heterologous protein kinases. In general, growth factor binding 
activates RTKs by inducing dimerization although a subset of RTKs forms oligomers 
even in the absence of activating ligand (such as insulin and IGF1 receptor. The human 
RTKs are composed of 20 subfamilies including the EGFR, PDGFR, MET and VEGFR 
(Lemmon and Schlessinger, 2010; Schlessinger, 2000).  
The epidermal growth factor (EGF) and platelet derived growth factor (PDGF) play 
important roles both in Central Nervous System (CNS) development and gliomagenesis 
(Furnari et al., 2007). The EGFR family is composed of four structurally related 
members: EGFR, ERBB2, ERBB3 and ERBB4 (Schlessinger, 2000). Variant III deletion of 
the extracellular domain (vIII mutant) has been described as the most commonly 
described event, occurring in 20-30% of all human GBM and in 50-60% of those that 
have amplified wild-type EGFR (Frederick et al., 2000; Sugawa et al., 1990). Extracellular 
domain point mutations and cytoplasmic domain deletions are also described (Ekstrand 
et al., 1992; Lee et al., 2006b). Analysis of TCGA samples (McLendon et al., 2008) 
revealed that EGFR alterations occurred in 41 of 91 sequenced samples. Even though 
ERRB2 mutation has previously been reported in only one GBM tumor sample (Stephens 
et al., 2004), in the TCGA cohort, 11 somatic ERRB2 mutations in 7 of 91 samples were 
validated, including mostly missense and splice-site mutations.  
The PDGFR family of receptors contains two members, PDGFR and PDGFR, that 
homodimerize and heterodimerize depending on which growth factor is bound to them 
(Heldin et al., 1992). PDGFRand its ligands, PDGFA and PDGFB, are expressed in 
gliomas, particularly in high-grade tumors, while PDGFR occurs in proliferating 
endothelial cells in GBM (Furnari et al., 2007). However, in contrast to EGFR, 
amplification or mutation of PDGFRA (13%) or MET (4%) are less frequent aberrations 
according to the TCGA (McLendon et al., 2008). 
Phosphoinositide 3-kinases (PI3Ks) belong to a conserved family of lipid kinases that 
phosphorylate the 3′-hydroxyl group of phosphoinositides. The most well-characterized 
product of this reaction is phosphatidylinositol-3,4,5-trisphosphate or PIP3, a critical 
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second messenger that recruits AKT (also known as PKB) which is subsequently 
phosphorylated by PDK1 and the mTOR-rictor kinase complex. Activation of AKT, in 
turn, phosphorylates many target proteins which regulate cell cycle and cell survival, 
protein synthesis, cell polarity and cell motility. Moreover, PI3K regulate migration and 
invasion by the Rho family member Cdc42, Rac and Rho. Class IA PI3Ks are heterodimers 
composed of a catalytic subunit, p110  (encoded by the PIK3CA gene), and a regulatory 
subunit, p85 (encoded by the PIK3R1 gene) (Lino and Merlo, 2011; Yuan and Cantley, 
2008). The catalytic subunit includes an N-terminal p85 binding domain, a Ras binding 
domain, a C2 domain a phosphatidylinositol kinase homology (PIK) domain and a C-
terminal catalytic domain. Somatic mutations in the PI3KCA p110 subunit were 
identified in 4 of 15 GBMs (27%) (Samuels et al., 2004) with the positions of the 
mutations indicating that they were likely to increase kinase activity. Subsequent 
studies identified mutations in 11 out of 73 GBM samples (15%). These mutations were 
found in 7 out of 38 (18%) of primary tumors, 1 of 11 (9%) xenografts and 3 of 24 (13%) 
cell lines with several of the mutations found increasing kinase activity while gene 
amplification was not detected (Gallia et al., 2006). In the TCGA analysis, 6 of 91 samples 
carried mutations in the PIK3CA gene (p110 domain). Although mutations in the 
regulatory subunit p85 were rarely reported previously, 9 of the 91 samples carried 
somatic mutations in the regulatory subunit gene PIK3R1, none of them in samples with 
PIK3CA mutations. The mutations in the p85 regulatory subunit clustered around the 
three aminoacids acting as contact points for the catalytic subunit, suggesting that these 
mutations might prevent inhibitory contact of the regulatory domain with the catalytic 
domain causing constitutive PI3K activity (McLendon et al., 2008).  
PTEN is a major tumor suppressor gene that encodes a phosphatase that catalyzes 
dephosphorylation of PIP3, negatively regulating the PI3K oncogenic pathway by 
inhibiting the activity of PI3K and AKT1 relocation (Lino and Merlo, 2011). Mutation, 
homozygous deletion or loss of expression of the PTEN gene was detected in 32% of 103 
GBM tumor samples (Knobbe and Reifenberger, 2003). PTEN mutations, including 
nonsense mutations and deletions or insertions leading to stop codons, occur almost 
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exclusively in primary GBMs (23.5% of samples) while it is rare in secondary GBMs (4%) 
(Ohgaki et al., 2004). Loss of heterozygosity 10q, which is the most frequent genetic 
alteration occurring in both primary and secondary GBMs, occurs mostly in three main 
loci: 10p14-p15, 10q23-24 and 10q25-pter. PTEN is located at 10q23.3, consequently 
being a tumor suppressor gene commonly deleted in GBM (Ohgaki and Kleihues, 2007). 
In the TCGA data, PTEN mutation or deletion was found in 36% of GBM samples 
(McLendon et al., 2008). 
NF1, is a tumor suppressor gene that encodes neurofibromin which functions as a Ras 
GTPase-activating protein. By promoting the dephosphorylation of Ras-GTP, 
neurofibromin negatively regulates the activation of the Ras-MAPK signaling by RTKs. 
The TCGA genomic characterization of GBM samples identified somatic mutations in the 
NF1 gene in 13 of 91 samples (14%). In addition 30 heterozygous deletions in NF1 were 
observed among the entire set of 206 cases. Overall, at least 47 of 206 patient samples 
(23%) harbored somatic NF1 inactivating mutations or deletions. 
P53 signalling pathway 
The p53 tumor suppressor prevents the propagation of cells with unstable genomes. It 
is a cellular stress sensor that triggers transient cell cycle arrest in the G1 phase, 
permanent cell cycle arrest (senescence) and apoptosis in response to a set of diverse 
stresses, including DNA damage, hyperproliferative signals, hypoxia, and oxidative 
stress. Beyond these classical responses, several additional cellular processes that are 
relevant to suppressing tumor development are modulated by p53. These include 
opposing oncogenic metabolic reprogramming and limiting the accumulation of reactive 
oxygen species (ROS), activating autophagy, promoting communication within the 
tumor microenvironment, inhibiting stem cell self-renewal and reprogramming of 
differentiated cells into stem cells, and restraining invasion and metastasis. It achieves 
this regulation of several critical cellular processes critical to tumor development 
primarily through its function as a transcriptional activator after being displaced from 
its negative regulators MDM2 and MDM4. P53 signaling is commonly dysregulated by 
amplification of MDM2 or by loss or mutation of the cyclin inhibitor p14ARF (encoded by 
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an alternative splice variant of the gene CDKN2A). p14ARF acts as a tumor suppressor by 
antagonizing MDM2 ubiquitin ligase activity and/or sequestering it to the nucleoli, 
enhancing p53 stability and activity (Bieging et al., 2014; Vogelstein et al., 2000). TP53, 
which encodes p53, is located at 17p13.1 and its inactivation through mutations or loss 
of chromosome 17p plays a crucial role in the development of secondary GBMs. TP53 
mutations are the first detectable genetic alteration in a series of 144 recurrent 
astrocytic brain tumors in patients with two or more biopsies. Mutations were detected 
in 58% of diffuse astrocytomas (grade II) and in 67% of anaplastic astrocytomas (grade 
III) (Watanabe et al., 1997). It also occurs in primary GBMs, albeit at a much lower 
frequency (28%) (Ohgaki et al., 2004). In the TCGA data, the inactivation of the p53 
tumor suppressor pathway occurred in the form of homozygous deletions of p14ARF 
(55%), amplifications of MDM2 (11%) and MDM4 (4%) in addition to mutations and 
homozygous deletions of TP53 itself which were detected in 27 of 72 (37.5%) untreated 
GBM samples which have similar survival to that of other reported primary GBMs. In 
treated samples (composed of secondary and recurrent GBMs), mutations were 
detected in 11 of 19 samples, coincident with previous reports that TP53 mutations play 
a crucial role in the development of secondary GBMs. In the integrated genomic analysis 
performed by Parsons, mutations and homozygous deletions of the TP53 gene were 
found in 40% of the analyzed tumors while mutations and homozygous deletions of 
CDKN2A were found in 50% of the tumors (Parsons et al., 2008). 
RB signaling pathway 
In quiescent cells, proliferation is blocked by binding of the hypophosphorylated RB1 to 
the E2F family of transcription factors, preventing the transactivation of genes essential 
through the progression of the G1-to-S-phase transition of the cell cycle. CDK4/CyclinD, 
CDK6/CyclinD and CDK2/CyclinE complexes, induced by the MAPK cascade, 
phosphorylate RB1 inducing the release and activation of the E2F transcription factor 
that activates genes that govern S-phase entry and progression. P16INK4a (encoded by 
CDKN2A) binds to CDK4, inhibiting the CDK4/CyclinD and CDK6/CyclinD complexes, 
and consequently the G1-to-S-phase transition (Furnari et al., 2007; Ohgaki and 
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Kleihues, 2007). Within the TCGA dataset, 78% showed genetic alterations in the RB 
pathway. The most common event was deletion of the CDKN2A/CDKN2B locus on 
chromosome 9p21 (55% and 53%) followed by amplification of the CDK4 locus. 
CDKN2A and CDKN2B both form complexes with CDK4 and CDK6 to block their 
activation. RB1 mutations and deletions were present in 11% of the samples. 
Interestingly, samples with RB1 nucleotide substitutions lacked CDKN2A/CDKN2B 
deletion or other copy number alterations in the pathway (McLendon et al., 2008). In 
the Parsons dataset, CDKN2A homozygous deletions were present in 50% of the GBM 
samples while CDK4 and RB1 were, respectively, altered in 14% and 12% of the 
samples. It seems to be equally important for primary and secondary GBMs since there 
was no significant difference in the overall frequency of P16INK4a alterations among both 
types of GBM (Ohgaki and Kleihues, 2007).  
Pathway crosstalk 
While the RTK/PI3K/PTEN, Ras/MAPK, p53 and RB pathways are often considered as 
distinct entities there is significant cross-talk between them that reinforce the 
inappropriate regulation of any single pathway perturbation (Fig. 4). In trying to assess 
if the pathway crosstalk was essential in genesis of GBM Chow et al looked into the 
cooperativity of these pathways in GBM by using genetically engineered mouse models 
(GEMMs) (Chow et al., 2011; Maire and Ligon, 2011). They introduced mutations in the 
PTEN, Rb1 and p53 tumor supressors in various combinations in astrocytes and neural 
precursors in mature GFAP-CreER mice with inducible targeting of approximately 50% 
of mature astrocytes, and less than 1% of neural precursor cells from the subventricular 
zone and subranuglar zone of the dentate gyrus (Chow et al., 2008), which developed 
into astrocytomas ranging from grade III to grade IV (GBM). None of the GEMMs carrying 
a a deletion in only one of the three tumor suppressors developed high-grade 
astrocytomas although the deletion of p53 led to a late onset and low frequency of low-
grade astrocytomas (Zheng et al., 2008a). The deletion of Pten, Rb1 and TP53 
significantly reduced the latency of tumor development and time to morbidity compared 
to double knockout Pten/TP53 with 85% of brains (26/31) containing high-grade 
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astrocytomas (of which 25% were GBMs). However double knockout of Pten/Tp53 led 
to higher frequency of tumor formation (87% - 55/63). Interestingly, p53 inactivation 
was a requirement for gliomagenesis since double knockout of Pten and Rb1 failed to 
cause gliomagenesis in GEMMs. This observation supports a role for p53 inactivation in 
low-grade astrocytoma initiation alongside other observations such as the low 
frequency of Rb1 and Pten mutations and high frequency of TP53 mutations in grade II 
and grade III astrocytomas (Ohgaki et al., 2004). 
 
Figure 1. 4 Pathway crosstalk between the three most commonly altered genetic pathways 
in glioma and GBM.  
Red indicates oncogenes that are either overexpressed or amplified in GBM samples and 
blue indicates tumor suppressor genes that are somatically mutated or deleted (except for 
p27 and p21). Figure from (Chen et al., 2012) 
Furthermore, in both the TCGA and Parsons analyses of genomic and transcriptional 
alterations in GBM samples, a majority of the tumors had alterations in genes encoding 
components of each of the p53, RB1 and RTK/PI3K pathways (74% in the TCGA data). 
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Interestingly, in both datasets it was observed a tendency for mutual exclusivity of 
alterations of components within each pathway. 
IDH1 mutation as a differentiator between primary and secondary GBMs 
The main genetic difference between primary and secondary GBMs was first reported 
by Parsons and colleagues in 2008. In this study (Parsons et al., 2008), they performed 
exome sequencing of 20,661 protein coding genes in 22 human GBM samples (7 samples 
extracted from patient tumors and 15 samples passaged as xenografts in nude mice) and 
analyzed this dataset for sequence alterations, copy number changes and expression 
changes and integrated these analyses to determine genes mutated during 
tumorigenesis that may provide selective advantage to the tumor cells (driver genes). 
The candidate cancer genes identified by this approach included TP53, PTEN and EGFR 
among others, validating their approach. Interestingly, they found that the IDH1 gene on 
chromosome 2q33 was somatically mutated in 5 of the 22 GBM tumors, with the same 
mutation that changed an arginine into a histidine (R132H). Further analysis identified 
another mutation of R132 in other 5 GBM samples, a third mutation in the same 
aminoacid residue was identified in other 2 samples and analysis of other 44 GBMs 
revealed another six tumors with somatic mutations affecting R132. In total, 18 of 149 
GBMs had mutations in IDH1, a mutation which had not been previously associated with 
GBM. IDH1 encodes isocitrate dehydrogenase 1, which catalyzes the oxidative 
carboxylation of isocitrate to -ketoglutarate resulting in the production of NADPH, and 
the R132 residue is located at the substrate binding site where it forms hydrophilic 
interactions with isocitrate. There are five isocitrate dehydrogenases encoded in the 
human genome, with at least three localized in mitochondria while IDH1 is localized 
within the cytoplasm and peroxisomes (Geisbrecht and Gould, 1999). IDH1 plays a role 
in the control of oxidative stress through the generation of NADPH (Kim et al., 2007; Lee 
et al., 2002). Mutated IDH1 was found in nearly all of the patients with secondary GBMs, 
while the median age of patients with the IDH1 mutation was 33 years as opposed to 53 
years for patients with wild-type IDH1. Finally, patients with IDH1 mutations had a 
significantly increased survival prognosis with a median overall survival of 3.8 years as 
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compared to 1.1 years for patients with wild-type IDH1. Even taking into consideration 
that both younger age and the TP53 mutation as positive prognostic factors for GBM 
patients, the association of IDH1 mutation with improved survivability is significant. 
The identification of IDH1 mutations as a differentiator between primary and secondary 
GBMs and as a positive prognostic factor was further corroborated in other studies. 
Namely, Watanabe et al (Watanabe et al., 2009) assessed IDH1 mutations in 321 gliomas 
of various histological types and biological behaviors. Interestingly, 130 mutations – all 
in the R132 residue – were detected at a high frequency in low-grade diffuse 
astrocytomas (88%), in secondary GBMs (82%) that developed through progression 
from low-grade diffuse or anaplastic astrocytoma, in oligodendrogliomas (79%) and 
oligoastrocytomas (94%). Analysis of multiple biopsies from the same patient showed 
that there were no cases in which IDH1 mutation occurred after the acquisition of either 
a TP53 mutation or loss of 1p/19q suggesting that IDH1 mutations are very early events 
in gliomagenesis that may affect a common glial precursor cell population. IDH1 
mutations were co-present with TP53 mutations in 63% of low-grade diffuse 
astrocytomas and with loss of heterozygosity 1p/19q in 64% of oligodendrogliomas 
however they were rare in pilocytic astrocytomas (10%) and primary GBMs (5%) and 
absent in ependymomas. These results reinforce the concept that despite their 
histological similarities, primary and secondary GBMs are genetically and clinically 
distinct entities. 
This study was followed further when Nobusawa and Watanabe (Nobusawa et al., 2009) 
screened GBMs from a population-based study for IDH-1 mutations to establish their 
frequency at a population level and to assess if they allow for a reliable discrimination 
between primary and secondary GBMs that progress from low-grade diffuse or 
anaplastic astrocytomas. They found IDH1 mutations in 36 of 407 GBMs (8.8%), with 
those mutations being frequent in GBMs diagnosed as secondary (22 of 30; 73%) but 
rare in primary GBMs (14 of 377). IDH1 mutations as genetic markers of secondary 
GBMs corresponded to the respective clinical diagnosis in 95% of cases while primary 
GBMs with IDH1 mutation had clinical and genetic profiles similar to secondary GBMs, 
suggesting they may have rapidly progressed from a less malignant precursor lesion 
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that escaped clinical diagnosis and were thus misclassified as primary. Conversely, 
secondary GBMs without IDH1 mutations typically developed anaplastic rather than 
lower-grade gliomas suggesting that at least some were actually primary GBMs.  
In an even larger study (Yan et al., 2009), the sequences of IDH1 and IDH2 were 
determined in 445 CNS tumors and 494 non-CNS tumors. Mutations that affected the 
R132 of IDH1 were found in more than 70% of WHO grade II and grade III astrocytomas 
and oligodendrogliomas and in GBMs derived from these lower-grade lesions while 
tumors without mutations in IDH1 often had mutations affecting the analogous 
aminoacid (R172) of the IDH2 gene. Similarly to the previous studies, it was found that 
tumors with IDH1 or IDH2 mutations had distinctive genetic and clinical characteristics 
that resulted in better outcomes for the patients with such tumors as opposed to 
patients with wild-type IDH genes. 
The impact of the IDH1 R132 mutation was assessed in cultured glioma cells (Zhao et 
al., 2009). By using the human cytosolic IDH1 crystal structure reported in 2004 (Xu et 
al., 2004) it was shown that tumor-derived IDH1 mutations impair the enzyme’s affinity 
for its substrate and dominantly inhibit wild-type IDH1 activity though the formation of 
catalytically inactive heterodimers. The forced expression of mutant IDH1 in cultured 
cells reduced the formation of -ketoglutarate but led to increased levels of HIF-1, a 
transcription factor that facilitates tumor growth when oxygen is low and whose 
stability is regulated by -ketoglutarate. HIF-1 was higher in human gliomas harboring 
an IDH1 mutation than in tumors without a mutation. Therefore, IDH1 may function as 
a tumor suppressor whose mutation contributes to tumorigenesis at least in part 
through activation of the HIF-1 pathway. 
GBM and glioma molecular subclassification 
Several decades of studies on GBM have highlighted that primary and secondary GBMs 
carry distinct genetic alterations. The identification of the IDH1 as a molecular marker 
of secondary GBM provided a clear distinction between the two types (Nobusawa et al., 
2009; Parsons et al., 2008; Watanabe et al., 2009; Yan et al., 2009; Zhao et al., 2009). 
Until the discovery of IDH1 mutations as a molecular marker, the distinction between 
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primary and secondary GBM was based on clinical observations. Tumors were 
considered primary if the diagnosis of GBM was made at the first biopsy without 
radiologic or histologic evidence of a preexisting precursor lesion while the diagnosis of 
secondary GBM required neuroimaging and/or histologic evidence of a preceding low-
grade or anaplastic astrocytoma (Ohgaki and Kleihues, 2013). Hence, previous to the 
discovery of mutations in the IDH1 gene, distinctions between primary and secondary 
GBMs were already made. However, none of the observed differences was specific 
enough to distinguish between the two types. Primary GBMs typically harbor EGFR 
amplification, PTEN mutation and entire loss of chromosome 10 while secondary GBMs 
harbor higher rates of TP53 mutations that are the first detectable genetic alteration in 
a series of 144 recurrent astrocytic brain tumors in patients with two or more biopsies 
(Watanabe et al., 1997) and 19q loss (Nakamura et al., 2000).  
An effort was undertaken to assess if a gene-expression based, histology independent 
classification system is predictive of survival and of response to treatment. Several 
studies used microarray expression profiling of glioma and GBM samples to classify 
primary and secondary GBMs into different gene-expression based molecular subtypes 
(Freije et al., 2004; Gravendeel et al., 2009; Phillips et al., 2006; Verhaak et al., 2010) that 
better correlate with patient survival than histologic groups. Thus, microarray gene 
expression data for hundreds of glioma and GBM samples were analyzed and revealed 
that most tumors can be classified into a small number of subtypes correlated with 
survival and response to therapy. 
By performing a microarray analysis of 74 Type III glioma and GBMs Freije (Freije et al., 
2004) found that its set of tumor samples could be classified into four different subtypes 
with distinct molecular signatures and prognosis. They further described a list of 44 
genes whose expression patterns reliably classified an independent data set of 50 
gliomas into these previously unrecognized biological and prognostic groups. The 
longer survival group was classified as hierarchical cluster 1A and is defined by 
expression of genes classified as being involved in neurogenesis, including BMP2, DLL3, 
HEY2 and NTRK2. The hierarchical cluster 1B was the most heterogeneous but samples 
in this group were characterized by the overexpression of genes associated with 
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synaptic transmission. Hierarchical clusters 2A and 2B were the clusters with the 
poorest survival. Cluster 2A gene expression signature is enriched with genes involved 
in mitosis and cellular proliferation while cluster 2B was defined by the expression of 
extracellular matrix components and regulators such as S100A4 or TGFB1 which may 
facilitate local invasion. Cluster 2B samples were also characterized by high expression 
of EGFR or AKT1. The finding that there are subclasses within the poor survival glioma 
patients, including one with a molecular signature indicative of invasion and one with a 
molecular signature associated with proliferation suggests that these classes may be 
susceptible to different molecular inhibitors. 
Phillips (Phillips et al., 2006) built a dataset from 76 samples of newly diagnosed cases 
of WHO grade III anaplastic astrocytomas and grade IV GBMs by resorting to DNA 
microarrays to identify gene expression patterns that classified tumors into 3 
prognostic groups associated with tumor aggressiveness as well as with disease 
progression and related these prognostic groups to differences in signaling pathways 
implicated in gliomagenesis. Each of the three molecular subtypes resembles a distinct 
set of tissues and is enriched for markers of different aspects of tissue growth. The 
Proneural subtype is composed by all of the histological grade III tumors and by grade 
IV tumors with and without necrosis. The average age of patients with Proneural tumors 
was around 40 years old. Tumors of this subtype are characterized by markedly better 
prognosis and by the expression of genes associated with neuroblasts and neurons such 
as NCAM, Olig2, NeuN and MAP2. Proneural tumors showed low rates of loss of 
chromosome 10 and of PTEN locus in chromosome 10, and EGFR locus also exhibited a 
normal status. Notch pathway elements DLL3, DLL1, Hey2 and ASCL1 were also 
overexpressed. The other two subtypes, Proliferative and Mesenchymal, were composed 
of tumors with worse prognosis than the Proneural subtype and are composed 
exclusively of GBMs from older patients (approximately 50 years old). Losses of 
chromosome 10, of the PTEN locus on chromosome 10 and chromosome 7 and EGFR 
amplifications were observed in both subtypes. Akt pathway marker p-Akt(ser473) was 
overexpressed in these two subtypes, while Notch pathway markers were not. The 
Proliferative molecular subtype displayed overexpression of markers of proliferation 
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such as Ki67, CD133, DLX2 and Nestin while Mesenchymal molecular subtype displayed 
overexpression of angiogenic and mesenchymal markers such as vimentin, YKL40, 
CD44, STAT3, VEGF, VEGFR1 and VEGFR2. The poor survival associated with these two 
subtypes is speculated to be related with a growth advantage conferred by either a rapid 
rate of cell division or enhanced survival of tumor cells afforded by neovascularization. 
The molecular subtypes described in this study allowed the clear identification of 
mutually exclusive pattern of expression of Proneural and Mesenchymal markers, 
corroborating previous studies regarding the existence of these two tumor types while 
the existence of the proliferative subtype was also observed in the Freije analysis (Freije 
et al., 2004). By studying matched pairs of primary and recurrent tumors from the same 
patients, however, it was observed that some tumors that originally arose as Proneural 
or Proliferative subtype would recur with a Mesenchymal signature with no instances of 
tumors gaining appreciable Proneural character between initial presentation and 
recurrence. This suggests that tumor cells can acquire the Mesenchymal phenotype 
through accumulation of genetic or epigenetic abnormalities. 
The largest study performed to date, whose established classification is the mostly 
followed, (Verhaak et al., 2010) built a dataset from 200 GBM samples and two brain 
tissue samples collected and processed through the TCGA and used it to identify four 
GBMs subtypes named Proneural, Neural, Classical and Mesenchymal, each characterized 
by a distinct gene expression signature encompassing a set of 210 up-regulated genes. 
An independent set of 260 GBMs expression profiles was compiled from the public 
domain, including the TCGA and Phillips et al, which successfully assessed subtype 
reproducibility. The Proneural subtype was associated with younger age, PDGFRA 
abnormalities and IDH1 and TP53 mutations, all aberrations associated with secondary 
GBMs. This indicates that the secondary GBMs are a very homogeneous group of the 
Proneural molecular subtype. This subtype shares many similarities to the previously 
identified Proneural and hierarchical cluster 1A subtypes in the Phillips and Freije 
studies. The Neural subtype was typified by the expression of neuron markers and 
included the two normal brain tissue samples. Their signature is suggestive of 
composition of cells with a differentiated phenotype, however it is associated with an 
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older age than the Proneural subtype. The Classical subtype was strongly associated 
with the astrocytic signature and contained all the common aberrations observed in 
GBM, such as chromosome 7 amplifications, chromosome 10 deletions, EGFR 
amplification and deletion of p53-stabilising isoform of CDKN2A. Like the Proliferative 
subtype in the Phillips study it expressed the neural precursor and stem cell marker 
Nestin. Just as the homonym in the Phillips study, the Mesenchymal subtype was 
characterized by high expression of mesenchymal markers such as YKL40, MET and 
CD44. Interestingly, there was a strong association of NF1 deletions with this subtype 
and the majority of samples had lower NF1 expression levels.  
This study also demonstrated that treatment efficacy differed per subtype with the 
Proneural subtype showing no survival advantage from aggressive treatment protocols 
of concurrent chemo- and radiotherapy whilst a clear treatment effect was observed in 
the Classical and Mesenchymal subtypes and suggested in the Neural subtype.  
Thus, this profiling-based classification is capable of finding important differences in 
response to therapeutic treatments, and may lead to the development of novel more 
effective therapeutic strategies for specific subtypes. This also indicates that primary 
GBMs, as opposed to secondary GBMs which are exclusively Proneural, are 
heterogeneous, with several different expression profiles (Fig. 2). 
Other studies focused on defining distinct subgroups of glioma identified CpG island 
methylator phenotypes (G-CIMP) (Noushmehr et al., 2010) and microRNA expression 
profiles (Kim et al., 2011) as factors capable of further characterize the different 
subtypes of gliomas and GBMs. In the study focusing on G-CIMP (Noushmehr et al., 
2010), promoter DNA methylation was assessed in 272 GBMs from the TCGA dataset 
and validated in a different set of non-TCGA GBMs and low-grade gliomas. Three DNA 
methylation clusters were identified on array-based methylation assay platforms and 
one of these formed a tight cluster with a highly characteristic DNA methylation profile 
designated as the glioma CpG island methylator phenotype or G-CIMP. This sample 
cluster was highly enriched for the Proneural expression profile subtype defined by 
Veerhak et al. The 24 G-CIMP positive patients were all significantly associated with 
IDH1 somatic mutations, characteristic copy number alterations such as gains in 
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chromosomes 8q23.1-q24.3 and 10p15.3-p11.21 and a longer survival time and 
younger patient age. Thus, G-CIMP status could be used as a potential predictor of 
improved patient survival. The authors suggest that if a transacting factor was involved 
in the protection from methylation of the CpG island promoters in the G-CIMP cluster, 
then the loss of its function could provide a favorable context for the acquisition of 
specific genetic mutations such as the IDH1 mutation. Therefore, the G-CIMP status 
identifies a specific subset of gliomas with specific clinical features and this can have an 
impact in the assessment of therapeutic strategies for GBM patients. 
The microRNA profiling study (Kim et al., 2011) analyzed 261 microRNA expression 
profiles from TCGA, identifying five clinically and genetically distinct subtypes that each 
related to a different neural precursor cell type: radial glia, oligoneural precursors, 
neuronal precursors, neuroepithelial/neural crest precursors and astrocyte precursors 
suggesting a relationship between each subclass and a distinct stage of neural 
differentiation. Each of the subtypes displayed significant differences in terms of patient 
race, age, treatment response and survival. The oligoneural subtype patients survived 
significantly longer than the other subtypes, and displayed a distinct pattern of somatic 
mutations, being enriched for IDH1 and PI3KR1 mutations while lacking NF1 mutations. 
When compared to the gene expression profiling subtypes identified by Veerhak et al, 
the microRNA-based oligoneural, radial glial and astrocytic subclasses were enriched in 
tumors from the Proneural, Classical and Mesenchymal subtypes, respectively. Several 
microRNAs were identified as potent regulators of subclass-specific gene expression 
networks in GBM. miR-9, which is upregulated in the oligoneural subtype, was found to 
suppress mesenchymal differentiation in GBM by downregulating expression of JAK 
kinases and inhibiting activation of STAT3. miR-222 was upregulated in the astrocytic 
precursor subtype. This suggests that these microRNAs might serve as regulators of 
gene expression in these specific subtypes. Overall, the findings in this study suggest 
that microRNAs are important determinants of GBM subtypes through their ability to 
regulate developmental growth and differentiation programs in several transformed 
neural precursor cell types. It also supports the use of developmental microRNA 
expression signatures to generate accurate prognosis. 
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Cancer stem cell model 
There is extensive debate about how the growth of tumors is sustained. There are two 
main models on the origin of cancer and its continued propagation: (1) the clonal 
evolution model and (2) the hierarchical cancer stem cell model (Fig. 5).  
 
Figure 1. 5 Current leading models of tumor propagation.  
A) Clonal evolution model postulates that a normal cell within the organism will accumulate 
genetic mutations that will eventually lead to the generation of a cancer cell that will then 
clonally expand. B) Hierarchical cancer stem cell model postulates that a population of CSCs 
(red) that are pluripotent and self-renewing originates a tumor mass that is mostly 
composed of cancer cells with low or no tumorigenic potential (light blue cells) and new 
CSCs or progenitor cells (dark blue) through accumulated mutations on the original CSC 
population. Figure from (Bradshaw et al., 2016) 
The first model proposes that cumulative genetic mutations that occur over time in a 
normal cell will eventually lead to the formation of a cancer cell which will then clonally 
expand to form identical copies with identical tumorigenic potential. In this model, most 
of the tumor cells are capable of self-renewal and can contribute to tumor maintenance. 
Tumor heterogeneity in this model is ascribed to differentiation and intraclonal genetic 
and epigenetic variation plus microenvironmental influences. Differences in tumor 
phenotype are ascribed to subclones at different stages of neoplastic transformation, 
each with a survival and growth advantage over normal cells, although to varying 
extents among themselves. There are several cancer types that conform to the clonal 
evolution model, with several studies having evaluated syngeneic transfers of mouse 
leukemias or lymphomas. Many of these studies demonstrated that leukemia-
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propagating cells were abundant and displayed relatively mature phenotypes rather 
than resemblance to stem cells (Adams and Strasser, 2008).  
The hierarchical cancer stem cell model proposes that a tumor is a heterogeneous 
population of cells that arises from CSCs generated by mutations thus acquiring the 
ability for uncontrolled growth, propagation and to divide asymmetrically into 
additional CSCs and downstream progenitors or differentiated cancer cells with low or 
no tumorigenic potential. These cancer cells with low or no tumorigenic potential form 
the main bulk of the tumor. While the term “cancer stem cell” is used, this does not imply 
that the cells of origin were transformed stem cells or progenitor cells since there is 
evidence that multiple cell types, including differentiated cells, can suffer oncogenic 
transformation into cancer stem cells (Adams and Strasser, 2008; Bradshaw et al., 2016; 
Lathia et al., 2015). There have been many terms used to describe self-renewing 
population of tumor cells with enhanced tumorigenic properties. CSCs can be defined as 
cells with (1) the ability to self-renew (2) that give rise to differentiated progeny and (3) 
that are capable of generating a tumor upon secondary transplantation that contains 
cellular heterogeneity and progeny with varying degrees of self-renewal capacity. It is a 
more restrictive term than cancer-initiating cells, which are cells with the capacity of 
initiating a tumor upon transplantation, but generation of heterogeneous population is 
not a requirement, while cancer propagating cells have the ability to propagate a tumor 
upon transplantation (Lathia et al., 2015). The first description of cancer stem-like cells 
was the isolation of leukemia-initiating cells performed nearly twenty years ago (Bonnet 
and Dick, 1997).  
Glioma and GBM stem cells 
GBM was only the second type of solid tumor (the first was breast cancer) where from 
so called CSCs were isolated (Al-Hajj et al., 2003; Singh et al., 2004). In this report, as few 
as one hundred GBM CSCs, isolated through FACS sorting for the cell surface antigen 
CD133, could give rise to tumors that recapitulated the parental tumors upon 
xenotransplantation in immunodeficient mice while as many as 1 million non-GBM CSCs 
were incapable of originating tumors.  
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Interestingly, it was observed (Lee et al., 2006a) that GBM CSCs isolated from human 
tumors and cultured in vitro in spheroids or monolayer with serum-free media 
containing EGF and FGF showed remarkable similarities to normal neural stem cells 
(NSCs), expressing several neural stem/progenitor markers such as Nestin, Sox2, Olig2 
and CD15(SSEA-1) with low levels of expression of glial (GFAP) and neuronal (Tuj1) 
markers. In this study, by using cells derived from the same primary tissue, the effect of 
culturing the cells in serum-containing medium or in serum-free media was assessed. 
Previously, most glioma cell lines were grown in serum-containing medium but it was 
reported that the most common established glioma cell lines – A172, Hs683, T98G, U251 
and U87 - are poor representatives of primary gliomas since they display significant 
differences in both genomic alterations and gene expression (Li et al., 2008). Serum has 
also been shown to cause irreversible differentiation of NSCs (F H Gage et al., 1995; 
Reynolds et al., 1992). Importantly, by performing gene expression profiling, spectral 
karyotyping and SNP arrays Lee et al observed that the genotype, gene expression 
profile and biology of the parental tumors can be stably preserved under stem cell 
culture conditions. Cells maintained in serum-containing medium did not express neural 
stem/progenitor markers while expressing glial and neuronal markers, indicating that 
the glioma CSC (GCSC) subpopulation was lost. They also showed dramatic differences 
in the genotype and gene expression patterns compared to the primary tumor.  
Interestingly, transplanting GBM CSCs into immunodeficient mice yielded tumors that 
shared similar histology and global gene expression patterns with their parental tumors. 
By contrast, early passage serum-grown cells were incapable of tumor formation after 
transplantation, while late passage cells gave rise to morphologically distinct tumors 
containing a different molecular signature than the original tumors. SNP analysis and 
spectral karyotyping showed that late-passage cells had gained a different set of 
mutations than the ones present in the original tumor. 
GCSCs and GBM CSC markers  
Embryonic stem cells and their more restricted progenitors all express a variety of 
markers, ranging from cell surface markers to transcription factors. CSCs in general, and 
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GBM CSCs in particular also express stem cell markers allowing their identification and 
isolation. However, due to the limited utility of intracellular proteins for enriching CSCs 
from non-stem tumor cells using methods such as flow cytometry, research has focused 
on the identification and use of cell surface markers to isolate the GBM CSC populations. 
The most extensively studied GBM CSC marker is CD133. The first reports about the 
isolation of human brain tumor initiating cells resorted to FACS sorting for the cell 
surface antigen CD133 which was originally identified in hematopoietic stem cells 
(HSCs) and also found in NSCs (Singh et al., 2003, 2004; Yin et al., 1997). Singh et al 
identified stem-like cells that lacked the expression of neural differentiation markers in 
pediatric brain tumors that expressed CD133 and Nestin (Singh et al., 2003), and then 
showed that the subpopulation of human GBM cells that were CD133-positive could 
initiate tumor formation in the brains of immunodeficient mice (Singh et al., 2004). 
CD133 expression was confined to de novo GBMs, and was not observed in lower-grade 
gliomas tumors. Primary GBM tumors that recurred after radiotherapy or treatment 
with temozolamide showed an increased proportion of the CD133-positive cells 
compared with the original tumor. The CD133 antigen was rarely expressed in 
secondary GBMs even after recurrence. This suggests a role for CD133 in tumor 
recurrence and invasion although it is not a marker that can be used for stem cells of 
lower grade gliomas (Tamura et al., 2013). The utility of CD133 in the isolation of GBM 
CSCs was questioned in several studies (Beier et al., 2007; Shmelkov et al., 2008; Wang 
et al., 2008a). This was corroborated by a recent study (Brescia et al., 2013) which 
reported that CD133 is capable of changing its subcellular localization between the 
cytoplasm and the plasma membrane of GBM CSCs neurospheres, thus cell sorting based 
on cell surface CD133 expression is incapable of isolating all the GBM CSCs. 
Furthermore, the fraction of GBM CSCs with cytoplasm-localized CD133 demonstrated 
reduced self-renewal and tumorigenic capacity as reported in the previous studies. 
Nevertheless, the authors also demonstrated that despite CD133 not being useful in 
GBM CSC isolation it is essential for GBM CSC maintenance since shRNA-mediated 
knockdown of CD133 impaired the self-renewal and tumorigenic potential of GBM CSCs. 
Furthermore, hypoxia significantly increases the percentage of CD133-positive cells 
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from the CD133-expressing GBM cell line IN669 from 69% to 96% suggesting that this 
factor is essential for GBM CSC function, maintenance of self-renewal and tumorigenic 
potential. 
CD44 is another cell surface marker that was shown to be expressed in 100% of the 
samples of a series of 38 primary human brain tumors (28 astrocytomas, WHO grade I-
III and 10 GBMs) and in cell lines derived from 9 GBMs, a result corroborated by another 
study that used immunohistochemical staining, which demonstrated cells from GBM 
expressing CD44 (Eibl et al., 1995; Kaaijk et al., 1995). CD44 was shown to activate 
NANOG in breast and ovarian cancers (Bourguignon et al., 2008) and stemness factor 
Bmi1 in head and squamous cell carcinoma (Prince et al., 2007). CD15 (also known as 
SSEA-1)  (Son et al., 2009) and A2B5 (Ogden et al., 2008) are also markers of GBM CSCs 
and glioma stem cells since cells expressing these markers were tumorigenic in-vivo, 
had self-renewal potential and had multilineage differentiation potential. As opposed to 
CD133, CD44 appears to be expressed in all GCSC lines and even in Proneural 
subpopulations of GBM CSCs (Mao et al., 2013; Pollard et al., 2009).  
It was shown that CD133, CD44 and cancer stem cell markers CD15 and A2B5 were 
present in genetically distinct tumor cell populations suggesting that even with the large 
amount of inter- and intra-tumor heterogeneity, some of the stem cell markers remain 
consistent. 
Nestin is another marker expressed in GBM CSCs. It is a known neural progenitor and 
stem cell marker whose presence is correlated with cellular propagation during the 
development of the CNS (Frederiksen and McKay, 1988; Ignatova et al., 2002). It is 
highly expressed in GBM CSCs (Hatanpaa et al., 2014; Singh et al., 2004; Zhang et al., 
2008) and differentiation of GBM cells leads to downregulation of Nestin (Staberg et al., 
2014).  
Besides these markers, GBM CSCs express other embryonic stem cell markers, similarly 
to other cancer stem cell types. SALL4 (He et al., 2013; Zhang et al., 2014), Oct4 (Guo et 
al., 2011), Sox2 (Guo et al., 2011), pSTAT3 (Iglesia et al., 2008a, 2008b; Rahaman SO, 
2002; Sherry et al., 2009), Nanog (Guo et al., 2011; Niu, 2013; Zbinden et al., 2010) and 
c-Myc (Herms et al., 1999; Wang et al., 2008b; Zheng et al., 2008b) are expressed in 
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GCSCs and GBM CSCs, and have been described as promoters of stem cell proliferation, 
self-renewal and their expression has been correlated with tumor aggressiveness. 
Since cell populations that are negative for certain cell surface markers retain the 
potential to generate multi-lineage tumor in vivo (Beier et al., 2007; Brescia et al., 2013; 
Shmelkov et al., 2008; Wang et al., 2008b) another method to isolate GBM CSCs is to rely 
on their ability to grow in serum-free conditions. However, this method also presents 
some limitations since neurosphere culture selects cells with a bias towards the 
expression of EGFR and FGFR due to the addition of these growth factors to the medium 
(Pastrana et al., 2011). 
GBM CSCs and intratumoral heterogeneity 
Intertumoral heterogeneity in GBMs and gliomas is evident with the existence of 
multiple molecular subtypes (Verhaak et al., 2010). This heterogeneity was also recently 
characterized for GBM CSCs: they were classified into two mutually exclusive subtypes, 
Proneural and Mesenchymal (Mao et al., 2013; Ricci-Vitiani et al., 2008), with distinct 
expression profiles. The Proneural subtype expressed markers associated with the 
Proneural signature such as Olig2, Sox2 and Notch1, while the Mesenchymal subtype 
expressed mesenchymal-associated genes such as WT1, Lyn and BCL2A1. Interestingly, 
Proneural GBM CSCs expressed CD133 with low expression levels of CD44 while 
mesenchymal GBM CSCs did not express CD133 but expressed CD44. IDH1 was 
expressed in all Proneural GBM CSCs (Mao et al., 2013). The Mesenchymal GBM CSCs are 
more aggressive, invasive, angiogenic and resistant to radiotherapy than Proneural GBM 
CSCs. However, radiation treatment of Proneural GBM CSCs upregulated mesenchymal 
markers and decreased Proneural markers. Other important differences between these 
two subtypes was that the glycolytic pathway and ALDH1A3 activities were robustly 
elevated in Mesenchymal GBM CSCs but not in Proneural GBM CSCs and inhibition of 
ALDH1A3 led to exclusive inhibition of the growth of Mesenchymal GBM CSCs. 
GBM tumors can also exhibit intratumoral heterogeneity. It was recently demonstrated 
(Sottoriva et al., 2013) by investigating genome-wide GBM intratumoral genomic 
heterogeneity, that most patients displayed the different GBM subtypes identified by 
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Veerhak within the same tumor. Interestingly, this heterogeneity was used to reveal 
tumor evolution at a single patient level, with each tumor containing a complex 
hierarchy of clone lineages. 
It was recently reported (Stieber et al., 2013) that primary GBMs could be either mono- 
or polygenomic tumors (64% vs 36% respectively), with the polygenomic tumors 
containing multiple tumor cell clones with distinct tumorigenic potential. By performing 
a ploidy analysis the chromosome content of the tumor cells was evaluated. The 
monogenomic tumors were composed of pseudodiploid tumor cells. These cells carry 
an apparently diploid genome (by DNA content) despite harboring multiple 
chromosomal aberrations including amplifications and deletions and are admixed with 
normal diploid stromal cells. Interestingly, the polygenomic tumors consisted of 
multiple clonally related tumor clones, always containing a pseudodiploid cell 
population and aneuploid tumor cell clones that carried the genomic aberrations 
already present in the pseudodiploid tumor cells. Different tumor cell clones from the 
same primary tumor could generate spheroids as well initiate tumors in mice, however, 
mice carrying aneuploid spheroids displayed significantly shorter survival times 
compared with diploid or unsorted bulk spheroids. This suggests that aneuploid clones 
lead to more aggressive tumors, with the aneuploidy fraction appearing to have a 
growth advantage over the pseudodiploid population. Interestingly, the pseudodiploid 
and aneuploidy tumor cells expressed putative GBM CSC markers such as CD133, CD15, 
A2B5 and CD44. However, the expression of these markers varied among the different 
subpopulations, but their expression could not be correlated with ploidy. 
Interestingly, a study investigated if the GBM subtype of isolated primary GBM 
neurospheres would also show variability in differentiation status and tumor properties 
(Joseph et al., 2014a). Six primary neurospheres were generated and characterized for 
the expression of Mesenchymal and Proneural markers, with 3 neurospheres of each 
subtype. Strikingly, upon intracranial transplantation in NOD SCID gamma (NSG) mice 
both subtypes formed equally effective invasive tumors with both Mesenchymal and 
Proneural tumors expressing the mesenchymal marker YKL40 contrasting with the low 
expression of this marker in the Proneural neurospheres in culture. This study 
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demonstrated that proneural GBM CSCs could also acquire mesenchymal properties in 
vivo. 
Therefore, intratumoral and extratumoral heterogeneity as well as the clonal diversity 
of GBM CSCs may be key to understanding resistance to treatment of GBM tumors. The 
fact that tumor cell populations are dynamic (with the capacity to interconvert between 
CSCs and non-CSCs) adds a layer of complexity to GBM progression and treatment. 
Interestingly, the existence of polygenomic tumors supports an evolutional view of the 
cancer stem cell model, a model that shares a similarity with the clonal evolution model: 
new CSC clones with different genetic alterations emerge over time due to natural 
selection and genomic instability within the same tumor.  
GBM cells of origin 
Even though differences in genetic alterations could be responsible for generating 
glioma and GBM subtype diversity, another potential contributing factor could be the 
tumor cells of origin. The main distinction between cells of origin and CSCs is that cells 
of origin are the normal cells in which the tumorigenic mutations first occurred and 
accumulated to trigger a malignant phenotype. CSCs, on the other hand, are defined as 
the cells that maintain an already formed tumor. Three major hypotheses about the cells 
responsible for the onset of malignant gliomas and GBMs have been put forward. The 
dedifferentiation of mature glia, the malignant transformation of neural progenitors of 
the adult brain and the malignant transformation of oligodendrocyte progenitors 
(OPCs) (Chen et al., 2012; Goffart et al., 2013; Stiles and Rowitch, 2008).  
Prior to the discovery of adult NSCs, mature astrocytes or committed astrocyte 
progenitors were thought to be the only replication-competent cells in the postnatal 
brain, and thus the only capable of malignant transformation. The malignant 
transformation process would require a “dedifferentiation” of the astrocytes in this 
scenario, by which the differentiated cells would regain immature glial and progenitor 
properties. The feasibility of this process was supported by studies in which a small set 
of transcription factors was sufficient to convert normal skin cells into induced 
pluripotent stem cells (Takahashi and Yamanaka, 2006). Indeed, multiple studies have 
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shown that neonatal cortical astrocytes could be reverted to a neural stem/progenitor-
like status by combined loss of INK4a/ARF in response to EGFR activation (Bachoo et 
al., 2002; Uhrbom et al., 2005). However, there are several caveats to these studies. First, 
in vivo efforts making use of genetically engineered mice or viral delivery are limited by 
the lack of a good mature astrocyte marker since GFAP is also expressed by adult NSCs 
(Doetsch et al., 1999). Second, transformation-competent astrocyte cultures can be 
generated from the neonatal cortex, which were reported to contain immature 
progenitor cells, but not the adult cortex (Laywell et al., 2000).  
The rediscovery of self-renewing NSCs in the subventricular zone (SVZ) of the adult 
mammalian brain provided an alternative candidate for the glioma cell of origin. This 
region maintains the ability to produce neurons and glia throughout life, functioning as 
a source of progenitors in adults (Doetsch et al., 1999; Luskin, 1993). Several studies 
suggest that NSCs are more susceptible to malignant transformation. Abnormalities first 
occur in the NSC niches of pretumorigenic mice that lack p53 and harbor a conditional 
allele of the NF1 tumor suppressor (Zhu et al., 2005). Temporal deletion of the tumor 
suppressors p53, NF and PTEN in postnatal mouse neural stem/progenitor cells using a 
tamoxifen-inducible Nestin-Cre resulted in glioma formation with 100% penetrance 
while ablation of these genes in non-neurogenic adult brain regions using the cre-
adenovirus did not yield tumors (Alcantara Llaguno et al., 2009). Notably, ablation of 
p53, PTEN and/or Rb in SVZ NSCs, but not in peripheral astrocytes produced gliomas 
(Jacques et al., 2010). Although the SVZ is considered the stem cell compartment for 
glioma formation in mice, following the introduction of genetic alterations observed in 
adult malignant brain tumors, there are reports that pediatric gliomas more likely arise 
from NSCs located in the third ventricle (Lee et al., 2012; Xu et al., 2005). One major 
caveat of these studies is that they hinged on introducing mutations or predisposing 
NSCs for mutation, but a study demonstrated the spontaneous transformation of adult 
rat SVZ stem cells into tumorigenic cell lines after expansion in vitro (Siebzehnrubl et 
al., 2009). These cells maintained the expression of stem cell markers such as CD133 
and Nestin but changed their morphological appearance by forming cellular aggregates 
and kept proliferating after differentiation induction (removal of growth factors from 
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media). Karyotyping detected multiple chromosomal aberrations and syngeneic 
transplantation into the brain of adult rats led to formation of tumors with necrotic 
areas that invaded the surrounding parenchyma. Deficient downregulation of PDGFR 
was identified as the candidate mechanism for tumor cell proliferation. This was the first 
direct observation of the malignant transformation of adult NSCs from the SVZ into 
malignant brain tumor CSCs. 
More recently, OPCs and NG2+ cells (composed of OPCs, pericytes and microglial cells) 
were also identified as potential cells of origin of malignant gliomas. Mosaic analysis 
with double markers confirmed that malignant transformation generating GBM only 
occurred in cells expressing OPC markers in a mouse model with homozygous mutation 
of p53 and NF1. In addition, gliomagenesis occurred whenever the same p53/NF1 
mutations were introduced into OPCs (Liu et al., 2011). 
  
Figure 1. 6 Cells of origin of glioma and GBM.  
There is evidence for neural progenitors, oligodendrocyte (Ng2+) progenitors and 
astrocytes as the potential cells of origin of gliomas and GBMs. Figure adapted from (Chen 
et al., 2012). 
However, the determination of the GBM cell of origin is still a matter of intense research 
where mouse models, whose genetic alterations and physiological setting closely 
resembles those seen human patients, are important tools. Nevertheless, the 
identification of different molecular subtypes that share similarities with profiles of 
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vastly different cell lineages also suggests that there may be potentially different origins 
for different GBM tumors (Verhaak et al., 2010). 
GBM CSCs as the primary source of invasion and influence of 
microenvironmental niches 
Although the most conventional anti-neoplastic therapies target proliferating cells, the 
malignancy of cancer also derives from its effects on vasculature, the immune system 
and invasion/metastasis. GBMs are highly invasive and GBM CSCs are considered the 
primary cause of GBM invasion, proliferation, angiogenesis and recurrence (Paw et al., 
2015; Xie et al., 2014) since they have been reported multiple times as being strongly 
invasive when injected into mouse brains as opposed to serum-grown GBM cells (Lee et 
al., 2006a). These cells are responsible for tumor recurrence within 1-2 cm of the 
original tumor site because some of the tumor cells invade the surrounding normal 
brain tissue where they escape from surgical removal and radiation therapy (Hou et al., 
2006). Furthermore, retinoic-acid (RA) induced differentiation of GBM CSCs in vitro 
impairs the secretion of angiogenic cytokines such as VEGF and bFGF, disrupts GBM CSC 
motility and decreases proliferation. Mice xenografted with differentiated GBM CSCs 
originated non-invasive tumors seven times smaller than the invasive tumors generated 
by undifferentiated GBM CSCs and with 5-fold higher numbers of TUNEL-positive 
apoptotic cells (Campos et al., 2010). 
Sequential switching between proliferation and invasion characterize tumor 
progression, with proliferation and migration appearing to be mutually exclusive 
phenotypes at the microscopic level - “go or grow” model. It was experimentally 
demonstrated that these phenotypes can switch under certain conditions (Gao et al., 
2005). Highly proliferative GBM cell subclones were selected from a highly invasive 
GBM cell population responsive to hepatocyte growth factor (HGF). The proliferative 
cells were selected for by growing the same subsets of cells in soft agar. Interestingly, 
further growth of these proliferative subclones in Matrigel, a gelatinous basement 
membrane extract that mimics complex extracellular environment, changed their 
morphology from spherical to branching - consistent with a switch from proliferation to 
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invasion. Furthermore, the description of the Proneural and Mesenchymal GBM CSCs 
populations (Mao et al., 2013; Ricci-Vitiani et al., 2008) further supports the “go or grow” 
with the Mesenchymal GBM CSCs being more invasive, angiogenic but with reduced 
mitotic index.  
Thus, the progression of GBM is determined by two key factors: cell proliferation rate 
and speed of cell migration of GBM CSCs. However, in a live tumor environment these 
factors depend on the heterogeneous environment in which these cells reside which 
includes extracellular matrix, white matter tracts, vasculature and a host of soluble 
factors. In live tumor environments, GBM CSCs and GCSCs have been reported as 
residing in two distinct microenvironmental niches which shift tumor progression 
toward a proliferative or invasive phenotype. Namely, the vascular niche and the 
hypoxic niche. 
It is known that normal adult NSCs reside in specific anatomic regions of the brain: the 
SVZ and the subgranular layer (SGZ) (Doetsch et al., 1999; Luskin, 1993; Zhao et al., 
2008). In those regions, they reside in vascular niches where endothelial cells release 
soluble factors that stimulate self-renewal, inhibit differentiation and enhance neuron 
production. Endothelial coculture stimulates neuroepithelial contact, activating Notch 
and Hes1 to promote self-renewal (Shen et al., 2004). Similarly to NSCs, Nestin-positive 
and CD133-positive brain tumor CSCS from medulloblastomas, ependymomas, 
oligodendrogliomas and GBMs were shown to reside within a vascular niche and to 
interact physically with endothelial cells. Coculture with vascular endothelial cells 
enhanced the self-renewal of undifferentiated CD133-positive brain tumor CSCs while 
coimplantation of both CD133-positive and endothelial cells promoted tumor growth, 
whereas angiogenesis antagonists eradicated brain tumor CSCs (Calabrese et al., 2007). 
Thus glioma and GBM CSCs become highly proliferative and retain an undifferentiated 
phenotype when they are present in a vascular niche, similar to NSCs. This is validated 
with patient data since glioma and GBM patients that underwent anti-VEGF therapy with 
monoclonal antibody bevacizumab or with pan-VEGF RTK inhibitor cediranib (Groot et 
al., 2010; Tomaso et al., 2011) demonstrated decreased endothelial proliferation and 
glomeruloid vessels and a significant improvement in progression-free survival rate, 
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although not in overall survival duration. This is similar to observations made in several 
tumor mouse models where inhibition of angiogenesis can shrink the original tumor 
(Ebos et al., 2009). 
However, anti-angiogenic therapy also led to a shift in the tumor phenotype to a 
predominantly infiltrative phenotype (Groot et al., 2010; Tomaso et al., 2011) 
demonstrating that exists one other microenvironmental niche in which GBM CSCs 
prosper: a hypoxic niche. Indeed, this may be the most significant niche for GBM CSCs 
since it is known that hypoxic conditions facilitate self-renewal of both NSCs and GCSCs 
in culture. HIF-2 regulates tumorigenic potential of GCSCs, with its expression 
correlating with poor clinical outcome (Clarke and van der Kooy, 2009; Li et al., 2009). 
In fact, hypoxia is accepted as the primary microenvironmental factor regulating GBM 
proliferation and invasion as well as promoting the production of pro-angiogenic factors 
by the brain tumor stem cells. Necrosis and vascular proliferation are the defining 
pathologic features of GBMs, which distinguish them from lower-grade gliomas. The 
rapid growth of GBM tumors lead to a deficient blood supply and thus a lack of nutrients 
and oxygen at the tumor core. Furthermore, tumors growing into adjacent brain tissue 
also cause intravascular thrombosis and hemorrhage. These hypoxia-causing events 
create a necrotic core, and in response tumor cells migrate away from this core, 
surrounded by hypoxic hypercelllular zones of cells migrating away from this core called 
pseudopalisades (Brat and Van Meir, 2004; Brat et al., 2004). A high percentage of the 
cells in the hypoxic pseudopalisades are CD133-positive GBM CSCs (Christensen et al., 
2008) and show nuclear expression of HIF-1 (Brat et al., 2004). While moving away 
from the necrotic core GBM CSCs express pro-angiogenic factors such as VEGF and SDF-
1, while non-GBM CSCs populations do not (Bao et al., 2006; Folkins et al., 2009). These 
factors induce endothelial cell proliferation and tubule organization.  
For brain tumor stem cells to invade the brain parenchyma and white matter tracts, they 
also require the ability to degrade the extracellular matrix proteins. Many studies have 
reported the overexpression, compared with normal brain cells, and involvement of 
matrix-metalloproteinases (MMPs) such as MMP14, MMP2 and MMP9 in this process 
and in angiogenesis promotion through upregulation of VEGF. Many of the pathways 
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that promote GBM invasion also up-regulate the expression of these MMPs (Koul et al., 
2001; Kubiatowski et al., 2001; Lee et al., 2013; Ulasov et al., 2014). 
 
Figure 1. 7 Vascular and Hypoxic niches of glioma and GBM stem cells.  
The vascular niche were found to be important for glioma growth since coculture with 
endothelial cells promotes GCSC self-renewal and proliferation. In the hypoxic niche GCSCs 
maintain their stemness through the activation of hypoxia related pathways. In the hypoxic 
niche GCSCs secrete angiogenic factors, differentiate into cells of endothelial lineage and 
shift to a mesenchymal phenotype invading the surrounding brain parenchyma. Figure from 
(Chen et al., 2012) 
Epithelial-Mesenchymal transition in a GBM context 
Two mutually exclusive subtypes of GCSCs and GBM CSCs have been described (Mao et 
al., 2013; Ricci-Vitiani et al., 2008): the Mesenchymal and Proneural subtype. The 
Mesenchymal GBM CSCs are more aggressive, invasive, angiogenic and resistant to 
radiotherapy than Proneural GBM CSCs. However, radiation treatment of Proneural 
GBM CSCs shifts them to a Mesenchymal phenotype, with upregulated mesenchymal 
markers and decreased Proneural markers. Furthermore, GBM CSCs in hypoxic 
conditions have a more invasive and angiogenic phenotype while those in the vascular 
niche proliferate more. 
This transition from Proneural to Mesenchymal subtype after radiation treatment, and 
this transition of GBM CSCs from a proliferative phenotype in the vascular niche to a 
more invasive and angiogenic phenotype in the hypoxic niche shares some similarities 
with the Epithelial-Mesenchymal transition (EMT).  
Since gliomas and GBMs do not metastasize the EMT had not been entertained as a 
relevant process to the disease. Nevertheless, there is increasing evidence that the 
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transition of GBM CSCs from the vascular niche, where they exhibit a predominantly 
proliferative phenotype, to the hypoxic niche, where they are predominantly invasive 
and angiogenic, shares many similarities to EMT with many reports shedding light on 
the role of EMT signaling pathways and EMT inducing transcription factors in a glioma 
and GBM context  
Epithelial-Mesenchymal Transition  
EMT is a process that is crucial during several steps of embryonic development - the first 
event of EMT is the formation of mesenchymal cells and mesoderm during gastrulation 
- that has been found to play an important role in human solid tumors of epithelial origin 
such as breast and colorectal cancer, controlling the switch between cancer proliferation 
and metastization (Micalizzi et al., 2010). Proliferative tumors often show an epithelial 
morphology, with tight cell junctions and overexpression of E-cadherin at adherens 
junctions. EMT begins with the loss of apico-basal polarity as tight junctions dissolve, 
together with the loss of other cell-cell junctions (such as adherens junctions) after the 
loss of expression of E-cadherin and epithelial integrins.  These factors are replaced by 
N-cadherin expression and other integrins that provide more transient adhesive 
properties priming the cells for a mesenchymal phenotype. Additionally, the cell 
cytoskeleton reorganizes with the peripheral actin cytoskeleton being replaced by 
stress fibers and cytokeratin intermediate filaments being replaced by vimentin. These 
changes transition the cell from a cuboidal to a spindle shape and the cell acquires the 
ability to invade and degrade the extracellular matrix. The mesenchymal cells will then 
migrate into the blood or lymphatic circulation system, until they encounter suitable 
extravasation sites. At such sites, the cells undergo the reverse process of Mesenchymal-
Epithelial Transition (MET) resulting in the formation of a secondary tumor (Fig. 8). 
Importantly, the EMT is also associated with the acquisition of a stem cell phenotype. 
The induction of EMT in immortalized human mammary epithelial cells (HMLEs) results 
in the expression of stem-cell markers. Furthermore, those cells, have an increased 
ability to form mammospheres, a property associated with mammary epithelial stem 
cells, and express markers similar to stem-like cells isolated from HMLE cultures. 
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Interestingly, stem-like cells isolated from mouse or human mammary glands or 
mammary carcinomas express EMT markers (Mani et al., 2008). Thus, cells that undergo 
the EMT gain the capacity to generate new tumors once they reach another tissue. 
 
Figure 1. 8 EMT and metastization in carcinomas.  
A) During EMT, epithelial cells lose apical-basal polarity with the loss of cell-cell junctions. 
Cell surface proteins such as E-cadherin (green) are replaced by N-cadherin (blue) and the 
actin cytoskeleton is remodeled. Meanwhile the basement membrane (red) is degraded and 
the cells invade the surrounding stroma without cell-cell contacts. B) Carcinomas usually 
metastasize at advanced stages. In the invasive stage, EMT allows the invasion through the 
basement membrane into the surrounding tissue either as single cells (blue) or as cell 
clusters (light blue). These individual cells or cell clusters can then disseminate from the 
primary tumor either through lymph nodes or through the bloodstream. When they exit the 
bloodstream they may form metastasis through a reversion back to the epithelial phenotype 
(MET). Figure adapted from (Micalizzi et al., 2010). 
 While EMT shares the same basic features during development, cancer and 
fibrosis/wound healing it can be subclassified into three different subtypes based on the 
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functional consequences and biological context. The three subtypes are developmental 
(Type I), fibrosis or wound healing (Type II) and cancer (Type III) (Kalluri and 
Weinberg, 2009). Interestingly, biomarkers specific for each subtype, common to two of 
the subtypes or common to all have been defined. Interestingly, the Type III subtype of 
EMT also invokes the expression of markers suggestive of stem cells, suggesting that this 
type of EMT also leads to dedifferentiation of tumor cells (Zeisberg and Neilson, 2009). 
This transdifferentiation of epithelial cells into motile mesenchymal cells is controlled 
by several pathways that regulate the expression of key transcription factors, including 
zinc finger proteins Snail and Slug, zinc-finger homeodomain proteins ZEB1/ZEB2 and 
the bHLH factor Twist. RTK pathways were the first uncovered as inducers of EMT. 
These signaling receptors responsive to FGF, EGF, PDGF, IGF1 and HGF are also capable 
of enhancing proliferation. Hypoxia has also been shown to trigger EMT since HIF-1 is 
also capable of enhancing the expression of EMT-inducing transcription factors 
(Lamouille et al., 2014). Interestingly, RTK pathways are the most commonly 
deregulated pathways in glioma and GBM as previously described. 
Besides RTK signaling, other extracellular signaling pathways have been reported and 
thoroughly studied as inducers of EMT: the TGF- pathway and the Wnt signaling 
pathway.  
Pathways and factors that regulate EMT and promote GBM CSC invasiveness 
TGF- pathway 
Transforming growth factor-beta (TGF-) is a representative of a large family of 
cytokines that include the bone morphogenetic proteins (BMPs), nodals and activins.  
There are three TGF- isoforms synthesized as latent dimers, which are converted to 
their active forms by proteases. TGF- first binds to the TGF- receptor II (TGF-RII) 
altering its conformation. TGF-RII then phosphorylates TGF-RI (also known as ALK5) 
which in turn, phosphorylates receptor-regulated Smad proteins (Smad2, 3). Activated 
R-Smads form heteromeric complexes with the Co-Smad (Smad4) and translocate to the 
nucleus where they cooperate with other transcription factors to regulate gene 
expression (Han et al., 2015; Joseph et al., 2013). TGF-RII has been shown to also act 
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through Smad-independent pathways, including pathways deregulated in gliomas and 
GBM such as MAPK, PI3K/Akt and Rho-like GTPase signaling. 
As opposed to RTK associated signaling pathways, TGF- acts as a tumor suppressor in 
normal epithelial cells and even in premalignant stages of cancer, inhibiting cell 
proliferation. However, certain malignant cancers selectively lose the capacity of TGF-
RII to inhibit cell proliferation while maintaining other functions of the pathway intact. 
Thus, TGF- can have a dual role in tumorigenesis as tumor suppressor or promoter. 
This shift from tumor suppressor to promoter is in part attributed to TGF- mediated 
pSmad3C (C-terminally phosphorylated Smad3) signaling. At the malignant 
transformation stage Smad3 signaling shifts from pSmad3C to a tumorigenic pSmad3L 
(linker-phosphorylated Smad3) and finally to more invasive and proliferative 
pSmad2L/C and pSmad3L/C (dually phosphorylated at linker and C-terminal regions of 
Smad2 and 3) (Matsuzaki, 2011). 
 The TGF- family is a fundamental player in multiple developmental processes (Wu and 
Hill, 2009) development and in tumor invasion and metastasis (Massagué, 2008) since 
it is a potent inducer of EMT. It has been described as a classic inducer of EMT in a wide 
variety of systems and it plays a significant dual role in breast cancer, as a tumor 
suppressor in early stages and as a promoter of metastatic spread in late stages of 
tumorigenesis. It promotes the expression of EMT inducing factors Snail, Slug, Twist and 
ZEB1/ZEB2 (Shirakihara et al., 2007; Thuault et al., 2006). It also promotes angiogenesis 
through the upregulation of VEGF, FGF and plasminogen activator inhibitor (Pepper, 
1997; Ueki et al., 1992). 
TGF- pathway in a glioma and GBM context 
In glioma and GBM, TGF-has been implicated in several tumorigenic processes and no 
evidence for antitumorigenic properties of TGF- were found (Joseph et al., 2013). 
Interestingly, BMP4, which activates a different set of R-Smads, enhances differentiation 
and depletes the pool of GCSCs (Piccirillo et al., 2006). TGF- was described as a 
promoter of cell proliferation in gliomas through the induction of PDGF-B in gliomas 
with an unmethylated PDGF-B gene (Bruna et al., 2007). It is involved in the 
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maintenance of stemness of GCSCs through induced expression of Sox2 mediated by 
Sox4, a direct target gene of the pathway (Ikushima et al., 2009). Furthermore, it was 
also found to play a role in angiogenesis, including in GBM cell lines (Holderfield and 
Hughes, 2008; Pen et al., 2008; Pepper, 1997), and in immunosuppression (Platten et al., 
2001). Finally, it promotes GBM CSC invasiveness by enhancing the expression of MMPs 
(Canazza et al., 2011; Wick et al., 2001) and by inducing a ZEB1-dependent 
mesenchymal transdifferentiation, which is associated with increased invasiveness of 
GBM CSCs in GBM tumors (Joseph et al., 2014b). 
Wnt signaling pathway 
Wnt factors, after palmitoylation by Porcupine in the endoplasmic reticulum, are 
secreted and can activate at least three distinct pathways: the canonical Wnt signaling 
pathway, the non-canonical planar cell polarity (PCP) pathway and the Wnt/Ca2+ 
pathway. The canonical Wnt signaling pathway (hereby referred to as Wnt/-catenin 
signaling) is activated by the Wnt1 class of Wnt growth factors (Wnt1, 2, 3, 3a, 8 and 8a) 
while the non-canonical pathways is triggered by the Wnt5a class (Wnt4, 5a, 5b, 6, 7a 
and 11). The activation of both the canonical and non-canonical branches is initiated by 
the binding to the corresponding seven-transmembrane cell surface Frizzled (Fzd) 
receptors, which play a role in the final output of Wnt signaling. It should be noted that 
Wnt factors can bind differently to distinct Fzd receptors and vice-versa. 
In the absence of a Wnt signal, free cytoplasmic -catenin is recruited into a large 
complex consisting of Axin, APC (adenomatous polyposis coli), CK1 (casein kinase I) and 
the serine/threonine kinase GSK (glucogen synthase kinase)-3. This complex 
phosphorylates -catenin at the N-terminus, targeting -catenin to degradation by 
binding to -TRCP of a E3 ubiquitin ligase complex. Activation of the Wnt/-catenin 
signaling pathway occurs when Wnt factor binds to the Fzd receptors and low density 
lipoprotein receptor-related proteins (Lrp5 or Lrp6) to form a ternary complex which 
will recruit Dishvelled (Dsh) and Axin. Then GSK3 is released from the scaffolding 
complex, leading to accumulation of unphosphorylated -catenin, which translocates to 
the nucleus and forms complexes with transcription factors of the TCF (T-cell factor) 
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and LEF (lymphocyte enhancer factor) family. When the Wnt/-catenin signaling is 
inactive, LEF/TCF factors are mostly described as acting as transcriptional repressors 
by forming complexes with Groucho/TLE corepressors (Kléber and Sommer, 2004; 
Michaelidis and Lie, 2007). The LEF/TCF family is composed of 4 factors: LEF1, TCF7 
(i.e.TCF1), TCF7L1 (i.e. TCF3), TCFL2 (i.e. TCF4). They are context-dependent regulators 
that also have the ability to regulate transcription independently of Wnt signaling. They 
have multiple isoforms, varying binding strength to the DNA and specificity as well as 
being differentially expressed in tissues. This suggests that Wnt/-catenin signaling 
pathway often relies on cross-talk with other factors to activate gene expression and 
that this complexity can influence Wnt signaling specificity and strength (Arce et al., 
2006). 
In the non-canonical PCP pathway, Wnt proteins bind to Fzd receptors and activates 
Rho/Rac small GTPases or the Jun-N-terminal kinase (JNK), a MAP kinase thereby 
regulating gene expression. In the non-canonical Wnt/Ca2+ pathway the binding to Fzd 
receptors and coreceptors ROR2 and RYK,  activating calcium/calmodulin-dependent 
kinase II (CAMK) and protein kinase C (PKC). Although the non-canonical pathways also 
play a role in the regulation of cytoskeletal organization in crucial morphogenetic events 
during development and during invasion/metastasis, the Wnt/-catenin signaling is 
strongly correlated with the EMT and is used as a marker of cells with a mesenchymal 
phenotype.  
-catenin is a protein that plays a dual role in EMT: not only does it serve as the 
cotranscriptional activator of the canonical Wnt signaling pathway, together with 
LEF/TCF factors, but it is also present in adherens junctions at the plasma membrane 
where it links E-cadherin to the cytoskeleton in epithelial cells (Schmalhofer et al., 
2009). The levels of -catenin in the cytoplasm are mainly controlled through 
recruitment to cadherin binding partners or ubiquitination and subsequent 
degradation. In normal epithelial cells and non-invasive tumor cells, -catenin is found 
only at the plasma membrane, being used as a marker of all the subtypes of EMT, since 
it is present in the cytoplasm or nucleus of cells that undergo EMT during several stages 
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of embryonic development, cancer and fibrosis (Zeisberg and Neilson, 2009). Wnt/-
catenin signaling has been reported as inducing EMT in mammary epithelial and 
carcinoma cancer cell lines as well as upregulating the expression of E-cadherin 
repressors Snail1 (Kim et al., 2002; Yook et al., 2006). It also promotes tumor 
invasiveness in colorectal carcinomas through the upregulation of ZEB1 expression 
(Sánchez-Tilló et al., 2011a).  
Activating mutations (e.g. inactivation of APC) on the Wnt signaling pathway occur 
frequently in human cancers, and its activation is crucial not only to the induction of 
EMT in many cancer cell types but also in the maintenance of stem cell properties of 
tumorigenic cells such as cutaneous squamous cell carcinoma stem cells or colorectal 
cancer stem cells (Reya and Clevers, 2005; Takebe and Ivy, 2010). Several studies also 
showed that inhibition of Wnt impeded the clonogenic growth of various types of cancer 
cells (Fodde and Brabletz, 2007; Kanwar et al., 2010; Ramachandran et al., 2014; 
Vermeulen et al., 2010) 
Wnt signaling in development 
Wnt signaling plays a vital role during development and in adult tissues in the regulation 
of cellular proliferation, motility, establishment of cell polarity as well as in stem cell 
maintenance, including  self-renewal of epithelial cells of the small intestine villi and 
crypts (Amerongen and Nusse, 2009; Clevers, 2006). Wnt signaling also plays important 
roles during embryonic development, as its proliferation-promoting role plays a key 
function in stem cell maintenance and in the expansion of progenitor pools. It regulates 
nearly every aspect of neural development including NSC maintenance, proliferation or 
fate determination (Ciani and Salinas, 2005; Kléber and Sommer, 2004). It is also 
involved in the spatial regulation of the dorso-ventral patterning of the developing 
neural tube. Wnt is secreted from the roof-plate together with BMPs, repressing the 
activity of Shh, which is expressed from the floor plate of the neural tube and notochord. 
In the telencephalon Wnt signaling promotes the expression of important pro-neural 
factors that promote dorsal fates such as Ngn1, Pax6 and, indirectly, Ngn2. Shh 
establishes ventral identities in the developing neural tube by opposing the dorsalizing 
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activity of the Wnt-induced Gli3 transcriptional repressor. It promotes the expression 
of the patterning homeodomain proteins Gsh1, Gsh2 and Nkx2.1, which induce the 
expression of Ascl1, Dlx1/2 and Lhx6. The dorsal determinants induced by the Wnt 
signaling repress the expression of the ventral determinants induced by Shh and vice-
versa. This mutual repression between the Shh and Wnt signaling cascades is 
responsible for the spatial specificity of neuronal differentiation with GABAergic 
neurons, including basal ganglia neurons and cortical interneurons, being specified 
ventrally by Ascl1 while glutamatergic projection neurons are specified by Ngn1/2 in 
the dorsal area of the developing telencephalon (Martynoga et al., 2012; Ulloa and Martí, 
2010). 
Wnt signaling in a glioma/GBM context 
In a glioma and GBM context, Wnt signaling plays multiple oncogenic roles. It is reported 
as being active in GBM CSCs, as necessary for stem cell maintenance and gliomagenesis, 
GBM invasion and consequently in therapeutic resistance (Lee et al., 2016).  
Interestingly, epigenetic alterations, but not genomic mutations of Wnt signaling 
components seem to have major roles in Wnt activation in gliomas and GBMs. It was 
observed that epigenetic silencing of Wnt pathway inhibitor genes, including promoter 
hypermethylation of sFRP1, sFRP2 and NKD2, occurred in more than 40% of primary 
GBM tumor samples (Roth W. et al, 2000). Wnt1 and Wnt3a are expressed in a graded 
manner in GBM tumors and in glioma stem cell lines. A selective inhibition of Wnt/-
catenin signaling through inhibition of Wnt1 and Wnt3a leads to decreased 
proliferation, migration, chemo-resistance as well as the capacity to form intra-cranial 
tumors in vivo of glioma-derived stem like cells (Kaur et al., 2013).  
Furthermore, downregulation of LEF1 led to the inhibition of U251 GBM CSCs 
migration/invasion, proliferation and self-renewal capacity. The Wnt/-catenin 
signaling, through overexpression and knockdown of -catenin, was shown to 
upregulate the expression of the EMT inducer ZEB1 in GBM CSCs, and to be 
overexpressed in the infiltrating edge of the tumor when compared to the central tumor 
parenchyma (Kahlert et al., 2012). 
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Several factors were shown to contribute to the maintenance of glioma/GBM CSC 
population through the upregulation of the Wnt signaling pathway. The zinc-finger 
transcription factor PLAGL2 was found to be amplified in primary GBM tumors and GBM 
cell lines (including GBM CSCs) and in this context it was found to maintain the self-
renewal capability of GBM cells and to restrain the differentiation of  NSCs through the 
upregulation of Wnt signaling components(Zheng et al., 2010).  
Another recent study demonstrated that FoxM1 can bind directly to -catenin and 
promote its nuclear translocation. Genetic deletion of FoxM1, or mutations that disrupt 
the FoxM1--catenin interaction prevent -catenin nuclear accumulation in glioma cells. 
Quite relevantly, high levels of FoxM1 have also been reported in GBM CSCs (Joshi et al., 
2013; Zhang et al., 2011).  
By performing a comparative analysis of the chromatin state in GBM CSCs with 
differentiated GBM cells and nonmalignant cells, Rheinbay et al (Rheinbay et al., 2013) 
identified a set of developmental transcription factors found to be deregulated in GBM 
CSCs. One such factor was the proneural bHLH factor Ascl1, which was found to activate 
Wnt signaling through the repression of Wnt negative regulator DKK1 and by this 
mechanism promote the maintenance and tumorigenicity of GBM CSCs. 
Besides the Wnt/-catenin signaling, the non-canonical Wnt signaling pathway was also 
shown to induce migration in glioma cells. Wnt5a knockdown significantly decreased 
the migratory and invasive capacity of glioma cells together with the expression of MMP-
2 while treatment with Wnt5a resulted in stimulation of cell migration and invasion 
(Kamino et al., 2011).  
Other pathways  
Yet, other pathways that play a crucial role in the regulation of EMT are also involved in 
the overall malignant phenotype of GBM.  
The Notch signaling pathway has been described as playing multiple roles during neural 
development: as an inhibitor of neuronal differentiation and sustainer of NSC 
populations during the neurogenesis phase, while promoting the astrocytic cell fate 
during gliogenesis. Notch signaling is stimulated in hypoxic conditions and by eNOS 
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signaling, and is required for the maintenance of glioma CSCs. Furthemore, it also plays 
a role as a promoter of radioresistance of GSCs (Charles et al., 2010; Qiang et al., 2012; 
Wang et al., 2010). Finally, aberrant Notch activation stimulates primary murine  
Ink4a/Arf−/− astrocytes to assume a NSC-like state accompanied by proliferation (Jeon 
et al., 2008) suggesting that it may play a role in the cells of origin of gliomas. 
The NF-B pathway is an important contributor to GBM cell survival, CSC maintenance 
and therapy resistance (Cahill et al., 2016). It was also reported as an important 
contributor to glioma and GBM invasion by inducing the expression of EMT inducer 
ZEB1. Interestingly, the Notch signaling regulator Numbl is down-regulated in glioma 
and GBM tissues, and overexpressing it in human glioma cell lines inhibited glioma 
migration and invasion by polyubiquitinating and targeting for degradation the NF-B 
pathway activator TRAF5 (Edwards et al., 2011; Holmes et al., 2012; Tao et al., 2012).  
As previously described, hypoxia also increases malignancy of GBM cells. It induces the 
expression of HIF-1, which is critical for maintenance of GBM CSCs through the 
activation of Notch signaling pathway, and for promoting invasiveness through the 
activation of EMT inducer ZEB1 (Kahlert et al., 2015; Qiang et al., 2012). Paradoxically, 
due to the oncogenic role of these pathways, overexpressing Wnt3a in GBM CSCs 
growing in hypoxic conditions induces neuronal differentiation of these cells through 
downregulation of the Notch signaling pathway (Rampazzo et al., 2013). Thus, the 
balance between all these pathways is critical to determine their tumorigenicity in GBM 
CSCs. 
The microRNA profiling study (Kim et al., 2011) which identified five clinically and 
genetically distinct subtypes of GBM samples suggested that microRNAs are also 
important determinants of GBM subtypes through their ability to regulate 
developmental growth and differentiation programs in several transformed neural 
precursor cell types. And an increasing body of evidence demonstrates that miRs have 
important and pleiotropic regulatory roles in the glioma and GBM CSC apoptotic 
pathway, differentiation, proliferation, migration/invasion and therapy resistance (Chu 
et al., 2013; González-Gómez et al., 2011; Safa et al., 2015). They play an important role 
in tumor dissemination and metastization as regulators of EMT, by acting upstream of 
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classical EMT-inducing factors (Zhang et al., 2009). For example, the miR-200 family of 
microRNAs are involved in a  double-negative feedback loop with the Zeb family of 
transcription factors triggering a Mesenchymal-to-Epithelial Transition (MET) of 
mesenchymal cells, while inhibiting the expression of stemness factors in carcinomas 
(Bracken et al., 2008; Burk et al., 2008; Wellner et al., 2009). However, very few studies 
have focused on the interaction of miRs with EMT inducing transcription factors in GBM 
(Siebzehnrubl et al., 2013).  
EMT activators in glioma and GBM 
Recently, EMT-inducing transcription factors that operate during embryonic 
development and in carcinomas have started to receive more attention in a glioma 
context.  
Twist1 is overexpressed in malignant gliomas, and increased expression accompanies 
transition from low grade to high grade gliomas in vivo (Elias et al., 2005). Its 
overexpression in a human glioma cell line significantly enhanced tumor invasiveness 
whereas its knockdown impaired GBM cells in vitro migration and invasion (Mikheeva 
et al., 2010). 
The Snail family (Snail and Slug) represents another group of transcriptional activators 
that plays a significant role in EMT and whose expression is closely associated with 
increased invasion, migration and proliferation of malignant gliomas (Han et al., 2011; 
Weissenberger et al., 2010). 
Finally, the evalution of 90 clinicopathologically characterized specimens derived from 
GBM patients showed significantly higher levels of ZEB2 in patients with early relapse 
and fast tumor progression. HIF-1upregulates ZEB2 expression, which represses 





Figure 1. 9 Signaling pathways and factors that regulate EMT.  
Figure from (Polyak and Weinberg, 2009) 
ZEB1 
The EMT-inducing transcription factor ZEB1 as recently emerged as a regulator of GBM 
malignancy (Siebzehnrubl et al., 2013). Strikingly, several of the major pathways that 
promote the invasiveness, stemness and proliferation of CSCs in malignant gliomas and 
GBMs have been shown to regulate ZEB1 expression further underlying the importance 
of studying the function of this transcription factor in this context.  
Structural properties and interacting partners of Zeb transcription factors 
ZEB1 forms, together with its closely related protein ZEB2, the ZEB family of 
transcription factors. The zinc-finger homeodomain transcription factors of this family 
have several functional domains. As other transcription factors, Zeb factors are highly 
modular proteins with independent regions mediating DNA binding, interaction with 
other sequence specific transcription factors and to cofactors – either coactivators or 
corepressors which lack the ability to bind to DNA (Fig. 10).  
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The DNA binding domains of ZEB1 and ZEB2 are composed of two zinc finger clusters 
located towards the N and C-terminal ends of the proteins (NZF and CZF respectively). 
The NZF cluster contains four Zn-fingers, while the CZF cluster contains three Zn-
fingers. There is a high degree of homology between the ZEB1 and ZEB2 NZF (88%) and 
CZF (95%) clusters. These zinc-finger clusters bind independently to a CACCTG DNA 
motif called E-box.  
In addition, these transcription factors also share a centrally located POU-like 
homeodomain (HD), which has 46% of sequence identity whereas regions outside of the 
Zn-fingers and the homeodomain are considerably less conserved (Remacle et al., 1999; 
Sánchez-Tilló et al., 2011b; Vandewalle et al., 2008; Verschueren et al., 1999). Thus, 
although being to some extent functionally redundant, ZEB1 and ZEB2 may also exhibit 
unique activities or distinct interactions with cofactors and other transcription factors 
through domains that both possess in their less conserved regions. 
A few interactions with sequence-specific TFs have been reported. Downstream of the 
NZF both ZEB1 and ZEB2 contain a Smad Interacting Domain (SID) that interacts with 
phosphorylated Smads, activated by the TGF-/BMP signaling pathways (Postigo, 2003; 
Postigo et al., 2003; Verschueren et al., 1999). Recently, ZEB1 was also reported as 
interacting with Hippo pathway effector YAP, but not its paralogue TAZ, through its N- 
and C-terminal regions (including the Zn-finger domains (Lehmann et al., 2016). 
Interestingly, TCF4 was reported as being the first transcription factor or 
coactivator/corepressor to interact with ZEB1 through its C-terminal region (aa 988-
1024), after the CZF (aa 904-981) (Sánchez-Tilló et al., 2015). Through this interaction, 
ZEB1 enhances the transcriptional activation of Wnt signaling pathway targets LAMC2 
and uPA in colorectal cancer cells with active Wnt signaling while repressing them in 
cells with inactive Wnt signaling. In addition to being important for DNA binding, the 
Zn-finger domains also mediate physical interactions with other transcription factors. 
The NZF and CZF of ZEB1 were shown to interact with SRF, while the same domains of 
ZEB2 interacted with Pc2 (Long et al., 2005; Nishimura et al., 2006). A single Zn-finger 




The transcriptional activity of the ZEB factors is mostly dictated by their interaction with 
corepressors and coactivators such as CtBP and p300, although their activity as 
transcriptional repressors has been more extensively reported. p300 has the ability to 
acetylate histones and activate transcription (Kim et al., 2005) while CtBPs interact with 
histone deacetylases and methyltransferases, polycomb proteins and coREST 
(Chinnadurai, 2009; Shi et al., 2003), blocking p300 activity as a coactivator. The activity 
of both ZEB1 and ZEB2 as transcriptional repressors relies on a CtBP interaction domain 
(CID) in-between the HD and CZF domains with multiple CtBP binding sequences 
(Furusawa et al., 1999; Postigo and Dean, 1999). ZEB1 was also shown to interact with 
NC2a/NC2b, a repressor of RNA polymerase II and III transcription, through roughly the 
same region (Ikeda et al., 1998). The N-terminal region of ZEB1 also interacts with 
corepressor BRG1, one of the two ATPases of the SWi/SNF chromatin remodeling 
complex while ZEB2 binds to the NuRD remodeling and deacetylase complex (Sánchez-
Tilló et al., 2010; Verstappen et al., 2008). Transcriptional activation has been reported 
to be associated with the ability of the N-terminal region to the NZF of ZEB1 and ZEB2 
to bind to the histone acetyl-transferases p300 and p/CAF (van Grunsven et al., 2006; 
Postigo et al., 2003). The N-terminal region of ZEB1, but not ZEB2 interacts with another 
histone acetyl-transferase, Tip60 (Hlubek et al., 2001).  
ZEB1 and ZEB2 were initially described as transcriptional repressors (Grooteclaes M.L., 
2000; Shi et al., 2003) and their capacity to act as transcriptional repressors is the most 
relevant to their activity as an EMT-inducer since repression of E-cadherin and other 
epithelial genes is crucial for triggering EMT. However, accumulating evidence indicates 
that the activity of ZEB factors as repressors or activators is strongly dependent on the 
factors that it interacts with, epigenetic context and cell type. ZEB factors repress 
transcription through competing and displacing transcriptional activators from their 
DNA binding sequences (Ponticos et al., 2004; Postigo and Dean, 1997, 1999; Postigo et 
al., 1999). Transcriptional activation involves promoter dependent recruitment of 
coactivators, and interaction with other transcription factors. ZEB1 has the capacity to 
interact with downstream effectors of different signaling pathways, assuming the role 
of transcriptional activator. Upon TGF-/BMP stimulation, ZEB1 binds to R-Smads, 
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synergizing with them in the activation of TGF-/BMP dependent genes through 
interaction with p300 and p/CAF (Postigo, 2003; Postigo et al., 2003). Its interaction 
with Hippo pathway effector also shifts ZEB1 transcriptional activity from a repressor 
to an activator in breast cancer cell lines (Lehmann et al., 2016). Several reports have 
shown that post-translational modifications of ZEB factors also contribute to the 
activator or repressor switch (van Grunsven et al., 2006; Long et al., 2005; Postigo et al., 
2003). 
 
Figure 1. 10 Schematic representation of the human Zeb family of transcription factors. 
Percentages indicate identity at the amino-acid level (Genbank accession number U12170 
and AB011141, respectively). Proteins labeled in green are coactivators, in red corepressors 
and in blue other transcription factors. Figure from (Sánchez-Tilló et al., 2011b). 
ZEB1 roles during development 
ZEB1 is an important transcriptional regulator in various developmental processes of 
tissues of mesodermal origin, such as cartilage, bone and muscle (Sánchez-Tilló et al., 
2011b; Vandewalle et al., 2008). 
In chick embryos, ZEB1 expression was initiated in the postgrastrulation period at 
embryonic stage 10 in the mesoderm: in the notochord, followed by somites, 
nephrotomes and other components. Afterwards, expression in the neural tube started 
at stage 12. Besides tissues of mesodermal origin, ZEB1 expression was observed in the 
nervous system and the lens, whereas in other tissues of ectodermal and endodermal 
origin the expression of ZEB1 remained very low (Funahashi et al., 1993). In mouse 
embryos, ZEB1 expression was first detected in the headfold and the presomitic and 
lateral plate mesoderm in embryonic day (E) 8.5 and in the derivatives of the cranial 
72 
 
neural crest and limb buds on E9.5. At E11.5, expression is detected in the neural tube, 
more prominently in the germinal layers. Dorsal root ganglia derived from the neural 
crest also expressed ZEB1. In the somites of the trunk, ZEB1 expression was confined to 
the myotome, and this expression was maintained in those cells that migrated in the 
limb.  
By generating ZEB1 null mice (which die perinatally), it was possible to determine that 
ZEB1 is necessary for skeletal patterning, since ZEB1 knock-out mice exhibit multiple 
skeletal defects including craniofacial abnormalities of neural crest origin, limb and 
sternum defects, malformed ribs and hypoplasia. In addition they also display severe T 
cell deficiency in the thymus. Strikingly, these mice exhibit skeletal defects similar to the 
phenotype of knock-out animals for TGF- gene family members (Takagi et al., 1998). 
Complex synergistic interactions between ZEB1 and ZEB2 occur during mouse 
embryogenesis (Miyoshi et al., 2006). This synergy was investigated by comparing the 
phenotype of ZEB2-/-; ZEB1-/- double homozygotes with single homozygous embryos of 
each of the factors. Unexpectedly, in ZEB2-/- embryos ZEB1 was ectopically expressed, 
suggesting a negative regulation of ZEB1 expression by ZEB2. Double homozygote 
embryos showed more severe defects in dorsal neural tube morphogenesis 
accompanied by a larger decrease of Sox2 expression than in ZEB2-/- embryos. 
ZEB1 is involved in the regulation of cell cycle and proliferation in progenitor cells, 
among other cell types. ZEB1 expression is repressed by the Rb1 tumor suppressor 
pathway, with Rb1/E2F1-HDAC1 repressor complexes regulating ZEB1 expression by 
direct binding to its promoter. Mouse embryonic fibroblasts (MEFs) from Rb1 and E2F1 
knockout mice display higher levels of ZEB1 (Liu et al., 2007). Furthermore, ZEB1 
knockout in mouse embryos is associated with decreased proliferation of progenitor 
cells, a phenotype also observed on mouse embryonic fibroblasts (MEFs) with ZEB1 
knockdown and that results in premature senescence. Circumvention of senescence by 
ZEB1 occurs independently of the INK4a pathway but rather through direct repression 
of CDK inhibitors p15 and p21 (Liu et al., 2007, 2008). 
ZEB1 is also a mediator of vascular smooth cell differentiation. Unlike striated muscle 
cells, smooth muscle cells (SMCs) are not terminally differentiated and retain some 
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plasticity to modify their phenotype in response to environmental cues. SMCs are 
derived from multiple embryonic progenitors, including regions with expression of 
ZEB1 such as lateral mesoderm, cranial mesenchyme and neural crest which suggested 
that ZEB1 plays a role in SMC biology. Indeed, ZEB1 synergizes with TGF- activated 
Smad3 and SRF in the activation of the smooth muscle differentiation marker gene SM 
-actin.  It is selectively expressed in vascular SMCs and by performing vascular injury 
experiments it was observed that ZEB1 knockdown led to much more prominent 
neointimal lesions than in wild-type animals, with severe disruption of SMC 
differentiation (Nishimura et al., 2006). 
As opposed to its activity in SMC differentiation, ZEB1 acts as a negative regulator of 
striated muscle differentiation in vitro by binding to the CACCTG subset of E-boxes in 
muscle genes promoters thus competing with MyoD, a bHLH transcription factor, for 
binding to these sites (Postigo and Dean, 1997). However, ZEB1-null mice have no 
muscle defects detectable by histological analysis or northern analysis of myogenin. 
Indeed, labeling for factors myosin and troponin, which are blocked by ZEB1 in in vitro 
studies, and ZEB1 show individual muscle fibers labeled for these factors and ZEB1. 
Therefore, ZEB1 expression does not block myogenesis in vivo, and in fact, recent results 
show that ZEB1 activity as a transcriptional repressor is important to regulate the 
temporal pattern of gene expression during muscle differentiation (Siles et al., 2013). 
There is an inverse correlation between ZEB1 expression and the differentiated 
phenotype of chondrocytes. ZEB1 is highly expressed in chick limb bud mesenchymal 
cells, but its expression is minimal in differentiated chondrocytes. Indeed, ZEB1 is a 
negative regulator of type II collagen (Col2a1) gene expression during chondrogenesis 
suggesting that ZEB1 plays a role in suppressing chondrocyte-specific genes in limb bud 
mesenchyme before the onset of chondrogenesis (Murray et al., 2000). Moreover, ZEB1 
also represses the expression of Collagen I by competing with Nkx2.5 for binding to the 
enhancer of the pro-Col1a2 gene (Ponticos et al., 2004; Terraz et al., 2001). 
In T cell development, ZEB1 also seems to play an important role since targeted 
disruption of ZEB1 in mice led to a large reduction of thymocytes (Higashi et al., 1997). 
Furthermore, ZEB1 negatively regulates expression of T-cell surface marker CD4, 
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reducing its expression in CD4 single-positive cells, but not CD4/CD8 double-positive 
cells (Brabletz et al., 1999).  
Recently, a large scale transcription factor screen overexpressing 734 transcription 
factors in 3T3-L1 cells and probing their effect on differentiation, identified ZEB1 as an 
essential regulator of adipogenesis in vivo and in vitro. By performing ChIP-seq and 
expression profiling the direct targets of ZEB1 were identified: controlling factors of the 
adipogenesis gene regulatory network that promote the development of fat cells, 
including factors that initially set an unspecialized cell on the path to becoming a fat cell 
(e.g. ZFP423, TCF7L1 and EVI1), and those that guide the changes as the cell matures 
(e.g. PPAR, KLF15) (Gubelmann et al., 2014). Indeed, both its activity as a 
transcriptional activator and repressor seem to be important for ZEB1 function in the 
adipogenic context. 
In the developing nervous sytem, the expression pattern of ZEB1 suggests a role in 
proliferating progenitor cells. Expression of ZEB1 is found in progenitor cells of the 
ventricular zone (VZ) and subventricular zone (SVZ) of the telencephalon around the 
lateral ventricles of rat, mice and human. During rat forebrain embryonic and postnatal 
development, it is expressed in this area of the VZ during E14-E16, a stage wherein 
proliferation is undergoing. During this developmental period, the ventricular zone 
expands followed by contraction by day E18 as proliferating cells differentiate and little 
expression is found in these cells that migrate to form the developing cortex (Yen et al., 
2001). These observations in rat is corroborated in mice where it is also highly 
expressed in proliferating neural progenitor cells, namely in forebrain and spinal cord 
regions (Darling et al., 2003; Funahashi et al., 1993). An additional correlation between 
a proliferative state and ZEB1 expression was also observed when induction of 
neurodifferentiation of p19 cells led to a decrease of ZEB1 expression (Yen et al., 2001). 
In the absence of ZEB1, decreased proliferation of VZ progenitors in the telencephalon 
is associated with ectopic expression of the CDK inhibitors p15 and p21, whose 
promoters were shown to be directly bound by ZEB1 (Liu et al., 2008).  
Additionally, ZEB1 seems to play a role in NSC migration. ZEB1 knockdown impaired 
migration of in vitro propagated human NSCs and moderate expression of ZEB1 was 
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observed in many of the neural progenitors deeper in the SVZ of three fetal human 
brains from the late first trimester or early second trimester besides strong expression 
of ZEB1 in VZ cells (Kahlert et al., 2015). 
ZEB1 in cancer 
ZEB1 Expression in carcinomas 
Carcinomas possess large areas that are relatively well-differentiated, with tumor cells 
maintaining their polarity and E-cadherin associated at the membrane with -catenin 
(Brabletz et al., 2005). As an inhibitor of E-cadherin and the epithelial phenotype, ZEB1 
is not expressed in well differentiated areas of carcinomas, but is expressed at high 
levels in invading tumor cells of endometrial, colorectal, lung, breast, prostate, 
gallbladder and pancreatic carcinomas among others (Sánchez-Tilló et al., 2011b). At 
their invasive front, tumor cells undergo EMT with loss of E-cadherin and nuclear 
translocation of -catenin. These cells are dedifferentiated, gain properties of stem cells 
(Mani et al., 2008) and are referred to as “migrating CSCs”.  
ZEB1 and ZEB2 expression have been linked in a multitude of reports to increased 
aggressiveness and higher metastatic capacity in a wide range of primary human 
carcinomas (Sánchez-Tilló et al., 2011b). For example, in mouse xenograft models, 
expression of ZEB1 promotes metastasis of colorectal carcinoma cells (Spaderna et al., 
2008). 
Molecular mechanisms of ZEB1 function in cancer 
Most research on ZEB1 (and to some extent also on ZEB2), is focused on their roles as 
EMT inducers in epithelial cancer cells. They mediate EMT induction by signaling 
pathways such as the TGF- pathway, NFB, Ras-ERK2 pathway, Hippo pathway, 
canonical Wnt pathway and hypoxia induced HIF-1 (Chua et al., 2006; Krishnamachary 
et al., 2006; Liu et al., 2010; Sánchez-Tilló et al., 2011a; Shin et al., 2010; Shirakihara et 
al., 2007). EMT begins with the loss of apico-basal polarity as tight junctions dissolve, 
together with the loss of other cell-cell junctions (such as adherens junctions) after the 
loss of expression of E-cadherin and epithelial integrins, thus, it was ZEB1 (as well as 
other EMT inducers) ability to act as a transcriptional repressor that is capable of 
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repressing E-cadherin - that set them as important regulators of tumor progression 
(Comijn et al., 2001; Eger et al., 2005). 
Yet, ZEB1 and ZEB2 induce a full EMT program in a carcinoma cell context by binding to 
regulatory regions and repressing not only E-cadherin expression but also several other 
epithelial genes such as P- and R-cadherins, epithelial markers involved in cell polarity 
(e.g. Crumbs3, HUGL2, PATJ), components of tight junctions (e.g. occludin, claudin 7, 
JAM1, ZO3), gap junctions (e.g. connexins 26 and 31) and desmosomes (e.g. 
desmoplakin, plakophilin 3) (Aigner et al., 2007a, 2007b; Eger et al., 2005; Vandewalle 
et al., 2005).  ZEB1 also represses components of the epithelial basement membrane 
LAMA3 and COL4A2 while upregulating LAMC2 in a colorectal carcinoma context, thus 
increasing tumor invasiveness (Spaderna et al., 2006).  
While regulating EMT and therefore invasiveness, ZEB1 has been described as a 
promoter of stemness through repression of stemness-inhibiting miRNAs of the miR-
200 family. ZEB1 and the miR-200 family of miRNAs form a double negative feedback 
loop since these RNAs also inhibit ZEB1 expression (Bracken et al., 2008; Burk et al., 
2008; Wellner et al., 2009). Owing to this feedback loop, ZEB1 and the miR-200 family 
of small RNAs induce opposite processes: ZEB1 promotes mesenchymal phenotype and 
stemness whereas miR-200 promotes differentiation and an epithelial phenotype by 
repressing ZEB1. The double-negative feedback loop regulate these processes since 
ZEB1 inhibits expression of microRNAs miR-183 and miR-203, which in turn repress 
stemness factors Sox2 and Klf4 expression. Furthermore, this double negative feedback 
loop regulates the activity of signaling pathways such as the Notch pathway with miR-
200 members targeting some of its components as Jag1 and the coactivators of the 
mastermind family Maml2 and Maml3 (Brabletz et al., 2011). The role of the 
ZEB1/miRNA-200 feedback loop in EMT has been extensively studied in the context of 
various cancer types (including prostate, colon, breast and pancreatic), since the 
activation of EMT is essential for the dissemination and invasion of epithelial-derived 
tumors (Brabletz and Brabletz, 2010). Furthermore, it was demonstrated that, in certain 
types of carcinomas, namely basal carcinomas of the breast, a non-CSC-to-CSC 
interconversion is dependent on the maintenance of the ZEB1 promoter in a bivalent 
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chromatin configuration (Mani et al., 2008). This was a follow-up to the initial study that 
demonstrated that EMT causes dedifferentiation and confers stemness to carcinoma 
cells. This enables the promoter to respond to micro-environmental signals such as 
increased TGF- signaling. In response, the ZEB1 promoter shifts from a bivalent to 
active chromatin configuration, ZEB1 transcription increases and non-CSCs 
subsequently shift to a CSC state (Chaffer et al., 2013). Basal breast carcinoma non-CSC 
cells were analyzed for tumorigenic potential, and cells with ZEB1 knockdown were 
incapable of generating tumors in vivo indicating that this interconversion is crucial for 
tumorigenicity of certain types of carcinomas. Importantly, the activity of Zeb1 in this 
process was shown to be mediated, at least in part, by repression of miR-200 targets. 
Thus, ZEB1 activity as a transcriptional repressor seems to be crucial for its activity as 
an EMT inducer in a cancer context. 
Furthermore, several reports suggest that its activity as a transcriptional activator may 
also be relevant for its function as an EMT inducer. ZEB1 (and ZEB2) induce the 
expression of mesenchymal genes such as vimentin and N-cadherin (Bindels et al., 2006; 
Liu et al., 2008; Vandewalle et al., 2005).Moreover, ZEB1 has been described as acting 
as a transcriptional activator in a carcinoma context, interacting with transcription 
factors activated by the TGF- pathway (Postigo, 2003; Postigo et al., 2003), the Hippo 
pathway (Lehmann et al., 2016) or the canonical Wnt pathway (Sánchez-Tilló et al., 
2015). Recently, ZEB1 was described as a promoter of angiogenesis by upregulating 
VEGFA expression in breast cancer cells. ZEB1 increased the recruitment of SP1 to the 
VEGFA promoter, which was mediated via the activation of PI3K and p38 pathways. 
Furthermore, its expression was positively correlated with  VEGFA and CD31 in breast 
cancer samples (Liu et al., 2016). In this regard, it seems to behave similarly to ZEB2, as 
ZEB2 overexpression led to an increase in expression of several MMPs, which are 
reported as inducers of angiogenesis (Bergers and Benjamin, 2003; Miyoshi et al., 2004).  
Thus, ZEB1 induces EMT in various cancer contexts by regulating various components 
of the program, including changes in cell adhesion properties, apical/basal polarity, and 
activation of mesenchymal genes. However, the relative importance of its activities as 
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repressor or activator in this context remains poorly understood, as well as how many 




Aims of the thesis 
Epithelial-Mesenchymal transition is a complex genetic program through which 
epithelial cells lose their apical-basal polarity and acquire the ability to invade and 
degrade the extracellular matrix. EMT and EMT-like programs are crucial during 
development, and also play a crucial role in a cancer context.   
The main aim of the current thesis was to get a better understanding of the mechanisms 
whereby the transcription factor ZEB1, a classical EMT inducer, regulates gene 
expression both in a malignant and in a developmental context. 
In the first part of this thesis, we focused on the ZEB1 function in a malignant context, 
namely in cancer stem cells of Glioblastoma Multiforme tumors. We used a genomics 
approach to characterize the transcriptional program of ZEB1, identify its target genes 
and understand how these are regulated.  The genome-wide data was combined with 
biochemical, transcriptional and gene expression analyses.  Finally, we validated and 
investigated the importance of selected ZEB1 target genes by performing correlative 
studies in GBM tumor samples. 
In the second part, we extended our studies to a neural stem cell context since ZEB1 is 
expressed in neural stem/progenitor cells in the developing brain and spinal cord. We 
performed genome-wide location analysis of ZEB1 in two distinct NSC lines to 
investigate to which extent the main mechanistic conclusions from the previous chapter, 
could also be extrapolated to a non-malignant cell context. In addition, results were used 
to identify ZEB1 target genes in mouse granule neuron progenitors (GNPs), a valuable 






Adams, J.M., and Strasser, A. (2008). Is Tumor Growth Sustained by Rare Cancer Stem 
Cells or Dominant Clones? Cancer Res. 68, 4018–4021. 
Aigner, K., Dampier, B., Descovich, L., Mikula, M., Sultan, A., Schreiber, M., Mikulits, W., 
Brabletz, T., Strand, D., Obrist, P., et al. (2007a). The transcription factor ZEB1 (deltaEF1) 
promotes tumour cell dedifferentiation by repressing master regulators of epithelial 
polarity. Oncogene 26, 6979–6988. 
Aigner, K., Descovich, L., Mikula, M., Sultan, A., Dampier, B., Bonné, S., van Roy, F., 
Mikulits, W., Schreiber, M., Brabletz, T., et al. (2007b). The transcription factor ZEB1 
(δEF1) represses Plakophilin 3 during human cancer progression. FEBS Lett. 581, 1617–
1624. 
Alcantara Llaguno, S., Chen, J., Kwon, C.-H., Jackson, E.L., Li, Y., Burns, D.K., Alvarez-
Buylla, A., and Parada, L.F. (2009). Malignant Astrocytomas Originate from Neural 
Stem/Progenitor Cells in a Somatic Tumor Suppressor Mouse Model. Cancer Cell 15, 45–
56. 
Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke, M.F. (2003). 
Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. 100, 
3983–3988. 
Amerongen, R. van, and Nusse, R. (2009). Towards an integrated view of Wnt signaling 
in development. Development 136, 3205–3214. 
Bachoo, R.M., Maher, E.A., Ligon, K.L., Sharpless, N.E., Chan, S.S., You, M.J., Tang, Y., 
DeFrances, J., Stover, E., Weissleder, R., et al. (2002). Epidermal growth factor receptor 
and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and 
transformation along the neural stem cell to astrocyte axis. Cancer Cell 1, 269–277. 
Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y., Li, Z., Hjelmeland, A.B., Shi, Q., McLendon, R.E., 
Bigner, D.D., and Rich, J.N. (2006). Stem Cell–like Glioma Cells Promote Tumor 
Angiogenesis through Vascular Endothelial Growth Factor. Cancer Res. 66, 7843–7848. 
81 
 
Beier, D., Hau, P., Proescholdt, M., Lohmeier, A., Wischhusen, J., Oefner, P.J., Aigner, L., 
Brawanski, A., Bogdahn, U., and Beier, C.P. (2007). CD133+ and CD133− Glioblastoma-
Derived Cancer Stem Cells Show Differential Growth Characteristics and Molecular 
Profiles. Cancer Res. 67, 4010–4015. 
Bergers, G., and Benjamin, L.E. (2003). Tumorigenesis and the angiogenic switch. Nat. 
Rev. Cancer 3, 401–410. 
Bieging, K.T., Mello, S.S., and Attardi, L.D. (2014). Unravelling mechanisms of p53-
mediated tumour suppression. Nat. Rev. Cancer 14, 359–370. 
Bindels, S., Mestdagt, M., Vandewalle, C., Jacobs, N., Volders, L., Noël, A., Roy, F. van, Berx, 
G., Foidart, J.-M., and Gilles, C. (2006). Regulation of vimentin by SIP1 in human epithelial 
breast tumor cells. Oncogene 25, 4975–4985. 
Bonnet, D., and Dick, J.E. (1997). Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737. 
Bourguignon, L.Y.W., Peyrollier, K., Xia, W., and Gilad, E. (2008). Hyaluronan-CD44 
Interaction Activates Stem Cell Marker Nanog, Stat-3-mediated MDR1 Gene Expression, 
and Ankyrin-regulated Multidrug Efflux in Breast and Ovarian Tumor Cells. J. Biol. Chem. 
283, 17635–17651. 
Brabletz, S., and Brabletz, T. (2010). The ZEB/miR-200 feedback loop—a motor of 
cellular plasticity in development and cancer? EMBO Rep. 11, 670–677. 
Brabletz, T., Jung, A., Hlubek, F., Löhberg, C., Meiler, J., Suchy, U., and Kirchner, T. (1999). 
Negative regulation of CD4 expression in T cells by the transcriptional repressor ZEB. 
Int. Immunol. 11, 1701–1708. 
Brabletz, T., Jung, A., Spaderna, S., Hlubek, F., and Kirchner, T. (2005). Migrating cancer 
stem cells — an integrated concept of malignant tumour progression. Nat. Rev. Cancer 
5, 744–749. 
Bracken, C.P., Gregory, P.A., Kolesnikoff, N., Bert, A.G., Wang, J., Shannon, M.F., and 
Goodall, G.J. (2008). A Double-Negative Feedback Loop between ZEB1-SIP1 and the 
82 
 
microRNA-200 Family Regulates Epithelial-Mesenchymal Transition. Cancer Res. 68, 
7846–7854. 
Bradshaw, A., Wickremsekera, A., Tan, S.T., Peng, L., Davis, P.F., and Itinteang, T. (2016). 
Cancer Stem Cell Hierarchy in Glioblastoma Multiforme. Front. Surg. 3, 21. 
Brat, D.J., and Van Meir, E.G. (2004). Vaso-occlusive and prothrombotic mechanisms 
associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab. 
Invest. 84, 397–405. 
Brat, D.J., Castellano-Sanchez, A.A., Hunter, S.B., Pecot, M., Cohen, C., Hammond, E.H., 
Devi, S.N., Kaur, B., and Meir, E.G.V. (2004). Pseudopalisades in Glioblastoma Are 
Hypoxic, Express Extracellular Matrix Proteases, and Are Formed by an Actively 
Migrating Cell Population. Cancer Res. 64, 920–927. 
Brescia, P., Ortensi, B., Fornasari, L., Levi, D., Broggi, G., and Pelicci, G. (2013). CD133 Is 
Essential for Glioblastoma Stem Cell Maintenance. STEM CELLS 31, 857–869. 
Bruna, A., Darken, R.S., Rojo, F., Ocaña, A., Peñuelas, S., Arias, A., Paris, R., Tortosa, A., 
Mora, J., Baselga, J., et al. (2007). High TGFβ-Smad Activity Confers Poor Prognosis in 
Glioma Patients and Promotes Cell Proliferation Depending on the Methylation of the 
PDGF-B Gene. Cancer Cell 11, 147–160. 
Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., and Brabletz, 
T. (2008). A reciprocal repression between ZEB1 and members of the miR‐200 family 
promotes EMT and invasion in cancer cells. EMBO Rep. 9, 582–589. 
Cahill, K.E., Morshed, R.A., and Yamini, B. (2016). Nuclear factor-κB in glioblastoma: 
insights into regulators and targeted therapy. Neuro-Oncol. 18, 329–339. 
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T.L., Fuller, C., Hamner, B., Oh, E.Y., Gaber, 
M.W., Finklestein, D., Allen, M., et al. (2007). A Perivascular Niche for Brain Tumor Stem 
Cells. Cancer Cell 11, 69–82. 
Campos, B., Wan, F., Farhadi, M., Ernst, A., Zeppernick, F., Tagscherer, K.E., Ahmadi, R., 
Lohr, J., Dictus, C., Gdynia, G., et al. (2010). Differentiation therapy exerts antitumor 
83 
 
effects on stem-like glioma cells. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 16, 2715–
2728. 
Canazza, A., Calatozzolo, C., Fumagalli, L., Bergantin, A., Ghielmetti, F., Fariselli, L., Croci, 
D., Salmaggi, A., and Ciusani, E. (2011). Increased migration of a human glioma cell line 
after in vitro CyberKnife irradiation. Cancer Biol. Ther. 12, 629–633. 
Chaffer, C.L., Marjanovic, N.D., Lee, T., Bell, G., Kleer, C.G., Reinhardt, F., D’Alessio, A.C., 
Young, R.A., and Weinberg, R.A. (2013). Poised Chromatin at the ZEB1 Promoter Enables 
Breast Cancer Cell Plasticity and Enhances Tumorigenicity. Cell 154, 61–74. 
Chakravarti, A., Loeffler, J.S., and Dyson, N.J. (2002). Insulin-like growth factor receptor 
I mediates resistance to anti-epidermal growth factor receptor therapy in primary 
human glioblastoma cells through continued activation of phosphoinositide 3-kinase 
signaling. Cancer Res. 62, 200–207. 
Charles, N., Ozawa, T., Squatrito, M., Bleau, A.-M., Brennan, C.W., Hambardzumyan, D., 
and Holland, E.C. (2010). Perivascular Nitric Oxide Activates Notch Signaling and 
Promotes Stem-like Character in PDGF-Induced Glioma Cells. Cell Stem Cell 6, 141–152. 
Chen, J., McKay, R.M., and Parada, L.F. (2012). Malignant Glioma: Lessons from Genomics, 
Mouse Models, and Stem Cells. Cell 149, 36–47. 
Chinnadurai, G. (2009). The Transcriptional Corepressor CtBP: A Foe of Multiple Tumor 
Suppressors. Cancer Res. 69, 731–734. 
Choi, P.S., Zakhary, L., Choi, W.-Y., Caron, S., Alvarez-Saavedra, E., Miska, E.A., McManus, 
M., Harfe, B., Giraldez, A.J., Horvitz, R.H., et al. (2008). Members of the miRNA-200 Family 
Regulate Olfactory Neurogenesis. Neuron 57, 41–55. 
Chow, L.M.L., Zhang, J., and Baker, S.J. (2008). Inducible Cre recombinase activity in 
mouse mature astrocytes and adult neural precursor cells. Transgenic Res. 17, 919–928. 
Chow, L.M.L., Endersby, R., Zhu, X., Rankin, S., Qu, C., Zhang, J., Broniscer, A., Ellison, D.W., 
and Baker, S.J. (2011). Cooperativity within and among Pten, p53, and Rb Pathways 
Induces High-Grade Astrocytoma in Adult Brain. Cancer Cell 19, 305–316. 
84 
 
Christensen, K., Schrøder, H.D., and Kristensen, B.W. (2008). CD133 identifies 
perivascular niches in grade II–IV astrocytomas. J. Neurooncol. 90, 157. 
Chu, P.-M., Ma, H.-I., Chen, L.-H., Chen, M.-T., Huang, P.-I., Lin, S.-Z., and Chiou, S.-H. 
(2013). Deregulated MicroRNAs Identified in Isolated Glioblastoma Stem Cells: An 
Overview. Cell Transplant. 22, 741–753. 
Ciani, L., and Salinas, P.C. (2005). WNTS in the vertebrate nervous system: from 
patterning to neuronal connectivity. Nat. Rev. Neurosci. 6, 351–362. 
Clarke, L., and van der Kooy, D. (2009). Low Oxygen Enhances Primitive and Definitive 
Neural Stem Cell Colony Formation by Inhibiting Distinct Cell Death Pathways. STEM 
CELLS 27, 1879–1886. 
Clevers, H. (2006). Wnt/β-Catenin Signaling in Development and Disease. Cell 127, 469–
480. 
Comijn, J., Berx, G., Vermassen, P., Verschueren, K., van Grunsven, L., Bruyneel, E., Mareel, 
M., Huylebroeck, D., and van Roy, F. (2001). The Two-Handed E Box Binding Zinc Finger 
Protein SIP1 Downregulates E-Cadherin and Induces Invasion. Mol. Cell 7, 1267–1278. 
Darling, D.S., Stearman, R.P., Qi, Y., Qiu, M.-S., and Feller, J.P. (2003). Expression of 
Zfhep/δEF1 protein in palate, neural progenitors, and differentiated neurons. Gene 
Expr. Patterns GEP 3, 709–717. 
Depner, C., zum Buttel, H., Böğürcü, N., Cuesta, A.M., Aburto, M.R., Seidel, S., Finkelmeier, 
F., Foss, F., Hofmann, J., Kaulich, K., et al. (2016). EphrinB2 repression through ZEB2 
mediates tumour invasion and anti-angiogenic resistance. Nat. Commun. 7, 12329. 
Doetsch, F., Caillé, I., Lim, D.A., García-Verdugo, J.M., and Alvarez-Buylla, A. (1999). 
Subventricular Zone Astrocytes Are Neural Stem Cells in the Adult Mammalian Brain. 
Cell 97, 703–716. 
Ebos, J.M.L., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G., and Kerbel, R.S. 
(2009). Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of 
Tumor Angiogenesis. Cancer Cell 15, 232–239. 
85 
 
Edwards, L.A., Woolard, K., Son, M.J., Li, A., Lee, J., Ene, C., Mantey, S.A., Maric, D., Song, H., 
Belova, G., et al. (2011). Effect of Brain- and Tumor-Derived Connective Tissue Growth 
Factor on Glioma Invasion. J. Natl. Cancer Inst. 103, 1162–1178. 
Eger, A., Aigner, K., Sonderegger, S., Dampier, B., Oehler, S., Schreiber, M., Berx, G., Cano, 
A., Beug, H., and Foisner, R. (2005). DeltaEF1 is a transcriptional repressor of E-cadherin 
and regulates epithelial plasticity in breast cancer cells. Oncogene 24, 2375–2385. 
Eibl, R.H., Pietsch, T., Moll, J., Skroch-Angel, P., Heider, K.-H., Ammon, K. von, Wiestler, 
O.D., Ponta, H., Kleihues, P., and Herrlich, P. (1995). Expression of variant CD44 epitopes 
in human astrocytic brain tumors. J. Neurooncol. 26, 165–170. 
Ekstrand, A.J., Sugawa, N., James, C.D., and Collins, V.P. (1992). Amplified and rearranged 
epidermal growth factor receptor genes in human glioblastomas reveal deletions of 
sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. U. S. 
A. 89, 4309–4313. 
Elias, M.C., Tozer, K.R., Silber, J.R., Mikheeva, S., Deng, M., Morrison, R.S., Manning, T.C., 
Silbergeld, D.L., Glackin, C.A., Reh, T.A., et al. (2005). TWIST is Expressed in Human 
Gliomas and Promotes Invasion. Neoplasia N. Y. N 7, 824–837. 
F H Gage, J Ray, and Fisher,  and L.J. (1995). Isolation, Characterization, and use of Stem 
Cells from the CNS. Annu. Rev. Neurosci. 18, 159–192. 
Fodde, R., and Brabletz, T. (2007). Wnt/β-catenin signaling in cancer stemness and 
malignant behavior. Curr. Opin. Cell Biol. 19, 150–158. 
Folkins, C., Shaked, Y., Man, S., Tang, T., Lee, C.R., Zhu, Z., Hoffman, R.M., and Kerbel, R.S. 
(2009). Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and 
Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1. 
Cancer Res. 69, 7243–7251. 
Frederick, L., Wang, X.-Y., Eley, G., and James, C.D. (2000). Diversity and Frequency of 




Frederiksen, K., and McKay, R.D. (1988). Proliferation and differentiation of rat 
neuroepithelial precursor cells in vivo. J. Neurosci. 8, 1144–1151. 
Freije, W.A., Castro-Vargas, F.E., Fang, Z., Horvath, S., Cloughesy, T., Liau, L.M., Mischel, 
P.S., and Nelson, S.F. (2004). Gene Expression Profiling of Gliomas Strongly Predicts 
Survival. Cancer Res. 64, 6503–6510. 
Frosina, G. (2009). DNA repair and resistance of gliomas to chemotherapy and 
radiotherapy. Mol. Cancer Res. MCR 7, 989–999. 
Funahashi, J., Sekido, R., Murai, K., Kamachi, Y., and Kondoh, H. (1993). Delta-crystallin 
enhancer binding protein delta EF1 is a zinc finger-homeodomain protein implicated in 
postgastrulation embryogenesis. Development 119, 433–446. 
Furnari, F.B., Fenton, T., Bachoo, R.M., Mukasa, A., Stommel, J.M., Stegh, A., Hahn, W.C., 
Ligon, K.L., Louis, D.N., Brennan, C., et al. (2007). Malignant astrocytic glioma: genetics, 
biology, and paths to treatment. Genes Dev. 21, 2683–2710. 
Furusawa, T., Moribe, H., Kondoh, H., and Higashi, Y. (1999). Identification of CtBP1 and 
CtBP2 as Corepressors of Zinc Finger-Homeodomain Factor δEF1. Mol. Cell. Biol. 19, 
8581–8590. 
Gallia, G.L., Rand, V., Siu, I.-M., Eberhart, C.G., James, C.D., Marie, S.K.N., Oba-Shinjo, S.M., 
Carlotti, C.G., Caballero, O.L., Simpson, A.J.G., et al. (2006). PIK3CA Gene Mutations in 
Pediatric and Adult Glioblastoma Multiforme. Am. Assoc. Cancer Res. 4, 709–714. 
Gao, C.-F., Xie, Q., Su, Y.-L., Koeman, J., Khoo, S.K., Gustafson, M., Knudsen, B.S., Hay, R., 
Shinomiya, N., and Woude, G.F.V. (2005). Proliferation and invasion: Plasticity in tumor 
cells. Proc. Natl. Acad. Sci. U. S. A. 102, 10528–10533. 
Geisbrecht, B.V., and Gould, S.J. (1999). The Human PICD Gene Encodes a Cytoplasmic 
and Peroxisomal NADP+-dependent Isocitrate Dehydrogenase. J. Biol. Chem. 274, 
30527–30533. 
Goffart, N., Kroonen, J., and Rogister, B. (2013). Glioblastoma-Initiating Cells: 
Relationship with Neural Stem Cells and the Micro-Environment. Cancers 5, 1049–1071. 
87 
 
González-Gómez, P., Sánchez, P., and Mira, H. (2011). MicroRNAs as Regulators of Neural 
Stem Cell-Related Pathways in Glioblastoma Multiforme. Mol. Neurobiol. 44, 235–249. 
Gravendeel, L.A.M., Kouwenhoven, M.C.M., Gevaert, O., de Rooi, J.J., Stubbs, A.P., Duijm, 
J.E., Daemen, A., Bleeker, F.E., Bralten, L.B.C., Kloosterhof, N.K., et al. (2009). Intrinsic 
gene expression profiles of gliomas are a better predictor of survival than histology. 
Cancer Res. 69, 9065–9072. 
Groot, J.F. de, Fuller, G., Kumar, A.J., Piao, Y., Eterovic, K., Ji, Y., and Conrad, C.A. (2010). 
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and 
pathologic correlation in humans and mice. Neuro-Oncol. 12, 233–242. 
Grooteclaes M.L. (2000). Evidence for a function of CtBP in epithelial gene regulation 
and anoikis. Publ. Online 28 July 2000 Doi101038sjonc1203721 19. 
van Grunsven, L.A., Taelman, V., Michiels, C., Opdecamp, K., Huylebroeck, D., and 
Bellefroid, E.J. (2006). δEF1 and SIP1 are differentially expressed and have overlapping 
activities during Xenopus embryogenesis. Dev. Dyn. 235, 1491–1500. 
Gubelmann, C., Schwalie, P.C., Raghav, S.K., Röder, E., Delessa, T., Kiehlmann, E., Waszak, 
S.M., Corsinotti, A., Udin, G., Holcombe, W., et al. (2014). Identification of the 
transcription factor ZEB1 as a central component of the adipogenic gene regulatory 
network. eLife 3, e03346. 
Guo, Y., Liu, S., Wang, P., Zhao, S., Wang, F., Bing, L., Zhang, Y., Ling, E.-A., Gao, J., and Hao, 
A. (2011). Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and 
Nanog in human gliomas. Histopathology 59, 763–775. 
H. J. Scherer (1940). Cerebral Astrocytomas and Their Derivatives. 40, 159–198. 
Han, J., Alvarez-Breckenridge, C.A., Wang, Q.-E., and Yu, J. (2015). TGF-β signaling and its 
targeting for glioma treatment. Am. J. Cancer Res. 5, 945–955. 
Han, S.-P., Kim, J.-H., Han, M.-E., Sim, H.-E., Kim, K.-S., Yoon, S., Baek, S.-Y., Kim, B.-S., and 
Oh, S.-O. (2011). SNAI1 is Involved in the Proliferation and Migration of Glioblastoma 
Cells. Cell. Mol. Neurobiol. 31, 489–496. 
88 
 
Hatanpaa, K.J., Hu, T., Vemireddy, V., Foong, C., Raisanen, J.M., Oliver, D., Hiemenz, M.C., 
Burns, D.K., White, C.L., Whitworth, L.A., et al. (2014). High expression of the stem cell 
marker nestin is an adverse prognostic factor in WHO grade II–III astrocytomas and 
oligoastrocytomas. J. Neurooncol. 117, 183–189. 
He, J., Zhang, W., Zhou, Q., Zhao, T., Song, Y., Chai, L., and Li, Y. (2013). Low-expression of 
microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4. Int. J. 
Biochem. Cell Biol. 45, 1962–1973. 
Heldin, C.-H., Östman, A., Eriksson, A., Siegbahn, A., Claesson-Welsh, L., and Westermark, 
B. (1992). Platelet-derived growth factor: Isoform-specific signalling via heterodimeric 
or homodimeric receptor complexes. Kidney Int. 41, 571–574. 
Herms, J.W., von Loewenich, F.D., Behnke, J., Markakis, E., and Kretzschmar, H.A. (1999). 
c-myc oncogene family expression in glioblastoma and survival. Surg. Neurol. 51, 536–
542. 
Higashi, Y., Moribe, H., Takagi, T., Sekido, R., Kawakami, K., Kikutani, H., and Kondoh, H. 
(1997). Impairment of  T Cell Development in δEF1 Mutant Mice. J. Exp. Med. 185, 1467–
1480. 
Hlubek, F., Löhberg, C., Meiler, J., Jung, A., Kirchner, T., and Brabletz, T. (2001). Tip60 Is 
a Cell-Type-Specific Transcriptional Regulator. J. Biochem. (Tokyo) 129, 635–641. 
Holderfield, M.T., and Hughes, C.C.W. (2008). Crosstalk Between Vascular Endothelial 
Growth Factor, Notch, and Transforming Growth Factor-β in Vascular Morphogenesis. 
Circ. Res. 102, 637–652. 
Holmes, K.M., Annala, M., Chua, C.Y.X., Dunlap, S.M., Liu, Y., Hugen, N., Moore, L.M., 
Cogdell, D., Hu, L., Nykter, M., et al. (2012). Insulin-like growth factor-binding protein 2-
driven glioma progression is prevented by blocking a clinically significant integrin, 
integrin-linked kinase, and NF-κB network. Proc. Natl. Acad. Sci. 109, 3475–3480. 
89 
 
Hou, L.C., Veeravagu, A., Hsu, A.R., and Tse, V.C.K. (2006). Recurrent glioblastoma 
multiforme: a review of natural history and management options. Neurosurg. Focus 20, 
E3. 
Iglesia, N. de la, Konopka, G., Puram, S.V., Chan, J.A., Bachoo, R.M., You, M.J., Levy, D.E., 
DePinho, R.A., and Bonni, A. (2008a). Identification of a PTEN-regulated STAT3 brain 
tumor suppressor pathway. Genes Dev. 22, 449–462. 
Iglesia, N. de la, Konopka, G., Lim, K.-L., Nutt, C.L., Bromberg, J.F., Frank, D.A., Mischel, 
P.S., Louis, D.N., and Bonni, A. (2008b). Deregulation of a STAT3–Interleukin 8 Signaling 
Pathway Promotes Human Glioblastoma Cell Proliferation and Invasiveness. J. Neurosci. 
28, 5870–5878. 
Ignatova, T.N., Kukekov, V.G., Laywell, E.D., Suslov, O.N., Vrionis, F.D., and Steindler, D.A. 
(2002). Human cortical glial tumors contain neural stem-like cells expressing astroglial 
and neuronal markers in vitro. Glia 39, 193–206. 
Ikeda, K., Halle, J.-P., Stelzer, G., Meisterernst, M., and Kawakami, K. (1998). Involvement 
of Negative Cofactor NC2 in Active Repression by Zinc Finger-Homeodomain 
Transcription Factor AREB6. Mol. Cell. Biol. 18, 10–18. 
Ikushima, H., Todo, T., Ino, Y., Takahashi, M., Miyazawa, K., and Miyazono, K. (2009). 
Autocrine TGF-β Signaling Maintains Tumorigenicity of Glioma-Initiating Cells through 
Sry-Related HMG-Box Factors. Cell Stem Cell 5, 504–514. 
Jacques, T.S., Swales, A., Brzozowski, M.J., Henriquez, N.V., Linehan, J.M., Mirzadeh, Z., 
Malley, C.O., Naumann, H., Alvarez‐Buylla, A., and Brandner, S. (2010). Combinations of 
genetic mutations in the adult neural stem cell compartment determine brain tumour 
phenotypes. EMBO J. 29, 222–235. 
Jeon, H.-M., Jin, X., Lee, J.-S., Oh, S.-Y., Sohn, Y.-W., Park, H.-J., Joo, K.M., Park, W.-Y., Nam, 
D.-H., DePinho, R.A., et al. (2008). Inhibitor of differentiation 4 drives brain tumor-
initiating cell genesis through cyclin E and notch signaling. Genes Dev. 22, 2028–2033. 
90 
 
Joseph, J.V., Balasubramaniyan, V., Walenkamp, A., and Kruyt, F.A.E. (2013). TGF-β as a 
therapeutic target in high grade gliomas – Promises and challenges. Biochem. 
Pharmacol. 85, 478–485. 
Joseph, J.V., Conroy, S., Tomar, T., Eggens-Meijer, E., Bhat, K., Copray, S., Walenkamp, 
A.M.E., Boddeke, E., Balasubramanyian, V., Wagemakers, M., et al. (2014a). TGF-β is an 
inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is 
associated with tumor invasion. Cell Death Dis. 5, e1443. 
Joseph, J.V., Conroy, S., Tomar, T., Eggens-Meijer, E., Bhat, K., Copray, S., Walenkamp, 
A.M.E., Boddeke, E., Balasubramanyian, V., Wagemakers, M., et al. (2014b). TGF-β is an 
inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is 
associated with tumor invasion. Cell Death Dis. 5, e1443. 
Joshi, K., Banasavadi-Siddegowda, Y., Mo, X., Kim, S.-H., Mao, P., Kig, C., Nardini, D., Sobol, 
R.W., Chow, L.M.L., Kornblum, H.I., et al. (2013). MELK-Dependent FOXM1 
Phosphorylation is Essential for Proliferation of Glioma Stem Cells. STEM CELLS 31, 
1051–1063. 
Kaaijk, P., Troost, D., Morsink, F., Keehnen, R.M.J., Leenstra, S., Bosch, D.A., and Pals, S.T. 
(1995). Expression of CD44 splice variants in human primary brain tumors. J. 
Neurooncol. 26, 185–190. 
Kahlert, U.D., Maciaczyk, D., Doostkam, S., Orr, B.A., Simons, B., Bogiel, T., Reithmeier, T., 
Prinz, M., Schubert, J., Niedermann, G., et al. (2012). Activation of canonical WNT/β-
catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 
and other activators of epithelial-to-mesenchymal transition. Cancer Lett. 325, 42–53. 
Kahlert, U.D., Suwala, A.K., Raabe, E.H., Siebzehnrubl, F.A., Suarez, M.J., Orr, B.A., Bar, E.E., 
Maciaczyk, J., and Eberhart, C.G. (2015). ZEB1 Promotes Invasion in Human Fetal Neural 
Stem Cells and Hypoxic Glioma Neurospheres. Brain Pathol. 25, 724–732. 
Kalluri, R., and Weinberg, R.A. (2009). The basics of epithelial-mesenchymal transition. 
J. Clin. Invest. 119, 1420–1428. 
91 
 
Kamino, M., Kishida, M., Kibe, T., Ikoma, K., Iijima, M., Hirano, H., Tokudome, M., Chen, L., 
Koriyama, C., Yamada, K., et al. (2011). Wnt-5a signaling is correlated with infiltrative 
activity in human glioma by inducing cellular migration and MMP-2. Cancer Sci. 102, 
540–548. 
Kanwar, S.S., Yu, Y., Nautiyal, J., Patel, B.B., and Majumdar, A.P. (2010). The Wnt/β-
catenin pathway regulates growth and maintenance of colonospheres. Mol. Cancer 9, 
212. 
Kaur, N., Chettiar, S., Rathod, S., Rath, P., Muzumdar, D., Shaikh, M.L., and Shiras, A. 
(2013). Wnt3a mediated activation of Wnt/β-catenin signaling promotes tumor 
progression in glioblastoma. Mol. Cell. Neurosci. 54, 44–57. 
Kim, J.-H., Cho, E.-J., Kim, S.-T., and Youn, H.-D. (2005). CtBP represses p300-mediated 
transcriptional activation by direct association with its bromodomain. Nat. Struct. Mol. 
Biol. 12, 423–428. 
Kim, K., Lu, Z., and Hay, E.D. (2002). Direct evidence for a role of beta-catenin/LEF-1 
signaling pathway in induction of EMT. Cell Biol. Int. 26, 463–476. 
Kim, S.Y., Lee, S.M., Tak, J.K., Choi, K.S., Kwon, T.K., and Park, J.-W. (2007). Regulation of 
singlet oxygen-induced apoptosis by cytosolic NADP+. Mol. Cell. Biochem. 302, 27–34. 
Kim, T.-M., Huang, W., Park, R., Park, P.J., and Johnson, M.D. (2011). A Developmental 
Taxonomy of Glioblastoma Defined and Maintained by MicroRNAs. Cancer Res. 71, 
3387–3399. 
Kléber, M., and Sommer, L. (2004). Wnt signaling and the regulation of stem cell 
function. Curr. Opin. Cell Biol. 16, 681–687. 
Kleihues, P., and Ohgaki, H. (1999). Primary and secondary glioblastomas: from concept 
to clinical diagnosis. Neuro-Oncol. 1, 44–51. 
Knobbe, C.B., and Reifenberger, G. (2003). Genetic Alterations and Aberrant Expression 
of Genes Related to the Phosphatidyl-lnositol-3′-Kinase/Protein Kinase B (Akt) Signal 
Transduction Pathway in Glioblastomas. Brain Pathol. 13, 507–518. 
92 
 
Koul, D., Parthasarathy, R., Shen, R., Davies, M.A., Jasser, S.A., Chintala, S.K., Rao, J.S., Sun, 
Y., Benvenisite, E.N., Liu, T.-J., et al. (2001). Suppression of matrix metalloproteinase-2 
gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 20. 
Kubiatowski, T., Jang, T., Lachyankar, M.B., Salmonsen, R., Nabi, R.R., Quesenberry, P.J., 
Litofsky, N.S., Ross, A.H., and Recht, L.D. (2001). Association of increased 
phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase 
activity in malignant gliomas. J. Neurosurg. 95, 480–488. 
Lamouille, S., Xu, J., and Derynck, R. (2014). Molecular mechanisms of epithelial–
mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178–196. 
Lathia, J.D., Mack, S.C., Mulkearns-Hubert, E.E., Valentim, C.L.L., and Rich, J.N. (2015). 
Cancer stem cells in glioblastoma. Genes Dev. 29, 1203–1217. 
Laywell, E.D., Rakic, P., Kukekov, V.G., Holland, E.C., and Steindler, D.A. (2000). 
Identification of a multipotent astrocytic stem cell in the  immature and adult mouse 
brain. Proc. Natl. Acad. Sci. U. S. A. 97, 13883–13888. 
Lee, D.Y., Gianino, S.M., and Gutmann, D.H. (2012). Innate Neural Stem Cell 
Heterogeneity Determines the Patterning of Glioma Formation in Children. Cancer Cell 
22, 131–138. 
Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N.M., Pastorino, S., Purow, B.W., 
Christopher, N., Zhang, W., et al. (2006a). Tumor stem cells derived from glioblastomas 
cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary 
tumors than do serum-cultured cell lines. Cancer Cell 9, 391–403. 
Lee, J.C., Vivanco, I., Beroukhim, R., Huang, J.H.Y., Feng, W.L., DeBiasi, R.M., Yoshimoto, K., 
King, J.C., Nghiemphu, P., Yuza, Y., et al. (2006b). Epidermal Growth Factor Receptor 
Activation in Glioblastoma through Novel Missense Mutations in the Extracellular 
Domain. PLOS Med 3, e485. 
93 
 
Lee, S.M., Koh, H.-J., Park, D.-C., Song, B.J., Huh, T.-L., and Park, J.-W. (2002). Cytosolic 
NADP+-dependent isocitrate dehydrogenase status modulates oxidative damage to 
cells. Free Radic. Biol. Med. 32, 1185–1196. 
Lee, W.S., Woo, E.Y., Kwon, J., Park, M.-J., Lee, J.-S., Han, Y.-H., and Bae, I.H. (2013). Bcl-w 
Enhances Mesenchymal Changes and Invasiveness of Glioblastoma Cells by Inducing 
Nuclear Accumulation of β-Catenin. PLOS ONE 8, e68030. 
Lee, Y., Lee, J.-K., Ahn, S.H., Lee, J., and Nam, D.-H. (2016). WNT signaling in glioblastoma 
and therapeutic opportunities. Lab. Invest. 96, 137–150. 
Lehmann, W., Mossmann, D., Kleemann, J., Mock, K., Meisinger, C., Brummer, T., Herr, R., 
Brabletz, S., Stemmler, M.P., and Brabletz, T. (2016). ZEB1 turns into a transcriptional 
activator by interacting with YAP1 in aggressive cancer types. Nat. Commun. 7, 10498. 
Lemmon, M.A., and Schlessinger, J. (2010). Cell Signaling by Receptor Tyrosine Kinases. 
Cell 141, 1117–1134. 
Li, A., Walling, J., Kotliarov, Y., Center, A., Steed, M.E., Ahn, S.J., Rosenblum, M., Mikkelsen, 
T., Zenklusen, J.C., and Fine, H.A. (2008). Genomic Changes and Gene Expression Profiles 
Reveal That Established Glioma Cell Lines Are Poorly Representative of Primary Human 
Gliomas. Am. Assoc. Cancer Res. 6, 21–30. 
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., 
McLendon, R.E., et al. (2009). Hypoxia-Inducible Factors Regulate Tumorigenic Capacity 
of Glioma Stem Cells. Cancer Cell 15, 501–513. 
Lino, M.M., and Merlo, A. (2011). PI3Kinase signaling in glioblastoma. J. Neurooncol. 103, 
417–427. 
Liu, C., Sage, J.C., Miller, M.R., Verhaak, R.G.W., Hippenmeyer, S., Vogel, H., Foreman, O., 
Bronson, R.T., Nishiyama, A., Luo, L., et al. (2011). Mosaic Analysis with Double Markers 
Reveals Tumor Cell of Origin in Glioma. Cell 146, 209–221. 
94 
 
Liu, L., Tong, Q., Liu, S., Cui, J., Zhang, Q., Sun, W., and Yang, S. (2016). ZEB1 Upregulates 
VEGF Expression and Stimulates Angiogenesis in Breast Cancer. PLOS ONE 11, 
e0148774. 
Liu, Y., Costantino, M.E., Montoya-Durango, D., Higashi, Y., Darling, D.S., and Dean, D.C. 
(2007). The zinc finger transcription factor ZFHX1A is linked to cell proliferation by Rb–
E2F1. Biochem. J. 408, 79–85. 
Liu, Y., El-Naggar, S., Darling, D.S., Higashi, Y., and Dean, D.C. (2008). ZEB1 Links 
Epithelial-Mesenchymal Transition and Cellular Senescence. Dev. Camb. Engl. 135, 579–
588. 
Long, J., Zuo, D., and Park, M. (2005). Pc2-mediated Sumoylation of Smad-interacting 
Protein 1 Attenuates Transcriptional Repression of E-cadherin. J. Biol. Chem. 280, 
35477–35489. 
Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., Scheithauer, 
B.W., and Kleihues, P. (2007). The 2007 WHO Classification of Tumours of the Central 
Nervous System. Acta Neuropathol. (Berl.) 114, 97–109. 
Luskin, M.B. (1993). Restricted proliferation and migration of postnatally generated 
neurons derived from the forebrain subventricular zone. Neuron 11, 173–189. 
Maire, C.L., and Ligon, K.L. (2011). Glioma Models: New GEMMs Add “Class” with 
Genomic and Expression Correlations. Cancer Cell 19, 295–297. 
Mani, S.A., Guo, W., Liao, M.-J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, 
F., Zhang, C.C., Shipitsin, M., et al. (2008). The Epithelial-Mesenchymal Transition 
Generates Cells with Properties of Stem Cells. Cell 133, 704–715. 
Mao, P., Joshi, K., Li, J., Kim, S.-H., Li, P., Santana-Santos, L., Luthra, S., Chandran, U.R., 
Benos, P.V., Smith, L., et al. (2013). Mesenchymal glioma stem cells are maintained by 
activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc. Natl. 
Acad. Sci. 110, 8644–8649. 
95 
 
Martynoga, B., Drechsel, D., and Guillemot, F. (2012). Molecular control of neurogenesis: 
a view from the mammalian cerebral cortex. Cold Spring Harb. Perspect. Biol. 4. 
Massagué, J. (2008). TGFβ in Cancer. Cell 134, 215–230. 
Matsuzaki, K. (2011). Smad phosphoisoform signaling specificity: the right place at the 
right time. Carcinogenesis 32, 1578–1588. 
McLendon, R., Friedman, A., Bigner, D., Meir, E.G.V., Brat, D.J., Mastrogianakis, G.M., Olson, 
J.J., Mikkelsen, T., Lehman, N., Aldape, K., et al. (2008). Comprehensive genomic 
characterization defines human glioblastoma genes and core pathways. Nature 455, 
1061–1068. 
Micalizzi, D.S., Farabaugh, S.M., and Ford, H.L. (2010). Epithelial-Mesenchymal 
Transition in Cancer: Parallels Between Normal Development and Tumor Progression. 
J. Mammary Gland Biol. Neoplasia 15, 117–134. 
Michaelidis, T.M., and Lie, D.C. (2007). Wnt signaling and neural stem cells: caught in the 
Wnt web. Cell Tissue Res. 331, 193–210. 
Mikheeva, S.A., Mikheev, A.M., Petit, A., Beyer, R., Oxford, R.G., Khorasani, L., Maxwell, J.-
P., Glackin, C.A., Wakimoto, H., González-Herrero, I., et al. (2010). TWIST1 promotes 
invasion through mesenchymal change in human glioblastoma. Mol. Cancer 9, 194. 
Miyoshi, A., Kitajima, Y., Sumi, K., Sato, K., Hagiwara, A., Koga, Y., and Miyazaki, K. (2004). 
Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular 
carcinoma cells. Br. J. Cancer 90, 1265–1273. 
Miyoshi, T., Maruhashi, M., Van De Putte, T., Kondoh, H., Huylebroeck, D., and Higashi, Y. 
(2006). Complementary expression pattern of Zfhx1 genes Sip1 and deltaEF1 in the 
mouse embryo and their genetic interaction revealed by compound mutants. Dev. Dyn. 
Off. Publ. Am. Assoc. Anat. 235, 1941–1952. 
Murray, D., Precht, P., Balakir, R., and Horton, W.E. (2000). The Transcription Factor 
δEF1 Is Inversely Expressed with Type II Collagen mRNA and Can Repress Col2a1 
Promoter Activity in Transfected Chondrocytes. J. Biol. Chem. 275, 3610–3618. 
96 
 
Nakamura, M., Yang, F., Fujisawa, H., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (2000). 
Loss of Heterozygosity on Chromosome 19 in Secondary Glioblastomas. J. Neuropathol. 
Exp. Neurol. 59, 539–543. 
Nishimura, G., Manabe, I., Tsushima, K., Fujiu, K., Oishi, Y., Imai, Y., Maemura, K., 
Miyagishi, M., Higashi, Y., Kondoh, H., et al. (2006). δEF1 Mediates TGF-β Signaling in 
Vascular Smooth Muscle Cell Differentiation. Dev. Cell 11, 93–104. 
Niu, C. (2013). MiR-134 regulates the proliferation and invasion of glioblastoma cells by 
reducing Nanog expression. Int. J. Oncol. 
Nobusawa, S., Watanabe, T., Kleihues, P., and Ohgaki, H. (2009). IDH1 Mutations as 
Molecular Signature and Predictive Factor of Secondary Glioblastomas. Clin. Cancer Res. 
15, 6002–6007. 
Noushmehr, H., Weisenberger, D.J., Diefes, K., Phillips, H.S., Pujara, K., Berman, B.P., Pan, 
F., Pelloski, C.E., Sulman, E.P., Bhat, K.P., et al. (2010). Identification of a CpG Island 
Methylator Phenotype that Defines a Distinct Subgroup of Glioma. Cancer Cell 17, 510–
522. 
Ogden, A.T., Waziri, A.E., Lochhead, R.A., Fusco, D., Lopez, K., Ellis, J.A., Kang, J., Assanah, 
M., McKhann, G.M., Sisti, M.B., et al. (2008). Identification of A2B5+CD133- tumor-
initiating cells in adult human gliomas. Neurosurgery 62, 505–515. 
Ohgaki, H., and Kleihues, P. (2005). Population-Based Studies on Incidence, Survival 
Rates, and Genetic Alterations in Astrocytic and Oligodendroglial Gliomas. J. 
Neuropathol. Exp. Neurol. 64, 479–489. 
Ohgaki, H., and Kleihues, P. (2007). Genetic pathways to primary and secondary 
glioblastoma. Am. J. Pathol. 170, 1445–1453. 
Ohgaki, H., and Kleihues, P. (2013). The Definition of Primary and Secondary 
Glioblastoma. Clin. Cancer Res. 19, 764–772. 
97 
 
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, 
C., Schüler, D., Probst-Hensch, N.M., Maiorka, P.C., et al. (2004). Genetic pathways to 
glioblastoma: a population-based study. Cancer Res. 64, 6892–6899. 
Ostrom, Q.T., Bauchet, L., Davis, F.G., Deltour, I., Fisher, J.L., Langer, C.E., Pekmezci, M., 
Schwartzbaum, J.A., Turner, M.C., Walsh, K.M., et al. (2014). The epidemiology of glioma 
in adults: a “state of the science” review. Neuro-Oncol. 16, 896–913. 
Ostrom, Q.T., Gittleman, H., Fulop, J., Liu, M., Blanda, R., Kromer, C., Wolinsky, Y., Kruchko, 
C., and Barnholtz-Sloan, J.S. (2015). CBTRUS Statistical Report: Primary Brain and 
Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro-
Oncol. 17, iv1-iv62. 
Parsons, D.W., Jones, S., Zhang, X., Lin, J.C.-H., Leary, R.J., Angenendt, P., Mankoo, P., 
Carter, H., Siu, I.-M., Gallia, G.L., et al. (2008). An integrated genomic analysis of human 
glioblastoma multiforme. Science 321, 1807–1812. 
Pastrana, E., Silva-Vargas, V., and Doetsch, F. (2011). Eyes Wide Open: A Critical Review 
of Sphere-Formation as an Assay for Stem Cells. Cell Stem Cell 8, 486–498. 
Paw, I., Carpenter, R.C., Watabe, K., Debinski, W., and Lo, H.-W. (2015). Mechanisms 
Regulating Glioma Invasion. Cancer Lett. 362, 1–7. 
Pen, A., Moreno, M.J., Durocher, Y., Deb-Rinker, P., and Stanimirovic, D.B. (2008). 
Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-
dependent TGF-β signaling. Oncogene 27, 6834–6844. 
Pepper, M.S. (1997). Transforming growth factor-beta: Vasculogenesis, angiogenesis, 
and vessel wall integrity. Cytokine Growth Factor Rev. 8, 21–43. 
Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D., Misra, A., 
Nigro, J.M., Colman, H., Soroceanu, L., et al. (2006). Molecular subclasses of high-grade 
glioma predict prognosis, delineate a pattern of disease progression, and resemble 
stages in neurogenesis. Cancer Cell 9, 157–173. 
98 
 
Piccirillo, S.G.M., Reynolds, B.A., Zanetti, N., Lamorte, G., Binda, E., Broggi, G., Brem, H., 
Olivi, A., Dimeco, F., and Vescovi, A.L. (2006). Bone morphogenetic proteins inhibit the 
tumorigenic potential of human brain tumour-initiating cells. Nature 444, 761–765. 
Platten, M., Wick, W., and Weller, M. (2001). Malignant glioma biology: role for TGF-beta 
in growth, motility, angiogenesis, and immune escape. Microsc. Res. Tech. 52, 401–410. 
Pollard, S.M., Yoshikawa, K., Clarke, I.D., Danovi, D., Stricker, S., Russell, R., Bayani, J., 
Head, R., Lee, M., Bernstein, M., et al. (2009). Glioma stem cell lines expanded in adherent 
culture have tumor-specific phenotypes and are suitable for chemical and genetic 
screens. Cell Stem Cell 4, 568–580. 
Ponticos, M., Partridge, T., Black, C.M., Abraham, D.J., and Bou-Gharios, G. (2004). 
Regulation of Collagen Type I in Vascular Smooth Muscle Cells by Competition between 
Nkx2.5 and δEF1/ZEB1. Mol. Cell. Biol. 24, 6151–6161. 
Postigo, A.A. (2003). Opposing functions of ZEB proteins in the regulation of the 
TGFbeta/BMP signaling pathway. EMBO J. 22, 2443–2452. 
Postigo, A.A., and Dean, D.C. (1997). ZEB, a vertebrate homolog of Drosophila Zfh‐1, is a 
negative regulator of muscle differentiation. EMBO J. 16, 3935–3943. 
Postigo, A.A., and Dean, D.C. (1999). ZEB represses transcription through interaction 
with the corepressor CtBP. Proc. Natl. Acad. Sci. U. S. A. 96, 6683–6688. 
Postigo, A.A., Ward, E., Skeath, J.B., and Dean, D.C. (1999). zfh-1, the Drosophila 
Homologue of ZEB, Is a Transcriptional Repressor That Regulates Somatic Myogenesis. 
Mol. Cell. Biol. 19, 7255–7263. 
Postigo, A.A., Depp, J.L., Taylor, J.J., and Kroll, K.L. (2003). Regulation of Smad signaling 
through a differential recruitment of coactivators and corepressors by ZEB proteins. 
EMBO J. 22, 2453–2462. 
Prince, M.E., Sivanandan, R., Kaczorowski, A., Wolf, G.T., Kaplan, M.J., Dalerba, P., 
Weissman, I.L., Clarke, M.F., and Ailles, L.E. (2007). Identification of a subpopulation of 
99 
 
cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. 
Natl. Acad. Sci. 104, 973–978. 
Qi, S., Song, Y., Peng, Y., Wang, H., Long, H., Yu, X., Li, Z., Fang, L., Wu, A., Luo, W., et al. 
(2012). ZEB2 Mediates Multiple Pathways Regulating Cell Proliferation, Migration, 
Invasion, and Apoptosis in Glioma. PLOS ONE 7, e38842. 
Qiang, L., Wu, T., Zhang, H.-W., Lu, N., Hu, R., Wang, Y.-J., Zhao, L., Chen, F.-H., Wang, X.-T., 
You, Q.-D., et al. (2012). HIF-1α is critical for hypoxia-mediated maintenance of 
glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ. 19, 
284–294. 
Rahaman SO (2002). Inhibition of constitutively active Stat3 suppresses proliferation 
and induces apoptosis in glioblastoma multiforme cells. Publ. Online 04 Dec. 2002 
Doi101038sjonc1206047 21. 
Ramachandran, I., Ganapathy, V., Gillies, E., Fonseca, I., Sureban, S.M., Houchen, C.W., 
Reis, A., and Queimado, L. (2014). Wnt inhibitory factor 1 suppresses cancer stemness 
and induces cellular senescence. Cell Death Dis. 5, e1246. 
Rampazzo, E., Persano, L., Pistollato, F., Moro, E., Frasson, C., Porazzi, P., Della Puppa, A., 
Bresolin, S., Battilana, G., Indraccolo, S., et al. (2013). Wnt activation promotes neuronal 
differentiation of Glioblastoma. Cell Death Dis. 4, e500. 
Remacle, J.E., Kraft, H., Lerchner, W., Wuytens, G., Collart, C., Verschueren, K., Smith, J.C., 
and Huylebroeck, D. (1999). New mode of DNA binding of multi-zinc finger transcription 
factors: deltaEF1 family members bind with two hands to two target sites. EMBO J. 18, 
5073–5084. 
Reya, T., and Clevers, H. (2005). Wnt signalling in stem cells and cancer. Nature 434, 
843–850. 
Reynolds, B.A., Tetzlaff, W., and Weiss, S. (1992). A multipotent EGF-responsive striatal 
embryonic progenitor cell produces neurons and astrocytes. J. Neurosci. 12, 4565–4574. 
100 
 
Rheinbay, E., Suvà, M.L., Gillespie, S.M., Wakimoto, H., Patel, A.P., Shahid, M., Oksuz, O., 
Rabkin, S.D., Martuza, R.L., Rivera, M.N., et al. (2013). An Aberrant Transcription Factor 
Network Essential for Wnt Signaling and Stem Cell Maintenance in Glioblastoma. Cell 
Rep. 3, 1567–1579. 
Ricci-Vitiani, L., Pallini, R., Larocca, L.M., Lombardi, D.G., Signore, M., Pierconti, F., 
Petrucci, G., Montano, N., Maira, G., and De Maria, R. (2008). Mesenchymal differentiation 
of glioblastoma stem cells. Cell Death Differ. 15, 1491–1498. 
Roth W. et al (2000). Secreted Frizzled-related proteins inhibit motility and promote 
growth of human malignant glioma cells. Publ. Online 31 August 2000 
Doi101038sjonc1203783 19. 
Safa, A.R., Saadatzadeh, M.R., Cohen-Gadol, A.A., Pollok, K.E., and Bijangi-Vishehsaraei, K. 
(2015). Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion 
between differentiated non-GSCs and GSCs. Genes Dis. 2, 152–163. 
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., 
Powell, S.M., Riggins, G.J., et al. (2004). High Frequency of Mutations of the PIK3CA Gene 
in Human Cancers. Science 304, 554–554. 
Sánchez-Tilló, E., Lázaro, A., Torrent, R., Cuatrecasas, M., Vaquero, E.C., Castells, A., Engel, 
P., and Postigo, A. (2010). ZEB1 represses E-cadherin and induces an EMT by recruiting 
the SWI/SNF chromatin-remodeling protein BRG1. Oncogene 29, 3490–3500. 
Sánchez-Tilló, E., de Barrios, O., Siles, L., Cuatrecasas, M., Castells, A., and Postigo, A. 
(2011a). β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition 
(EMT)-activator ZEB1 to regulate tumor invasiveness. Proc. Natl. Acad. Sci. U. S. A. 108, 
19204–19209. 
Sánchez-Tilló, E., Siles, L., de Barrios, O., Cuatrecasas, M., Vaquero, E.C., Castells, A., and 
Postigo, A. (2011b). Expanding roles of ZEB factors in tumorigenesis and tumor 
progression. Am. J. Cancer Res. 1, 897–912. 
101 
 
Sánchez-Tilló, E., de Barrios, O., Valls, E., Darling, D.S., Castells, A., and Postigo, A. (2015). 
ZEB1 and TCF4 reciprocally modulate their transcriptional activities to regulate Wnt 
target gene expression. Oncogene 34, 5760–5770. 
Schlessinger, J. (2000). Cell Signaling by Receptor Tyrosine Kinases. Cell 103, 211–225. 
Schmalhofer, O., Brabletz, S., and Brabletz, T. (2009). E-cadherin, beta-catenin, and ZEB1 
in malignant progression of cancer. Cancer Metastasis Rev. 28, 151–166. 
Seymour, T., Nowak, A., and Kakulas, F. (2015). Targeting Aggressive Cancer Stem Cells 
in Glioblastoma. Front. Oncol. 5, 159. 
Shen, Q., Goderie, S.K., Jin, L., Karanth, N., Sun, Y., Abramova, N., Vincent, P., Pumiglia, K., 
and Temple, S. (2004). Endothelial Cells Stimulate Self-Renewal and Expand 
Neurogenesis of Neural Stem Cells. Science 304, 1338–1340. 
Sherry, M.M., Reeves, A., Wu, J.K., and Cochran, B.H. (2009). STAT3 Is Required for 
Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells. STEM CELLS 
27, 2383–2392. 
Shi, Y., Sawada, J., Sui, G., Affar, E.B., Whetstine, J.R., Lan, F., Ogawa, H., Po-Shan Luke, M., 
Nakatani, Y., and Shi, Y. (2003). Coordinated histone modifications mediated by a CtBP 
co-repressor complex. Nature 422, 735–738. 
Shirakihara, T., Saitoh, M., and Miyazono, K. (2007). Differential Regulation of Epithelial 
and Mesenchymal Markers by δEF1 Proteins in Epithelial–Mesenchymal Transition 
Induced by TGF-β. Mol. Biol. Cell 18, 3533–3544. 
Shmelkov, S.V., Butler, J.M., Hooper, A.T., Hormigo, A., Kushner, J., Milde, T., St. Clair, R., 
Baljevic, M., White, I., Jin, D.K., et al. (2008). CD133 expression is not restricted to stem 
cells, and both CD133+ and CD133– metastatic colon cancer cells initiate tumors. J. Clin. 
Invest. 
Siebzehnrubl, F.A., Jeske, I., Müller, D., Buslei, R., Coras, R., Hahnen, E., Huttner, H.B., 
Corbeil, D., Kaesbauer, J., Appl, T., et al. (2009). Spontaneous In Vitro Transformation of 
Adult Neural Precursors into Stem-Like Cancer Cells. Brain Pathol. 19, 399–408. 
102 
 
Siebzehnrubl, F.A., Silver, D.J., Tugertimur, B., Deleyrolle, L.P., Siebzehnrubl, D., Sarkisian, 
M.R., Devers, K.G., Yachnis, A.T., Kupper, M.D., Neal, D., et al. (2013). The ZEB1 pathway 
links glioblastoma initiation, invasion and chemoresistance. EMBO Mol. Med. 5, 1196–
1212. 
Siles, L., Sánchez-Tilló, E., Lim, J.-W., Darling, D.S., Kroll, K.L., and Postigo, A. (2013). ZEB1 
Imposes a Temporary Stage-Dependent Inhibition of Muscle Gene Expression and 
Differentiation via CtBP-Mediated Transcriptional Repression. Mol. Cell. Biol. 33, 1368–
1382. 
Singh, S.K., Clarke, I.D., Terasaki, M., Bonn, V.E., Hawkins, C., Squire, J., and Dirks, P.B. 
(2003). Identification of a Cancer Stem Cell in Human Brain Tumors. Cancer Res. 63, 
5821–5828. 
Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M., 
Cusimano, M.D., and Dirks, P.B. (2004). Identification of human brain tumour initiating 
cells. Nature 432, 396–401. 
Smith, G.E., and Darling, D.S. (2003). Combination of a Zinc Finger and Homeodomain 
Required for Protein-Interaction. Mol. Biol. Rep. 30, 199–206. 
Son, M.J., Woolard, K., Nam, D.-H., Lee, J., and Fine, H.A. (2009). SSEA-1 Is an Enrichment 
Marker for Tumor-Initiating Cells in Human Glioblastoma. Cell Stem Cell 4, 440–452. 
Sottoriva, A., Spiteri, I., Piccirillo, S.G.M., Touloumis, A., Collins, V.P., Marioni, J.C., Curtis, 
C., Watts, C., and Tavaré, S. (2013). Intratumor heterogeneity in human glioblastoma 
reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. 110, 4009–4014. 
Spaderna, S., Schmalhofer, O., Hlubek, F., Berx, G., Eger, A., Merkel, S., Jung, A., Kirchner, 
T., and Brabletz, T. (2006). A Transient, EMT-Linked Loss of Basement Membranes 




Spaderna, S., Schmalhofer, O., Wahlbuhl, M., Dimmler, A., Bauer, K., Sultan, A., Hlubek, F., 
Jung, A., Strand, D., Eger, A., et al. (2008). The Transcriptional Repressor ZEB1 Promotes 
Metastasis and Loss of Cell Polarity in Cancer. Cancer Res. 68, 537–544. 
Staberg, M., Villingshøj, M., Stockhausen, M., and Poulsen, H. (2014). P01.20epigenetic 
Treatment and Induction of Differentiation in Glioblastoma Multiforme Neurosphere 
Cells Leads to Downregulation of Egfr, Egfrviii and Nestin Together with Reduced 
Colony Formation in Vitro. Neuro-Oncol. 16, ii31-ii31. 
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O’Meara, 
S., Smith, R., Parker, A., et al. (2004). Lung cancer: Intragenic ERBB2 kinase mutations in 
tumours. Nature 431, 525–526. 
Stieber, D., Golebiewska, A., Evers, L., Lenkiewicz, E., Brons, N.H.C., Nicot, N., Oudin, A., 
Bougnaud, S., Hertel, F., Bjerkvig, R., et al. (2013). Glioblastomas are composed of 
genetically divergent clones with distinct tumourigenic potential and variable stem cell-
associated phenotypes. Acta Neuropathol. (Berl.) 127, 203–219. 
Stiles, C.D., and Rowitch, D.H. (2008). Glioma Stem Cells: A Midterm Exam. Neuron 58, 
832–846. 
Stupp, R., Hegi, M.E., Mason, W.P., van den Bent, M.J., Taphoorn, M.J.B., Janzer, R.C., 
Ludwin, S.K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009). Effects of radiotherapy 
with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in 
glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. 
Lancet Oncol. 10, 459–466. 
Sugawa, N., Ekstrand, A.J., James, C.D., and Collins, V.P. (1990). Identical splicing of 
aberrant epidermal growth factor receptor transcripts from amplified rearranged genes 
in human glioblastomas. Proc. Natl. Acad. Sci. U. S. A. 87, 8602–8606. 
Takagi, T., Moribe, H., Kondoh, H., and Higashi, Y. (1998). DeltaEF1, a zinc finger and 
homeodomain transcription factor, is required for skeleton patterning in multiple 
lineages. Dev. Camb. Engl. 125, 21–31. 
104 
 
Takahashi, K., and Yamanaka, S. (2006). Induction of Pluripotent Stem Cells from Mouse 
Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell 126, 663–676. 
Takebe, N., and Ivy, S.P. (2010). Controversies in Cancer Stem Cells: Targeting 
Embryonic Signaling Pathways. Am. Assoc. Cancer Res. 16, 3106–3112. 
Tamura, K., Aoyagi, M., Ando, N., Ogishima, T., Wakimoto, H., Yamamoto, M., and Ohno, 
K. (2013). Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas 
after radiotherapy and chemotherapy. J. Neurosurg. 119, 1145–1155. 
Tao, T., Cheng, C., Ji, Y., Xu, G., Zhang, J., Zhang, L., and Shen, A. (2012). Numbl inhibits 
glioma cell migration and invasion by suppressing TRAF5-mediated NF-κB activation. 
Mol. Biol. Cell 23, 2635–2644. 
Terraz, C., Toman, D., Delauche, M., Ronco, P., and Rossert, J. (2001). δEF1 Binds to a Far 
Upstream Sequence of the Mouse Pro-α1(I) Collagen Gene and Represses Its Expression 
in Osteoblasts. J. Biol. Chem. 276, 37011–37019. 
Thuault, S., Valcourt, U., Petersen, M., Manfioletti, G., Heldin, C.-H., and Moustakas, A. 
(2006). Transforming growth factor-beta employs HMGA2 to elicit epithelial-
mesenchymal transition. J. Cell Biol. 174, 175–183. 
Tomaso, E. di, Snuderl, M., Kamoun, W.S., Duda, D.G., Auluck, P.K., Fazlollahi, L., 
Andronesi, O.C., Frosch, M.P., Wen, P.Y., Plotkin, S.R., et al. (2011). Glioblastoma 
Recurrence after Cediranib Therapy in Patients: Lack of “Rebound” Revascularization as 
Mode of Escape. Cancer Res. 71, 19–28. 
Ueki, N., Nakazato, M., Ohkawa, T., Ikeda, T., Amuro, Y., Hada, T., and Higashino, K. (1992). 
Excessive production of transforming growth-factor beta 1 can play an important role 
in the development of tumorigenesis by its action for angiogenesis: validity of 
neutralizing antibodies to block tumor growth. Biochim. Biophys. Acta 1137, 189–196. 
Uhrbom, L., Kastemar, M., Johansson, F.K., Westermark, B., and Holland, E.C. (2005). Cell 
Type-Specific Tumor Suppression by Ink4a and Arf in Kras-Induced Mouse 
Gliomagenesis. Cancer Res. 65, 2065–2069. 
105 
 
Ulasov, I., Yi, R., Guo, D., Sarvaiya, P., and Cobbs, C. (2014). The emerging role of MMP14 
in brain tumorigenesis and future therapeutics. Biochim. Biophys. Acta BBA - Rev. 
Cancer 1846, 113–120. 
Ulloa, F., and Martí, E. (2010). Wnt won the war: Antagonistic role of Wnt over Shh 
controls dorso-ventral patterning of the vertebrate neural tube. Dev. Dyn. 239, 69–76. 
Vandewalle, C., Comijn, J., De Craene, B., Vermassen, P., Bruyneel, E., Andersen, H., 
Tulchinsky, E., Van Roy, F., and Berx, G. (2005). SIP1/ZEB2 induces EMT by repressing 
genes of different epithelial cell–cell junctions. Nucleic Acids Res. 33, 6566–6578. 
Vandewalle, C., Roy, F.V., and Berx, G. (2008). The role of the ZEB family of transcription 
factors in development and disease. Cell. Mol. Life Sci. 66, 773–787. 
Verhaak, R.G.W., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., 
Ding, L., Golub, T., Mesirov, J.P., et al. (2010). Integrated Genomic Analysis Identifies 
Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in 
PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98–110. 
Vermeulen, L., Melo, F.D.S.E., van der Heijden, M., Cameron, K., de Jong, J.H., Borovski, T., 
Tuynman, J.B., Todaro, M., Merz, C., Rodermond, H., et al. (2010). Wnt activity defines 
colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 
468–476. 
Verschueren, K., Remacle, J.E., Collart, C., Kraft, H., Baker, B.S., Tylzanowski, P., Nelles, L., 
Wuytens, G., Su, M.-T., Bodmer, R., et al. (1999). SIP1, a Novel Zinc Finger/Homeodomain 
Repressor, Interacts with Smad Proteins and Binds to 5′-CACCT Sequences in Candidate 
Target Genes. J. Biol. Chem. 274, 20489–20498. 
Verstappen, G., Grunsven, L.A. van, Michiels, C., Putte, T.V. de, Souopgui, J., Damme, J.V., 
Bellefroid, E., Vandekerckhove, J., and Huylebroeck, D. (2008). Atypical Mowat–Wilson 
patient confirms the importance of the novel association between ZFHX1B/SIP1 and 
NuRD corepressor complex. Hum. Mol. Genet. 17, 1175–1183. 
106 
 
Vogelstein, B., Lane, D., and Levine, A.J. (2000). Surfing the p53 network. Nature 408, 
307–310. 
Wang, J., Sakariassen, P.Ø., Tsinkalovsky, O., Immervoll, H., Bøe, S.O., Svendsen, A., 
Prestegarden, L., Røsland, G., Thorsen, F., Stuhr, L., et al. (2008a). CD133 negative glioma 
cells form tumors in nude rats and give rise to CD133 positive cells. Int. J. Cancer 122, 
761–768. 
Wang, J., Wang, H., Li, Z., Wu, Q., Lathia, J.D., McLendon, R.E., Hjelmeland, A.B., and Rich, 
J.N. (2008b). c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells. PLOS ONE 
3, e3769. 
Wang, J., Wakeman, T.P., Latha, J.D., Hjelmeland, A.B., Wang, X.-F., White, R.R., Rich, J.N., 
and Sullenger, B.A. (2010). Notch Promotes Radioresistance of Glioma Stem Cells. Stem 
Cells Dayt. Ohio 28, 17–28. 
Watanabe, K., Sato, K., Biernat, W., Tachibana, O., Ammon, K. von, Ogata, N., Yonekawa, 
Y., Kleihues, P., and Ohgaki, H. (1997). Incidence and timing of p53 mutations during 
astrocytoma progression in patients with multiple biopsies. Am. Assoc. Cancer Res. 3, 
523–530. 
Watanabe, T., Nobusawa, S., Kleihues, P., and Ohgaki, H. (2009). IDH1 Mutations Are 
Early Events in the Development of Astrocytomas and Oligodendrogliomas. Am. J. 
Pathol. 174, 1149–1153. 
Weissenberger, J., Priester, M., Bernreuther, C., Rakel, S., Glatzel, M., Seifert, V., and Kögel, 
D. (2010). Dietary Curcumin Attenuates Glioma Growth in a Syngeneic Mouse Model by 
Inhibition of the JAK1,2/STAT3 Signaling Pathway. Am. Assoc. Cancer Res. 16, 5781–
5795. 
Wellner, U., Schubert, J., Burk, U.C., Schmalhofer, O., Zhu, F., Sonntag, A., Waldvogel, B., 
Vannier, C., Darling, D., zur Hausen, A., et al. (2009). The EMT-activator ZEB1 promotes 




Westhoff, M.-A., Karpel-Massler, G., Brühl, O., Enzenmüller, S., La Ferla-Brühl, K., Siegelin, 
M.D., Nonnenmacher, L., and Debatin, K.-M. (2014). A critical evaluation of PI3K 
inhibition in Glioblastoma and Neuroblastoma therapy. Mol. Cell. Ther. 2, 32. 
Wick, W., Platten, M., and Weller, M. (2001). Glioma Cell Invasion: Regulation of 
Metalloproteinase Activity by TGF-β. J. Neurooncol. 53, 177–185. 
Wu, M.Y., and Hill, C.S. (2009). TGF-β Superfamily Signaling in Embryonic Development 
and Homeostasis. Dev. Cell 16, 329–343. 
Xie, Q., Mittal, S., and Berens, M.E. (2014). Targeting adaptive glioblastoma: an overview 
of proliferation and invasion. Neuro-Oncol. 16, 1575–1584. 
Xu, X., Zhao, J., Xu, Z., Peng, B., Huang, Q., Arnold, E., and Ding, J. (2004). Structures of 
Human Cytosolic NADP-dependent Isocitrate Dehydrogenase Reveal a Novel Self-
regulatory Mechanism of Activity. J. Biol. Chem. 279, 33946–33957. 
Xu, Y., Tamamaki, N., Noda, T., Kimura, K., Itokazu, Y., Matsumoto, N., Dezawa, M., and 
Ide, C. (2005). Neurogenesis in the ependymal layer of the adult rat 3rd ventricle. Exp. 
Neurol. 192, 251–264. 
Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos, I., Batinic-
Haberle, I., Jones, S., Riggins, G.J., et al. (2009). IDH1 and IDH2 Mutations in Gliomas. N. 
Engl. J. Med. 360, 765–773. 
Yen, G., Croci, A., Dowling, A., Zhang, S., Zoeller, R.T., and Darling, D.S. (2001). 
Developmental and functional evidence of a role for Zfhep in neural cell development. 
Brain Res. Mol. Brain Res. 96, 59–67. 
Yin, A.H., Miraglia, S., Zanjani, E.D., Almeida-Porada, G., Ogawa, M., Leary, A.G., Olweus, J., 
Kearney, J., and Buck, D.W. (1997). AC133, a Novel Marker for Human Hematopoietic 
Stem and Progenitor Cells. Blood 90, 5002–5012. 
Yook, J.I., Li, X.-Y., Ota, I., Hu, C., Kim, H.S., Kim, N.H., Cha, S.Y., Ryu, J.K., Choi, Y.J., Kim, J., 
et al. (2006). A Wnt–Axin2–GSK3β cascade regulates Snail1 activity in breast cancer 
cells. Nat. Cell Biol. 8, 1398–1406. 
108 
 
Yuan, T.L., and Cantley, L.C. (2008). PI3K pathway alterations in cancer: variations on a 
theme. Oncogene 27, 5497–5510. 
Zbinden, M., Duquet, A., Lorente-Trigos, A., Ngwabyt, S.-N., Borges, I., and Ruiz i Altaba, 
A. (2010). NANOG regulates glioma stem cells and is essential in vivo acting in a cross-
functional network with GLI1 and p53. EMBO J. 29, 2659–2674. 
Zeisberg, M., and Neilson, E.G. (2009). Biomarkers for epithelial-mesenchymal 
transitions. J. Clin. Invest. 119, 1429–1437. 
Zhang, H., Li, Y., and Lai, M. (2009). The microRNA network and tumor metastasis. 
Oncogene 29, 937–948. 
Zhang, L., Yan, Y., Jiang, Y., Cui, Y., Zou, Y., Qian, J., Luo, C., Lu, Y., and Wu, X. (2014). The 
expression of SALL4 in patients with gliomas: high level of SALL4 expression is 
correlated with poor outcome. J. Neurooncol. 121, 261–268. 
Zhang, M., Song, T., Yang, L., Chen, R., Wu, L., Yang, Z., and Fang, J. (2008). Nestin and 
CD133: valuable stem cell-specific markers for determining clinical outcome of glioma 
patients. J. Exp. Clin. Cancer Res. 27, 85. 
Zhang, N., Wei, P., Gong, A., Chiu, W.-T., Lee, H.-T., Colman, H., Huang, H., Xue, J., Liu, M., 
Wang, Y., et al. (2011). FoxM1 Promotes β-Catenin Nuclear Localization and Controls 
Wnt Target-Gene Expression and Glioma Tumorigenesis. Cancer Cell 20, 427–442. 
Zhao, C., Deng, W., and Gage, F.H. (2008). Mechanisms and Functional Implications of 
Adult Neurogenesis. Cell 132, 645–660. 
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. 
(2009). Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity 
and Induce HIF-1α. Science 324, 261–265. 
Zheng, H., Ying, H., Yan, H., Kimmelman, A.C., Hiller, D.J., Chen, A.-J., Perry, S.R., Tonon, G., 
Chu, G.C., Ding, Z., et al. (2008a). p53 and Pten control neural and glioma 
stem/progenitor cell renewal and differentiation. Nature 455, 1129–1133. 
109 
 
Zheng, H., Ying, H., Yan, H., Kimmelman, A.C., Hiller, D.J., Chen, A.-J., Perry, S.R., Tonon, G., 
Chu, G.C., Ding, Z., et al. (2008b). Pten and p53 converge on c-Myc to control 
differentiation, self-renewal, and transformation of normal and neoplastic stem cells in 
glioblastoma. Cold Spring Harb. Symp. Quant. Biol. 73, 427–437. 
Zheng, H., Ying, H., Wiedemeyer, R., Yan, H., Quayle, S.N., Ivanova, E.V., Paik, J.-H., Zhang, 
H., Xiao, Y., Perry, S.R., et al. (2010). PLAGL2 Regulates Wnt Signaling to Impede 
Differentiation in Neural Stem Cells and Gliomas. Cancer Cell 17, 497–509. 
Zhu, Y., Guignard, F., Zhao, D., Liu, L., Burns, D.K., Mason, R.P., Messing, A., and Parada, 
L.F. (2005). Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss 






ZEB1 potentiates gene transcription 
genome-wide in glioblastoma cancer stem 









GBM is the most prevalent and lethal type of brain and CNS tumor. Tumor recurrence 
after surgical resection and radiation invariably occurs, regardless of aggressive 
chemotherapy. GBM tumor harbor a CSC population crucial for driving tumor growth 
and relapse, due to their potential to proliferate and infiltrate the surrounding brain 
tissue. 
Here, we investigated the function of the zinc-finger transcription factor ZEB1, a 
classical EMT inducer highly expressed in glioma and GBM, previously implicated in 
invasion, chemoresistance and tumorigenesis in GBM by characterizing its 
transcriptional program in GBM CSCs. Although ZEB1 has been widely viewed as a 
transcriptional repressor in a carcinoma context due to its capacity to trigger EMT by 
repressing expression of epithelial genes, we found that genome-wide binding of ZEB1 
associates with both gene repression and activation, resulting from two distinct modes 
of recruitment to regulatory regions.  Transcriptional repression requires direct ZEB1 
binding to its consensus sites, while indirect recruitment by the downstream effector of 
the Wnt pathway LEF1 results in gene activation, in the absence of active Wnt signaling.  
Notably, genes activated by ZEB1 include predicted mediators of tumor cell migration 
and invasion, including the guanine nucleotide exchange factor Prex1.  We found Prex1 
and ZEB1 expression strongly correlate in tumor samples, with high levels of Prex1 
resulting in low patient survival, suggesting an important role for the novel ZEB1/LEF1 





There are several contributors to the poor responsiveness of GBM tumours to treatment, 
including their high inter- and intratumoral heterogeneity and the existence of CSC 
subpopulations within tumors. 
GBM tumors have enormous phenotypic, cellular, genetic and epigenetic heterogeneity 
and multiple studies have focused on categorizing them in a histology independent 
system predictive of survival and response to treatment. The different subtypes of GBM 
were classified according to distinct gene expression signatures, microRNA expression 
signatures or by promoter DNA methylation (Freije et al., 2004; Kim et al., 2011; 
Noushmehr et al., 2010; Phillips et al., 2006; Verhaak et al., 2010) but the most followed 
classification is the one established by Veerhak et al., based on gene expression 
signature, which divides tumors in four different subtypes:  Proneural, Classical, 
Mesenchymal and Neuronal. Subtype variation correlates with distinct survival times 
and response to treatments: the Proneural subtype is less responsive to therapy but has 
higher survival times while the Mesenchymal and Classical subtypes are more 
responsive to therapy but have lower survival times.  
Besides intertumoral heterogeneity, most GBM tumors also exhibit intratumoral 
heterogeneity (Sottoriva et al., 2013; Stieber et al., 2013). The CSC population is thought 
to be a major determinant of GBM malignancy and intratumoral heterogeneity , since 
they have been shown to be more invasive and therapy resistant than non-CSCs. 
Interestingly, these cells can be classified into two mutually exclusive subtypes, 
Proneural and Mesenchymal (Mao et al., 2013; Ricci-Vitiani et al., 2008), with Proneural 
CSCs shifting to a Mesenchymal phenotype after radiation treatment. The Mesenchymal 
CSCs are more aggressive, invasive and angiogenic than Proneural cells. 
In a live tumor environment, GBM CSCs reside in two distinct microenvironmental 
niches, the vascular niche and the hypoxic niche. GBM CSCs residing in a vascular niche 
have enhanced self-renewal due to interaction with endothelial cells (Calabrese et al., 
2007). Anti-angiogenic therapy (Groot et al., 2010; Tomaso et al., 2011) leads to a 
significant improvement in progression-free survival rate, although not in overall 
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survival duration since it also leads to a shift in the tumor phenotype to a predominantly 
infiltrative phenotype.  
The infiltrative phenotype is strongly promoted by the hypoxic microenvironmental 
niche. The rapid growth of GBM tumors leads to the creation of necrotic areas 
surrounded by pseudopalisades, hypoxic regions formed by actively migrating cell 
populations (Brat and Van Meir, 2004; Brat et al., 2004). A high percentage of the cells 
in these pseudopalisades are GBM CSCs (Christensen et al., 2008) that express HIF-1 
(Brat et al., 2004) and pro-angiogenic factors (Bao et al., 2006; Folkins et al., 2009). 
EMT was shown to play an important role in carcinomas by controlling the switch 
between proliferation and metastization (Micalizzi et al., 2010). The EMT is also 
associated with the acquisition of stem cell properties. Thus, it allows epithelial cancer 
cells to transdifferentiate into motile mesenchymal cells with CSC properties to invade 
neighboring tissues (Mani et al., 2008). Since gliomas and GBMs do not have epithelial 
origin and do not metastasize the EMT had not been entertained as a relevant process 
in this type of cancer.  There is increasing evidence that the GBM CSCs transition from 
the vascular niche to the hypoxic niche as well as their shift to a Mesenchymal phenotype 
after radiation treatment share many similarities to EMT. In line with that, several 
pathways deregulated in GBM were described as triggering EMT in a carcinoma context, 
such as RTK-activated pathways, hypoxia, TGF- pathway, Wnt/-catenin signaling 
pathway through the activation of key transcription factors such as Snail/Slug, Twist or 
ZEB1/ZEB2 (Polyak and Weinberg, 2009).   
2.1. ZEB1 in a glioma/GBM context 
The EMT inducer ZEB1 has recently emerged as a pivotal regulator of invasiveness, 
chemoresistance and tumorigenesis in GBM (Siebzehnrubl et al., 2013). It was found to 
be highly expressed both in hypercellular proliferative zones and less cellular zones 
from the periphery of the tumor. Expression is associated with increase in tumor grade 
and it is more highly expressed in infiltrative tumors. Higher expression was observed 
in grade III-IV anaplastic astrocytomas, pediatric and adult GBMs compared with grade 
II diffuse astrocytomas. Its expression was lowest in the more compact ependymomas 
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(grade I-III) and pilocytic astrocytomas (grade I) (Kahlert et al., 2015). Interestingly, a 
Kaplan-Meyer survival analysis showed that among a set of EMT inducing factors 
composed of ZEB1, ZEB2, Twist1, En1, Snail and Slug it was the only whose expression 
negatively correlated with reduced GBM patient survival in the TCGA dataset 
(Siebzehnrubl et al., 2013).  
ZEB1 is highly expressed in GBM CSC cell lines where it is associated with the CSC 
marker Nestin. ZEB1 expression has been described as occurring preferentially at the 
invasive tumor front of mouse xenografts in experiments using three distinct GBM CSC 
lines (Siebzehnrubl et al., 2013). However, whether ZEB1 expression occurs indeed 
preferentially at GBM tumor borders, similarly to what is observed in various epithelial 
carcinomas, remains to be established. 
ZEB1 expression in GBM CSCs is controlled by several different pathways and 
microenvironmental cues. TGF-was reported as an inducer of mesenchymal 
transdifferentiation of GBM through its regulation of ZEB1 (Joseph et al., 2014).  TGF-
exposure of both serum-grown GBM cells and newly established GBM CSCs enhanced 
the expression of mesenchymal markers, their migratory and invasive capacity in vitro 
and in an orthotopic mouse model. ZEB1 was identified as the mediator of this TGF-
induced mesenchymal transition since ZEB1 knockdown prevented TGF- induced 
transdifferentiation and invasive behavior. Interestingly, a difference in responsiveness 
to TGF- was also reported depending on the GBM subtype of isolated primary GBM 
gliomaspheres. Gliomaspheres expressing Proneural markers were responsive to TGF-
, significantly increasing in size and overexpressing ZEB1 and mesenchymal markers 
when incubated with TGF-, an effected prevented by TGF-inhibitor A8301. Strikingly, 
upon intracranial transplantation in NSG mice gliomaspheres of both subtypes formed 
equally effective invasive tumors with both Mesenchymal and Proneural tumors 
expressing ZEB1 and Mesenchymal marker YKL40. Expression of ZEB1 and YKL40 was 
also observed by immunohistochemical staining in the original patient material, 
contrasting with low expression of YKL40 in the gliomaspheres in culture. This suggests 
that in a tumor microenvironment, Proneural tumors are responsive to TGF- signaling 
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from the surrounding microenvironment and express mesenchymal markers and ZEB1, 
which appears to mediate invasiveness. 
Wnt/-catenin signaling was also reported as inducing the expression of ZEB1 and other 
EMT inducers in GBM CSCs and serum-derived cells (Kahlert et al., 2012). Knockdown 
or overexpression of -catenin led to decreased or increased migratory and invasive 
potential and expression of ZEB1 and other EMT-inducing transcription factors, 
respectively. 
A high percentage of the cells in hypoxic pseudopalisades are GBM CSCs (Christensen et 
al., 2008) that express HIF-1 (Brat et al., 2004). HIF-1 induced ZEB1 expression in 
GBM CSCs grown in serum-free media in hypoxic conditions and this induction was 
partially blocked by the HIF-1 inhibitor digoxin. Furthermore, ZEB1 was reported as a 
promoter of invasion of hypoxic glioma neurospheres since ZEB1 knockdown inhibited 
invasion in hypoxic conditions (Kahlert et al., 2015) besides normoxic conditions 
(Siebzehnrubl et al., 2013).  
The activation of the NF-B pathway by a complex containing CTGF, Integrin 1 (ITGB1) 
and tyrosine receptor type A (TrkA) was yet another mechanism reported as an 
important contributor to glioma/GBM invasion by inducing the expression of ZEB1 
(Edwards et al., 2011). 
Very little is known on how ZEB1 functions at the molecular level in a GBM context, 
which have been so far ascribed to its ability to repress the expression of miR-200 
microRNAs (Siebzehnrubl et al., 2013). Through this repression ZEB1 indirectly 
upregulates the expression levels of ROBO1, which severs N-cadherin anchorage to the 
cytoskeleton thus reducing cell-cell adhesion and promoting migration and 
invasiveness. It also upregulates MGMT, which is a chemoresistance enzyme increasing 
resistance to TMZ treatment. Its knockdown or overexpression in GBM CSC lines led, 
respectively, to decreased or increased levels of stemness factors associated with GBM 
CSCs Sox2, Olig2 and CD133. It also led to decreased or increased sphere-forming ability 
and decreased or increased tumor forming capability of orthotopic grafts. In addition, a 
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previous study reported that ZEB1 knockdown in two serum-grown glioblastoma cell 
lines (U-138 or U-343 GBM cell lines) lead to decreased proliferation (Yen et al., 2001) 
To sum up, ZEB1 is highly expressed in glioma and glioblastoma samples and its 
expression correlates with tumor grade and invasiveness. It regulates invasiveness, 
chemoresistance and tumorigenicity of GBM CSCs from distinct subtypes of GBM, in 
normoxic and hypoxic conditions and its expression is regulated by multiple oncogenic 
pathways in GBMs. These observations highlight the importance of understanding the 
contribution of ZEB1 to the biology of GBM. 
2.2. GBM cell lines  
Contrary to GBM derived cell lines grown in the presence of serum, GBM CSCs isolated 
from human tumors and cultured in stem cell culture conditions (serum-free media 
containing EGF and FGF) stably preserved the genotype, gene expression profile and 
biology of the parental tumors (Lee et al., 2006). Furthermore, GBM CSCs share several 
similarities with NSCs such as the capability to proliferate as neurospheres in non-
adherent conditions and expression of high-levels of NSC markers such as Nestin, CD133 
or Sox2 (Campos et al., 2010; Pollard et al., 2009). In sharp contrast, GBM cells 
maintained in serum-containing medium do not express neural stem/progenitor 
markers while expressing glial and neuronal markers and show dramatic differences in 
the genotype and gene expression patterns compared to the primary tumor from which 
they are derived (Li et al., 2008). Furthermore, transplanting GBM CSCs into 
immunodeficient mice yield tumors that shared similar histology and global gene 
expression patterns with their parental tumors. By contrast, early passage serum-grown 
cells are incapable of tumor formation after transplantation, while late passage serum-
grown cells originate morphologically distinct tumors containing a different molecular 
signature than the original tumors (Lee et al., 2006).  
Experiments reported in this thesis used one of three GBM CSC lines – NCH421K, 
NCH441 and NCH644 - isolated and expanded in serum free conditions from resected 
GBM tumors, previously characterized on their gene expression profile and tumor 
initiating capacity upon xenotransplantation. These cell lines, express high levels of the 
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NSC markers Nestin and CD133 and were able to grow large infiltrative tumors in 
immunodeficient mice (Campos et al., 2010). These cell lines belong to the Proneural 
category of GBM subtypes as defined by Veerhak. All of these cell lines showed loss of 
chromosome 10, gain of chromosome 7 as well as amplifications of the PDGFRA and 
CDk4 gene loci. Furthermore, they lack amplification of the EGFR gene locus (Ernst et 
al., 2009; Podergajs et al., 2013).  
In order to better understand the function of ZEB1 in a GBM CSC context, it is important 
to characterize the molecular basis for its activity as a transcription factor, namely the 
identity of its target genes. Therefore, in this chapter we started by characterizing the 
ZEB1 transcriptional program in the GBM CSC context by combining location analysis 





3. Materials and methods 
3.1. Expression vectors 
The expression vectors used are listed on table 2.1. 
Table 2. 1 Expression vectors 
Vectors Reference 
pCAGGS-LinkerA-IRES-NLS-GFP  
(aka pCAG-IRES- GFP) 
(Guillemot et al.) 
pCAGGS-hZEB1-IRES-GFP (This thesis) 
pME-FNIC (Vasconcelos et al. Unpublished) 
pME-18F-LEF1-Flag (Billin et al., 2000) 
pME-18F-LEF1mut-Flag (This thesis) 
LN/bCTAD (Vleminckx et al., 1999) 
LN/VP-16 (Aoki et al., 1999) 
pcDNA 3.1  
pcDNA 3.1 -catenin S33Y (Kolligs et al., 1999) (Addgene #19286) 
pcDNA 3.1 TCF7 (Grumolato et al., 2013) 
pcDNA 3.1 TCF7mut (Grumolato et al., 2013) 
TCF4E pcDNA3 (TCF7L2) (Tetsu and McCormick, 1999) (Addgene #32738) 
3.2. Luciferase vectors 
The luciferase reporter plasmids used are listed on table 2.2. 
Table 2. 2 Luciferase vectors 
Vector Genomic coordinates Company / Reference 
Nrp2::Luc chr2: 206586315-206587239 (This thesis) 
Prex1::Luc chr20: 47345117-47345506 (This thesis) 
M50 Super 8x TOPFlash   
(Veeman et al., 2003) 
(Addgene #12456) 





3.3. Lentiviral vectors 
The lentiviral vectors used are listed on table 2.3. 
Table 2. 3 Lentiviral vectors 
Vector Company / Reference 
LeGO-T-shGFP (Weber et al., 2008) 
LeGO-T-shZEB1 (This thesis) 
pLKO.1 (Moffat et al., 2006) (Addgene #10878) 
pLKO.1-shLuc (Sarbassov et al., 2005) (Addgene #1864) 
pLKO.1-shb-catenin (This thesis) 
pLKO.1-shLEF1 (This thesis) 
3.4. Transformation into chemically competent E.coli 
100μL of chemically competent E.coli DH5α were incubated with approximately 500ng 
of vector DNA for 15min on ice. After a 60sec heat shock at 37ºC the bacteria were chilled 
on ice for at least 2min, 250μL LB was added. The bacteria were incubated for 
approximately 1h at 37ºC on a shaker incubator, subsequently plated on LB-Amp plates 
and placed overnight at 37ºC. 
3.5. DNA purification 
Plasmids were isolated from E.coli DH5α using Qiagen Mini, Midi or Maxi-Prep Kits. PCR-
Products were purified with the Qiagen PCR Purification Kit, DNA bands from agarose 
gels were purified with the Qiagen Gel Extraction Kit. All steps were performed as 
recommended by the supplier. 
Alternatively, DNA was separated by phenol-chloroform extraction. For that, one 
volume (relative to the sample volume) of phenol:chloroform:isoamyl alcohol 25:24:1 
(Sigma-Aldrich) was added. The mixture was vortexed shortly and centrifuged for 5min 
at maximum speed in a tabletop microcentrifuge. The upper phase was recovered and 
1/10 volume of 3M sodium acetate and 0.7 volumes of 100% ethanol (RNase free) were 
added to precipitate DNA. The sample was incubated for 30-60min at RT and 
centrifuged (10min at RT, 13000rpm). The supernatant was discarded and the pellet 
was washed with 70% ethanol. After air drying, the pellet was resuspended in an 
appropriate volume of RNAse and DNase free water (Sigma-Aldrich). 
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3.6. DNA restriction digestion 
Analytical digestions were performed in 50μL total volume with 1-2μg DNA and ∼2units 
enzyme overnight at 37ºC. 
3.7. Ligation 
Ligations were performed with a 10:1 or 3:1 molar ratio insert/vector, for sticky end 
ligations, or with a 100:1 and 10:1 molar ratio, for shRNA oligonucleotides ligations, 
respectively, using the DNA and Takara Long ligation kit (Takara Bio) according to 
manufacturers’ instructions. The samples were incubated at 16ºC overnight and 
transformed the next day. Colonies were selected and inoculated in LB medium with 
Ampicillin at 37ºC overnight. To confirm the correct insertion of the insert into the 
vector, digestion was performed at 37ºC for 1.5h and the resulting products were 
analyzed on a 1% agarose gel. 
3.8. Subcloning 
Table 2. 4 Primers used for ZEB1 bound regulatory region amplification 
Nrp2::Luc 





Table 2. 5 shRNA oligonucleotides 






















The full-length cDNA of human ZEB1 was excised from the pCI-Neo-hZEB1 vector (kind 
gift from Michel Sanders) and sub-cloned into pCAGS-IRES-GFP vector using NheI.  
Nrp2::Luc (-globin) 
The Nrp2 enhancer sequence was amplified by PCR using Malme-3M human melanoma 
cell line genomic DNA as template. The primers used annealed with the Nrp2 ZEB1 
bound enhancer region and have restriction sites for XhoI and NheI in the 5’- and 3’-
extremities, respectively. PCR was run under the following cycling conditions: 1 cycle 
95ºC/3min; 30 cycles (95ºC/1min; 60ºC/1min; 72ºC/6.5min); 1 cycle 72ºC/10min. The 
PCR product was purified with the PCR Cleanup kit (Qiagen). The enhancer was digested 
with XhoI and NheI and purified via agarose gel. 
The -globin vector was digested with SalI and NheI. The linearized backbone was 
purified via agarose gel. The Nrp2 enhancer bound by ZEB1 was ligated as described 
above into the -globin vector upstream of the luciferase gene. Bacteria were 
transformed and positive colonies were screened by digesting the purified DNA with 
EcoRI and by subsequent analysis of the digestion pattern in agarose gel. The positive 
colonies were sequenced to confirm the lack of mutations.  
Prex1::Luc (-globin) 
The Prex1 enhancer sequence was amplified by PCR using Malme-3M human melanoma 
cell line genomic DNA as template. The primers used annealed with the Nrp2 ZEB1 
bound enhancer region and have restriction sites for XhoI and SpeI in the 5’- and 3’-
extremities, respectively. PCR was run under the following cycling conditions: 1 cycle 
95ºC/3min; 30 cycles (95ºC/1min; 60ºC/1min; 72ºC/6.5min); 1 cycle 72ºC/10min. The 
PCR product was purified with the PCR Cleanup kit (Qiagen). The enhancer was digested 
with XhoI and NheI and purified via agarose gel.  
The -globin vector was digested with SalI and NheI. The linearized backbone was 
purified via agarose gel. The Prex1 enhancer bound by ZEB1 was ligated as described 
above into the -globin vector upstream of the luciferase gene. Bacteria were 
transformed and positive colonies were screened by digesting the purified DNA with 
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EcoRI and by subsequent analysis of the digestion pattern in agarose gel. The positive 
colonies were sequenced to confirm the lack of mutations. 
NH7x::Luc (-globin) 
The oligonucleotides were resuspended in water at 100uM. Sense and antisense 
oligonucleotides were mixed in Annealing Buffer (10mM Tris pH7.5, 0.1mM EDTA, 
50mM NaCl) at a concentration of 10µM each. The oligonucleotide mix was incubated at 
95ºC for 15 minutes, and allowed to cool to 25ºC in a dry bath. The -globin vector was 
digested with SalI and NheI. The linearized backbone was purified via agarose gel. The 
oligonucleotide was ligated as described above into the -globin vector upstream of the 
luciferase gene. Bacteria were transformed and positive colonies were screened by 
digesting the purified DNA with EcoRI and by subsequent analysis of the digestion 
pattern in agarose gel. The positive colonies were sequenced to confirm the lack of 
mutations. 
pME-FNIC empty 
Activated Notch1 (Act Notch) was excised from pME-FNIC Act Notch vector with EcoRI 
restriction enzyme. The pME-FNIC backbone was purified via agarose gel and re-ligated 
ON. The positive colonies were sequenced to confirm the lack of mutations. 
LeGO-T-shZEB1 and LeGO-T-shGFP 
LeGO-T-ShZEB1 and LeGO-T-shGFP lentiviral plasmids were produced as follows. 
Molecular cloning was performed according to standard procedures as described above 
to generate lentiviral expression constructs. DNA sequences (Table 3.7) were ordered 
as custom made oligonucleotides from BioSpring. Oligonucleotides were dissolved in 
water at 100 µM. Sense and antisense oligonucleotides were mixed in water at a 
concentration of 4µM each. The mixture was heated to 95 ºC in a heating block. 
Remaining in the heating block, which was switched off, the mixture was allowed to 
reach 37 ºC. After one more hour at 37 ºC the mixture of annealed oligos was stored at -
20 ºC. The annealed oligos were cloned into the plasmid LeGO-T via HpaI and XhoI 
restriction sites. The blunt end restriction site HpaI was inactive after cloning. Final 
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constructs were verified by sequencing. The cloning resulted in the constructs LeGO-T-
shZEB1 and LeGO-T-shGFP. 
pLKO.1-sh-catenin and pLKO.1-shLEF1 
The shLEF1 and sh-catenin oligonucleotides are based on sequences from the TRC 
shRNA library and on sequences validated by SigmaAldrich. The TRC code for the 
shLEF1 oligonucleotide is TRCN0000428355 and the TRC code for shb-catenin is 
TRCN0000314990. The shRNA cloning followed the TRC protocol “Clone Oligos into 
pLKO vectors for shRNA constructs”. The oligonucleotides were resuspended in water 
at 100uM. Sense and antisense oligonucleotides were mixed in water at a concentration 
of 3µM each. The oligonucleotide mix was incubated in a Mycycler Thermal Cycler 
(Biorad) at 95ºC for 4 minutes, by 70ºC for 10 minutes followed by decrease to 25ºC at 
a rate of 0.5ºC every 3 minutes. 
The pLKO.1 vector was digested with AgeI and EcoRI. The linearized backbone was 
purified via agarose gel. The shRNA oligonucleotides were ligated as described above 
into thevector. Bacteria were transformed and positive colonies were screened by 
digesting the purified DNA with EcoRI and by subsequent analysis of the digestion 
pattern in agarose gel. Final constructs were verified by sequencing. 
3.9. Site directed mutagenesis 
The mutations on the HMG motifs on the Nrp2 and Prex1 enhancer luciferase reporter 
plasmids were generated by site-directed mutagenesis using the plasmids Nrp2::Luc 
and Prex1::Luc and the primers listed on the Table 3.4. The primers were designed 
according to the instructions of the QuickChange Site-Directed Mutagenesis Kit 
(Stratagene). PCR reactions were performed with 50nM of each primer, 100ng of each 
plasmid, 100μM dNTPs, 7.5U of Cloned Pfu polymerase and Pfu buffer with MgSO4 
(Stratagene). Reaction was run under the following cycling conditions: 1 cycle 
95ºC/5min; 18 cycles (95ºC/60sec; 55ºC/50sec; 72ºC/15min); 1 cycle 72ºC/15min, 
followed by DpnI digestion for 3h at 37ºC. DH5α bacteria were transformed with DpnI-
digested DNA. Multiple mutations on Nrp2::Luc and Prex1::Luc were inserted by 




Table 2. 7 Binding sites and primers for site-directed mutagenesis 
3.10. Cell culture 
NCH421K and Cb192 cells 
NCH421K cells (Campos et al., 2010) and Cb192 cells (Sun et al., 2008) were cultured in 
DMEM-F12 GlutaMAX medium (GIBCO) supplemented with 1x N-2 Supplement 
(GIBCO), 0.05x B-27 supplement (GIBCO), Penicillin-Streptomycin (100U/mL) (Gibco), 
EGF (10ng/mL) (Peprotech), bFGF (10ng/mL) (Peprotech) and Laminin (1μg/mL) 
(Sigma-Aldrich) in T-flasks, plates or well plates (Corning) pre-coated with sterile-
filtered Poly-L-Lysine (Sigma-Aldrich). 
Nrp2::Luc 
Nrp2 enhancer HMG motif  mutations  
HMG1 Wild-type -  CCATCCACACCACAAAGGAGCCAGAAGCC 
Nrp2(M1)::Luc  -  CCATCCACACCACAGGGGAGCCAGAAGCC 
HMG2 Wild-type -  GTGACAGAGGCC ACAAAGAAAGGCATCTTCTTC 








Prex1 enhancer HMG motif  mutations  
HMG1 Wild-type -  CTCACACTCAGGCCTTTGTCCTAGGAGCC 
Prex1(M1)::Luc  -  CTCACACTCAGGCCCCTGTCCTAGGAGCC 
HMG2 Wild-type -  GAAGGGCCCATCTTTGTCCAGGATCAAGG 
Prex1(M2)::Luc  -  GAAGGGCCCATCTCCGTCCAGGATCAAGG 
Prex1(M1) 











P19 and 293T cells  
P19 embryonic carcinoma cells and human embryonic kidney cells (293T) were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) / High glucose (Gibco) 
supplemented with Fetal Bovine Serum Heat Inactivated (10%) (PAA Laboratories, GE 
Healthcare), Penicillin-Streptomycin (100 U/mL) (Gibco) and L-Glutamine (2mM) 
(Gibco) in T-flasks, plates or well plates (Corning). 
3.11. Transfection of P19 and 293T cells 
On the previous day, P19 and 293T cells were plated to obtain an 80% confluency on 
the day of the transfection. Transfection was carried out with linear polyethylenimine 
(PEI) (Sigma-Aldrich) in the proportion of DNA:PEI (w/w) of 1:3 for P19 cells and 293T 
cells. Total amount of DNA/cm2, 500 ng. Medium was replaced with fresh medium 4-6h 
after transfection.  
3.12. Transfection of Cb192 cells 
On the previous day, Cb192 cells were plated in confluency on the day of the 
transfection. Transfection was carried out with Lipofectamine 2000 transfection 
reagent (Invitrogen) in the proportion of 1uL per 100ng of DNA. Total amount of 
DNA/cm2, 500 ng. Transfection was stopped by adding fresh medium 4h after 
transfection. 
3.13. Lentivirus production and infection of NCH421K cells  
Replication-incompetent lentiviruses were produced by transient transfection of 293T 
cells with lentiviral vectors (Table 3.5) cotransfected with the viral packaging vector 
psPAX2 and the viral envelope vector pCMV-VSVG. Medium was replaced with fresh 
medium 14h post transfection. 48h after medium replacement, lentiviral particles were 
concentrated from supernatant by ultracentrifugation at 90000g for 4h and 
resuspended in 0.1% BSA PBS. NCH421K cells were infected 24 hours after plating. 
3.14. Reporter gene assays 
P19 cells were seeded into 48-well plates at a density of 75 000 cells/cm2. Cells were 
transiently cotransfected with expression plasmids (Table 3.2), firefly luciferase 
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reporter plasmid (Table 3.3) and pCMV-
control 24h after seeding. 24-36h after transfection, cells were lysed with RGA lysis 
buffer (Potassium phosphate 100μM pH7.8, 1uM EDTA, 10% glycerol, 1% Triton X-100, 
1μM DTT in MilliQ water). Cell lysates were assayed for luciferase and b-galactosidase 
activities. Fold induction represents the values of (luciferase activity/b-galactosidase 
activity) for each condition normalized to control condition. Data are presented as mean 
± CI of quadruplicate assays and One-Way ANOVA with Bonferroni correction for 
multiple testing was applied for statistical significance. 
3.15. Electromobility shift assay 
Probes (Table 3.7) were annealed (100mM Tris-HCl pH 7.5, 1 M NaCl, 10mM EDTA) and 
[γ32P] ATP-labeled (PerkinElmer) with T7 polynucleotide kinase (New England Biolabs). 
ZEB1 and LEF1 proteins were produced by coupled in vitro transcription and translation 
in rabbit reticulocyte lysates (TNT, Promega) (Table 3.8). To ensure proper synthesis of 
the protein of interest, reticulocyte lysates were analyzed by Western blot. For 
electromobility shift assays, the indicated proteins were incubated with probe in 20μL 
binding reactions (4% Glycerol, 10mM Tris-HCl pH 7.5, 1mM MgCl2, 50mM NaCl, 5mM 
DTT, 0.5mM EDTA, 0.1mM ZnSO4, 10mM PMSF, 0.2μg/uL herring sperm DNA (Sigma-
Aldrich-D7290) in MilliQ water) for 20min at RT. The mixtures were loaded onto 6% 
non-denaturing polyacrylamide gels in TBE running buffer (89mM Tris-base, 89mM 




Table 2. 8 Primers used for EMSA probes 
EMSA probe primer  Sequence 
NRP2 HMG2 Fw GACAGAGGCCACAAAGAAAGGCATCTTCT 
NRP2 HMG2 Rv AGAAGATGCCTTTCTTTGTGGCCTCTGTC 
NRP2 HMG2 mut Fw GACAGAGGCCGCGCCGAAAGGCATCTTCT 
NRP2 HMG2 mut Rv AGAAGATGCCTTTCGGCGCGGCCTCTGTC 
NRP2 HMG1 Fw CCATCCACACCACAAAGGAGCCAGAAGCC 
NRP2 HMG1 Rv GGCTTCTGGCTCCTTTGTGGTGTGGATGG 
Prex1 HMG1 Fw GAAGGGCCCATCTTTGTCCAGGATCAAGG 
Prex1 HMG1 Rv CCTTGATCCTGGACAAAGATGGGCCCTTC 
Prex1 HMG1 mut Fw GAAGGGCCCATCGGCGCCAGGATCAAGG 
Prex1 HMG1 mut Rv CCTTGATCCTGGCGCCGATGGGCCCTTC 
Prex1 HMG2 Fw CACACTCAGGCCTTTGTCCTAGGAGCCAG 
Prex1 HMG2 Rv CTGGCTCCTAGGACAAAGGCCTGAGTGTG 
ZEB1 E-box Fw CTCCCCACCACACCTGAGGAAAACTTTT 
ZEB1 E-box Rv AAAAGTTTTCCTCAGGTGTGGTGGGGAG 
ZEB1 E-box_Mut Fw CTCCCCACCATCGGGAAGGAAAACTTTT 
ZEB1 E-box_Mut Rv AAAAGTTTTCCTTCCCGATGGTGGGGAG 
Table 2. 9 Vectors and enzymes used for In vitro transcription and translation 
Vector Enzyme Reference 
pCAGGS-ZEB1-IRES-GFP  T7 (This thesis) 
pcDNA3 LEF1-HA T7 (Grumolato et al., 2013) 
3.16. Protein lysates preparation 
293T cells were transiently transfected with expression constructs using PEI as 
described above. 24h post transfection cells were washed once with PBS and harvested 
by scraping in ice-cold lysis buffer (50mM Tris HCl pH 8.0, 150mM NaCl, 10% Glycerol, 
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0.1% NP-40 and proteinase inhibitors (Roche)) and protein quantification was carried 
out using the Bradford method.  
3.17. Protein immunoprecipitation 
An equal amount of each protein lysate (1000µg) was incubated with an antibody (Table 
3.9) in non-denaturing conditions (50mM Tris HCl pH 8.0, 150mM NaCl, 10% Glycerol, 
0.1% NP-40) for 2h at 4ºC, followed by incubation with 25µl of pre-blocked Protein G 
Dynabeads (Invitrogen) for 2h. Negative controls without antibody were run in parallel. 
Elution was performed by adding 50uL of 100mM Glycine pH 2.5 to the beads. The 
immune complexes were analyzed by Western blot using the anti-tag antibodies. 
Table 2. 10 Antibodies used in protein immunoprecipitation 
Antigen (Species) 
Volume used in Protein 
immunoprecipitation 
Catalog number Company / Reference 
FLAG M2 (mouse) 1μL/50μL beads F1804 Sigma-Aldrich 
V5-tag (mouse) 2μL/50μL beads R960-25 Life Technologies 
3.18. Western Blot 
Table 2. 11 Primary antibodies used in Western blot 
Antigen (Species) Working dilution in WB Catalog number Company / Reference 
FLAG M2 (mouse)  1:3000 F1804 Sigma-Aldrich 
V5-tag (mouse)   1:5000 R960-25 Life Technologies 
α-tubulin (mouse)  1:10 0000 T6074 Sigma-Aldrich 
Table 2. 12 Secondary antibodies used in Western blot 
Antigen / Species 
Working dilution 
in WB 
Company / Source 
Goat Anti-Rabitt IgG (H+L) Poly-HRP 1:4000 Jackson ImmunoResearch 
Donkey Anti-Mouse IgG (H+L) Poly-HRP 1:4000 Jackson ImmunoResearch 
Crude cell lysates and immmunoprecipitated samples were diluted in 2x Laemmli buffer 
(Sigma-Aldrich) and denatured for 5min at 95ºC. Samples were separated in 10% SDS-
PAGE gels and transferred to nitrocellulose membranes (GE Healthcare) using standard 
procedures. Blots were probed with the primary and HRP-conjugated secondary 




NCH421K cells were grown on glass coverslips coated with poly-L-Lysine (Sigma-
Aldrich) and fixed with 4% formaldehyde for 10min. Immunofluorescence on fixed cells 
was performed using standard procedures. Cells were stained with the primary 
antibody mouse anti -catenin (1:1000, BD Transduction Laboratories #610153) and 
secondary antibody Alexa Fluor 488 Goat Anti-mouse IgG (1:1000, Life Technologies). 
Cell nuclei were stained with DAPI (4',6-diamidino-2-phenylindole; Sigma-Aldrich) 
before mounting in Aqua Poly/Mount (Polysciences).  
3.20. Microscopy  
Bright field images or fluorescent images of fixed sections and coverslips were acquired 
using the microscope Leica DMRA2, equipped with a CoolSNAP HQ CCD (1.3MPx 
monochrome) digital camera. Confocal fluorescent images of fixed sections were 
acquired using the laser scanning confocal microscope Zeiss LSM 510 Meta. All images 
were treated using ImageJ. 
3.21. Human tissue samples and immunohistochemistry 
Intraoperative specimens of brain tumor patients were obtained from the Department 
of Neurosurgery or the Edinger Institute of the University Hospital. All work involving 
human tissue was approved by the local ethical committee (ethical votes No. GS-04/09 
and GS-249/11). All specimens obtained were used for extensive histological analysis to 
characterize brain tumors. For this purpose, tissue samples were dehydrated and 
embedded in paraffin prior to cutting into 2-3µm sections on a microtome (Leica 
SM2000R, Wetzlar, Germany, http://www.leica-microsystems. com/de/). 
For histology, the following antibodies were used: polyclonal rabbit anti-PREX1 
(SigmaAldrich, Germany); rabbit anti-ZEB1 (ab1424, Abcam). 
3.22. Chromatin isolation from NCH421K cells 
Cells were washed with PBS and fixed in PBS-Mg (1 mM MgCl2 PBS) containing Di-
succinimidyl-glutarate (DSG) (Sigma-Aldrich) for 45min at RT on a rocking platform. 
Cells were washed with PBS and fixed in PBS-Mg with 1% formaldehyde (Sigma-
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Aldrich) for 10min at RT on a rocking platform. Crosslinking was quenched by addition 
of glycine to a final concentration of 125mM for 5min at RT. Subsequently, cells were 
washed twice in PBS and harvested by scraping in 1mg/mL BSA PBS (with proteinase 
inhibitors (Roche)). After a low speed centrifugation, cell pellets were resuspended in 
SDS lysis buffer (1% SDS, 10mM EDTA, 50mM Tris pH 8.0, Proteinase inhibitors 
(Roche)) and incubated for, at least, 10min at 4ºC. 5-7.5μL of lysis buffer/μL of pellet 
were added.  Chromatin was transferred to non-sticky eppendorfs (Ambion) and 
sheared by sonication using a Bioruptor sonicator (Diagenode) at high power settings 
for 14min in 30s ON/OFF cycles at 4ºC. Centrifugation at 14 000rpm for 10min at 4ºC 
allowed the precipitation of cell debris and the soluble chromatin fraction on the 
supernatant was collected. DNA concentrations were typically 0.7-3μg/uL. Chromatins 
were snap-frozen in liquid nitrogen and stored at -80ºC. To verify the efficiency of the 
sonication, one aliquot of the chromatin was subjected to crosslinking reversal and 
Proteinase K (0.1mg/mL) (Roche) digestion followed by DNA purification by phenol-
chloroform extraction. Fragment size was determined by agarose gel electrophoresis. 
Typical chromatin fragment size was 300-500bp. 
The above described protocol for chromatin isolation was performed prior to all ChIPs. 
3.23. Chromatin immunoprecipitation  
Reactions were performed in non-sticky eppendorfs (Ambion) using approximately 
70μg of chromatin and 50μL of magnetic beads and the appropriate antibody in each 
ChIP reaction (Table 3.14). As a negative control, an IP without antibody (Mock) was run 
in parallel. Bound chromatin was eluted by incubation of the beads with elution buffer 
(50mM Tris-HCl pH 8.0, 10mM EDTA, 1% SDS) for 15 minutes at 65ºC. Proteins were 
digested by Proteinase K (0.1mg/mL) (Roche) for 2h at 42ºC and crosslinking was 
reverted overnight at 65ºC. The DNA was purified performing one phenol/chloroform 
extraction and one chloroform:isoamyl alcohol 25:24:1 extraction followed by 
isopropanol precipitation and centrifugation for 20min at 14 000rpm, +4ºC. Glycogen 
(40μg) (Sigma-Aldrich) was added on the isopropanol precipitation step to facilitate the 
visualization of the pellet after centrifugation. 
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For anti-ZEB1 ChIP, Protein G Dynabeads (Invitrogen), high salt IP buffer (20mM HEPES 
pH 8.0, 200mM NaCl, 2mM EDTA, 0.1% Na-DOC, 1% Triton X-100, 1mg/mL BSA, 
Proteinase inhibitors (Roche)) were used and 5 washes with LiCl buffer (50mM HEPES 
pH 7.6, 20mM EDTA, 1% NP-40, 0.7% NaDOC, 0.5M LiCl) were performed followed by a 
final wash with TE buffer pH 8.0 (10mM Tris-HCl, 1mM EDTA).  
For LEF1 and -catenin antibodies, Protein G Dynabeads (Invitrogen), high salt IP buffer 
(20mM HEPES pH 8.0, 200mM NaCl, 2mM EDTA, 0.1% Na-DOC, 1% Triton X-100, 
1mg/mL BSA, Proteinase inhibitors (Roche)) were used and 1 wash with Low-Salt 
Buffer (0.1%SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH 8.0, 150mM NaCl), 1 
wash with High-Salt buffer (0.1%SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH 8.0, 
500mM NaCl), 1 wash with LiCl buffer (1% NP-40, 1% Na-DOC, 1mM EDTA, Tris pH 8.0, 
0.25M LiCl) were performed followed by a final wash with TE buffer pH 8.0 (10mM Tris-
HCl, 1mM EDTA).  
Table 2. 13 Antibodies used in ChIP 
Antigen 
(Species) 
Volume used in ChIP Catalog number Company / Reference 
-catenin 
(mouse) 
2ug/50μL beads 610153 
BD Transduction 
Laboratories 
LEF1 (mouse) 3μg/50μL beads 17-604 Merck-Millipore 
ZEB1 (rabbit) 0.75ug/50μL beads HPA027524 Sigma Aldrich 
3.24. ChIP-qPCR 
The purified DNA retrieved from the ChIP was analyzed by qPCR (primers listed on 
Table 3.15) using the standard mix protocol of PerfeCTa SYBR Green FastMix, ROX 
(Quanta Biosciences). Reaction was run under the following cycling conditions: 1 cycle 
(50ºC/ 2min; 95ºC/ 3min); 40 cycles (95ºC/ 15sec; 60ºC/ 1min); 1 cycle (95ºC/ 15sec; 
60ºC/ 15sec; 95ºC/ 15sec) in CFX-384 (Bio-Rad). Quantities of immmunoprecipitated 
DNA were calculated by comparison with a standard curve generated by serial dilutions 
of input DNA. ORFs were used as negative control regions. Results are shown as 
Mean+SD of fraction of input chromatin for triplicate assays and One-Way ANOVA with 
Fisher LSD test comparing the mean of each tested region with the mean of a negative 
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control ORF region was applied for statistical significance. The primers used on ChIP-
qPCR are listed on table 2.14. 
Table 2. 14 Primers used in ChIP-qPCR 
Primers Forward Primer Reverse primer 
Axin2 ORF (ORF1) CATCCCATCCAACACAACCC TTTGCACTACGTCCCTCCAA 
Itgb1 ORF (ORF2) GCTGGTGCAGTTCTGTTCAC AGGATTTGGCTCATTTGTGG 
Fbxw7 ORF (ORF3) ATTCACCCGTTTTCAAGTCC CTAGGTCCCAACAAGCATCA 
ZEB1 ORF GGGGTGAATGATAGCACTTG GGACTCAGGCTTCTCAGCTT 
miR 200b ORF GCACCAGTCCTTCCAGACTC TTGGTCTCAGGTAGGTGCAG 
miR 200c ORF AGGTCACAGGGCTATGGAAC GAACTCAGCATCAGGGGAGT 
miR 200b CAGGGGACACACCTGTCG CCCGTCTCTGGGAGAGTTT 
miR 203 CCAACCCCATACAGACACAC GCCGGTCCTACCCACTTA 
miR 200c(1) TATGGCAGGAGGACACACC CAGATTCCACGGCCTAGAG 
miR 200c(2) TTAAAGCCCCTTCGTCTCC CCGATTTACCCACCCTCAT 
ZEB1 TTACCTTTCCAACTCCGACA GCCGGAACCTTGTTGCTA 
Prex1 CTCACACTCAGGCCTTTGTC GAGTGTTTGTGGGGAAGTGTC 
Nrp2(1) TCAGGAGAGAAACAAGGCCA GTTGGGGATGTTAAAGGCCG 
Nrp2(2) TATGTTGCTTCAAGGGCCAC CGTTGGGGCTTGTGAAGTTT 
Itgb1 ACAGGAAAGGAGAGGCAGAG GCTCAGGGATTGTGGATTTT 
Axin2 GCTCTCGGGCTGTTACTGA GGGCGCTGTCCCTTTAAG 
Tnfrsf19 ACTAGGAGGTGGGAGGGTAA CAAGCCCAGACGAAACTTCA 
NKD1 AGAATTCCTGACCTCCACCG GACACGGGCTGATCTCCTAA 
Pard6b AGCCGAGCCCTTCTTCAG CTCCTCAAAACCCCGCCTA 
3.25. ChIP-Seq  
For Sequencing, DNA purified from 8 anti-ZEB1 ChIPs of NCH421K cells was merged. 
Libraries were prepared from 10ng of input and immunoprecipitated DNA according to 
the standard Illumina ChIP-Seq protocol and sequenced with Illumina GAIIx.  
Raw reads were mapped to the human genome (GRCh37/hg19) with Bowtie 0.12.7 
(Langmead et al., 2009). Sequenced reads were processed after mapping with SAMTools 
for format conversion and removal of PCR duplicates (Li et al., 2009). Peaks for each 
sample were called against the input using MACS 1.4.1.  
134 
 
3.26. ChIP-Seq peak visualization   
To visualize the ChIP-Seq peaks, the bigwig files from each ChIP-Seq dataset were loaded 
onto the UCSC genome browser (http://genome.ucsc.edu/). 
3.27. Peak annotation  
Annotation of ChIP-Seq peaks was done with GREAT (McLean et al., 2010) using single 
nearest TSS annotation. Maximal distance, 100 Kb. The percentage of peaks at a certain 
distance from the nearest TSS was plotted using GREAT and the overlap with gene 
feature was plotted using PAVIS (Huang et al., 2013) with default settings. 
3.28. Density plots 
ChIP-seq normalized tag signals were calculated using a 10bp sliding window over the 
± 2kb region around each peak summit to generate the occupancy profiles (in-house 
developed algorithm). These were plotted as heat maps of signal density using 
R/Bioconductor packages (http://www.Rproject.org/ and http://CRAN.R-
project.org/package=gplots).  
3.29. Gene expression analysis  
NCH421K cells were plated in 6-well plates (700 000 cells/ well), for ZEB1 knockdown, 
lentiviral particles were added 24h after seeding and samples were collected 72h after 
infection. All samples were prepared in triplicate. 
3.30. RNA extraction  
Total RNA was isolated from cells by using Trizol reagent (Invitrogen) and alcohol 
precipitation. Extracted RNA was purified by DNAse I (Roche) treatment followed by 
Rneasy column purification (RNA CleanUp protocol, Qiagen). EDTA inactivation of 
DNAse I step was omitted.  
3.31. cDNA production and quantitative real-time PCR (RT-qPCR) 
cDNA was synthetized using the High-Capacity RNA-to-cDNA kit (Applied Biosystems) 
according to the manufacturers’ instruction. An equal amount (500-1000 ng) of total 
input RNA was used on each experiment. 
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Gene expression analysis by quantitative real-time PCR using PerfeCTa SYBR Green 
FastMix, ROX (Quanta Biosciences) was carried out according to the manufacturer’s 
instructions on CFX-384 (Bio-Rad). Values are normalized to reference gene expression 
levels and to untreated samples. The primers used are listed on table 3.16. Triplicates of 
each biological replicate were used in the RT-qPCR. Results are shown as Mean + SEM 
of triplicate assays and unpaired, two-tailed t test was applied for statistical significance.  
Table 2. 15 Primers used in expression-qPCR 
Gene Forward Primer Reverse primer 
IPO8 GATGCAGGAGAAGATGCAGA TTGAACGAAGAGTGGAATGC 
TBP CGCAAGGGTTTCTGGTTT AATAGGCTGTGGGGTCAGTC 
GAPDH ATCCCTCCAAAATCAAGTGG GGCAGAGATGATGACCCTTT 
LEF1 ACGAGCACTTTTCTCCAGGA CAAGAGGTGGGGTGATCTGT 
TCF7 GTCGAGGGAAAAGCACCAAG AGCACTGTCATCGGAAGGAA 
TCF7L1 CTGATGATCCCGGACCTGAG AAGTGTGCTGGAGATGGTGA 
TCF7L2 ACTTACCAGCCGACGTAGAC GGGTAGGGGTGTCTGAATCC 
b-catenin GCAATCCCTGAACTGACAAA GCAGACACCATCTGAGGAGA 
Axin2 GGAGCCTAAAGGTCGTGTGT GGTGCAAAGACATAGCCAGA 
NKD1 ATGGAGAGAGTGAGCGAACC TCATACAGGGTGAAGGTCCA 
Myo6 TGGATTTCAGATGGGCAATA TTATGGAGCAGTGTGGCTTC 
Pard6b GCCAATCCACTGCTTAGGATA TATGGTTGTCAGGACGCAAT 
NRP2 TTCCTCTCACCTGGGTTTTC AATCCACTCGCAGTTCTGGT 
Prex1 GTCCCTGGAGAAAGTTCAGC GGGTGGACAAAGGACTTCAT 
ZEB1 AAACACCACCTGAAAGAGCA AAGAGATGGCGAGGAACACT 
ZEB2 GACACGGCCATTATTTACCC GGCAAAAGCATCTGGAGTTC 
ITGB1 GTTTGCTGTGTGTTTGCTCA TCGTGCAGAAGTAGGCATTC 
3.32. Gene expression microarrays 
Samples used for microarray analysis were obtained from biological triplicates of 
NCH421K cells 72h post-infection with shZEB1 or shGFP. Total RNA was extracted as 
described above. RNA concentration and purity were determined by spectrophotometry 
and integrity was confirmed using an Agilent 2100 Bioanalyzer with a RNA Nano Kit 
(Agilent Technologies). 100ng of RNA were processed by using the Ambion WT 
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Expression Kit (Life Technologies) and hybridized to the Affymetrix Primeview Human 
Gene Expression Array, according to the manufacturers’ protocol.  
3.33. Gene expression microarrays analysis 
Analysis of microarray CEL files was performed using Chispter software (v 3.0.2, (Kallio 
et al., 2011)). 
Annotation of probesets was performed using the Chipster tool “Annotation / 
Affymetrix, Illumina or Agilent gene list” and used the Brainarray custom CDFs version 
18 PrimeView_Hs_ENTREZG (probe coverage 80.9%, nº probesets 18504). Calculation 
of expression estimates was done using the RMA normalization use R3.0.2 followed by 
log2 transformation for expression values using Chipster. 
To determine the similarity between the chips, dendrogram and principal component 
analyses were run on normalized chips. Clustering of chips using Pearson correlation 
and average linkage method can be visualized with the dendrogram. Both dendrogram 
and principal component analysis of chips allows to visualize that biological replicates 
cluster, samples are distinct.  
For significance analysis, differentially regulated genes between shGFP and shZEB1 
conditions were identified using an empirical Bayes t-test and considered statistically 
significant below a Benjamini-Hochberg corrected p-value of 0.05 using Chipster. To 
determine list of ZEB1 directly regulated genes, intersected the obtained list with the 
ZEB1 ChIP-seq list (p-value< 10-10). 
3.34. In silico transcription factor (TF) motif identification  
We have used CisFinder (Sharov and Ko, 2009) in order to identify motifs enriched in 
the vicinity of ChIP-Seq peak summits. Searches were run against a control dataset with 
the same number and the same length of the test dataset peaks located 5 Kb upstream. 
FDR<0.05%. The motifs shown are the result of “Identify motifs” tool, in the 100bp 
region surrounding the peak summits with the default settings. 
Frequency distributions were plotted using the frequency tables obtained with the 
Cisfinder Search tool upon search of the motifs in the 4000bp regions centered on the 
ChIP-Seq peak summit.  Number of false positives per 10 Kb, 1. Interval for frequency 
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distribution, 100bp. Control dataset with the same number of peaks and the same length 
of the test dataset but located 5 Kb upstream. E-box and HMG motif were searched as 
consensus motifs. ChIP-Seq dataset cutoffs and intersection between ChIP-seq and 
expression profiling as previously mentioned on the figures legend.  
Clustering of ChIP-Seq peaks based on the presence or absence of the represented 
motifs. E-box and HMG motif were searched as consensus motifs. Abundance tables 
obtained with the Cisfinder Search tool were converted to binary (1-presence, 0-
absence) CSV files. Only the peaks that have at least one of the motifs searched are 
represented. These CSV files were then converted into matrixes and plotted as heatmaps 
with RStudio using the “gplots” packages, resorting to heatmaps.2. ChIP-Seq dataset 
cutoffs and fragment size are mentioned on the figures legend. Same procedure for 
peaks associated with activated or repressed genes. 
3.35. Gene ontology analysis  
Gene ontology-based analysis was used for the identification of enriched gene functions 
of ZEB1 activated and repressed target genes (bound by ZEB1 and downregulated and 
upregulated, respectively, in ZEB1 LoF microarrays). Gene Ontology Biological Process 
analysis with functional annotation was carried out using DAVID v6.7 (Huang et al., 
2009a, 2009b). Background Homo Sapiens, annotation category GOTERM_BP_FAT, 
clustering of GO terms associated with ZEB1 repressed genes was performed with 
classification stringency “Medium” and selected terms representative of each cluster. 
Selected GO terms with a modified Fisher Exact p-value (EASE score) < 0.05. Shown GO 
terms associated with ZEB1 activated genes had a modified Fisher Exact p-value (EASE 
score) < 0.05. 
3.36. Binding and expression data integration 
Calculation of p-values for the association between binding events and up- or down-
regulated genes was performed by sampling the total number of genes represented in 
the microarray 1000 times and assuming a normal distribution. ZEB1 ChIP-Seq peak 
overlap with expression data from ZEB1 LoF microarray calculated and plotted as heat 
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maps with R/Bioconductor packages “genomeIntervals”, “gplots”, and in-house 
developed scripts.  
3.37. Analysis of microarray data 
Level 3 microarray data from a custom Agilent microarray where downloaded from the 
TCGA data portal and matched with clinical annotation files.  Only G-CIMP negative 
primary Glioblastoma where used for correlation and regression analysis (n =465). Data 
analysis was performed by the statistic environment R version 3.1.2. Linear Regression 
was performed using Graphpad Prism 6. 
Glioblastoma expression data of the Gravendeel glioma dataset (Gravendeel et al., 2009) 
(GEO Accession number GSE16011) was analyzed and extracted through the GlioVis 
portal (http://gliovis.bioinfo.cnio.es/) (Bowman R. et al., 2016). Data was treated with 
GraphPad Prism 6. The Kaplan–Meier method was used to perform survival analyses on 
groups classified by Prex1 expression levels. In all survival analyses, the outcome 
variable was time from start of treatment until death. Subjects still alive at the time or 
analysis and subjects lost to follow ‐ up were considered censored. P-value determined 





4.1. Characterization of the ZEB1 transcriptional program in GBM CSCs 
We started by assessing the expression of ZEB1 protein in three previously 
characterized GBM CSC lines (NCH421K, NCH441 and NCH644) (Campos et al., 2010). 
The human fetal neural stem cell line Cb192 was also included for comparative 
purposes.  Analysis by western-blot revealed strong ZEB1 expression in all cell lines, 
denoted by a band of the expected molecular weight, which was reduced upon 
expression of a sequence-specific shRNA against ZEB1 (Figure 2. 1A).  Immunostaining 
in NCH421K shows ZEB1 expression occurring in virtually all cells, similar to Cb192 cells 
(Figure 2. 1B). 
 
Figure 2. 1 ZEB1 is highly expressed in GBM CSCs lines. 
A) ZEB1 protein levels in GBM CSC lines and CB192 NSC lines before and after ZEB1 
knockdown detected by Western Blot. B) Immunostaining of ZEB1 and NSC/GBM CSC 
marker Nestin in Cb192 and NCH421K cells. 
With the aim of characterizing the transcriptional program regulated by ZEB1 in GBM 
CSCs, we combined location analysis and expression profiling upon ZEB1 knock-down 
(Figure 2. 2A) in the proneural GBM cancer stem cell line NCH421K. To identify the 
genomic regions bound by ZEB1 we performed genome-wide mapping of these regions 




Figure 2. 2 Characterization of the ZEB1 transcriptional program in NCH421K cells. 
A) Scheme depicting the combination of genome-wide mapping of ZEB1 binding events in 
NCH421K cells and expression profiling after ZEB1 lentivirus-mediated knockdown. B) 
Percentage of ZEB1 ChIP-Seq peaks at indicated distances from the nearest TSS. P<10 -10. C) 
Percentage of ZEB1 ChIP-Seq peaks overlapping gene features. P<10 -10. D) Examples of 
ZEB1 ChIP-seq peaks in the vicinity of previously characterized ZEB1 regulated genes.   
Location analysis was performed using chromatin extracted from semi-adherent cells 
growing in control proliferative conditions and identified 6,879 high-confidence ZEB1 
binding events (p-value<10-10) associated with 4430 unique genes following a nearest 
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gene annotation. ZEB1 binds preferably at long distances from the nearest identified 
transcription start sites (TSS) with 81% of the binding events occurring at distances 
superior to 5kb from TSS (Figure 2. 2B), within intronic and intergenic regions (Figure 
2. 2C). Binding events were detected at the vicinity of previously characterized ZEB1 
regulated genes associated with epithelial cell polarity, including E-cadherin, Pard6B 
and Crb3 (Figure 2. 2D) (Aigner et al., 2007; Eger et al., 2005; Singh et al., 2016). 
Because not all binding events are regulatory, we next characterized changes in 
transcriptome resulting from ZEB1 knock-down by performing expression profiling 
through DNA microarrays upon ZEB1 loss-of-function (LoF). With that aim, we 
harvested mRNA from puromycin selected NCH421K cells infected with a lentivirus 
expressing a sequence specific shRNA against ZEB1 (Figure 2. 3A, B) resulting in 
approximately an 80% knockdown of ZEB1 expression as determined by western blot 
72 hours post-infection. This approach uncovered 298 deregulated genes (Figure 2. 3A, 
3C) (fold change>1.2; p<0.05), with 200 of them being downregulated while 98 were 
upregulated. From these, 60 ZEB1 activated genes and 42 repressed genes are 
associated with ZEB1 binding following a nearest gene annotation (p-value cutoff of 10-
10).  
4.2. ZEB1 binding is associated with both activation and repression of 
gene expression in NCH421k cells 
Although ZEB1’s role as an inducer of Epithelial-Mesenchymal Transition and as a 
maintainer of stemness seems to rely mostly on its activity as a transcriptional repressor 
(Aigner et al., 2007; Eger et al., 2005; Postigo, 2003; Postigo et al., 2003; Sánchez-Tilló 
et al., 2011; Schmalhofer et al., 2009; Takagi et al., 1998; Wellner et al., 2009) there are 





Figure 2. 3 ZEB1 transcriptional characterization through ChIP-seq and expression profiling 
through microarrays after Loss-of-Function. 
A) ZEB1 protein levels in NCH421K cells 72 hours after ZEB1 knockdown detected by Western 
Blot with rabbit anti-ZEB1 antibody. B) RT-PCR of ZEB1 expression levels after ZEB1 
knockdown in NCH421K cells 72 hours post-infection. C) Intersection of ZEB1 ChIP-seq list 
of binding events (P<10-10) with the list of deregulated genes after ZEB1 loss-of-function 
(fc>1.2; p<0.05). 
Therefore, to gain insight into the global transcriptional response triggered by ZEB1 we 
integrated the genomic binding profile with the expression profiling results. We found 
the association of ZEB1 binding events to the downregulated (p=3.2E-23) and 
upregulated (P=5.5E-15) genes after loss-of-function to be statistically significant when 
compared to the association with one thousand similarly sized randomized sets of genes 
(Figure 2. 4A), suggesting ZEB1 binding associates with both activation and repression 
of gene expression. Additionally, we determined the fraction of up- and downregulated 
genes associated with ZEB1 binding events grouped, which were then considered direct 
targets of ZEB1. The statistical significance of this association was assessed by 
comparison of the up- and downregulated genes with one hundred similarly sized sets 
of random binding events. Interestingly, the resulting heatmaps indicate that both up- 
and downregulated genes are significantly enriched with ZEB1 direct targets (Figure 2. 
4B). Overall, our analysis demonstrates a dual association of ZEB1 binding with both 




Figure 2. 4 ZEB1 binding is significantly associated with both gene repression and activation.  
A) Number of ZEB1 binding events associated with up (red bar) or down-regulated (blue 
bar) genes in ZEB1 LoF microarrays. Test data represented as box with median of test and 
first and third quantiles; whiskers, ±1.5 x interquartile range (IQR). P (ZEB1 ChIP-Seq) <10-
15. P (ZEB1 LoF microarrays) <0.05, FC>|1.2|. B) Heatmap displaying the cumulative fraction 
of deregulated genes in ZEB1 LoF that are directly regulated by ZEB1 (Up/Zeb1 kd, 
Down/Zeb1 kd). Number of transcripts with expression fold change >1.2 are plotted against 
ZEB1 BEs with increasing p value. Control: 100 sets of random BEs (Up/Random; 
Down/Random). 
4.3. Biological functions of ZEB1 target genes 
Considering that ZEB1 has already been described as being involved in a double 
negative feedback loop with the miR200 family of microRNAs in GBM CSCs 
(Siebzehnrubl et al., 2013) we then investigated if ZEB1 regulates the expression of the 
miR200 microRNAs in the NCH421K cell line. Analysis of the ChIP-seq enrichment 
profile at previously characterized ZEB1 sites at promoters of the miR-200 polycistronic 
transcripts previously described in other cancer contexts where the ZEB1-miR200 
double negative feedback loop is active (Wellner et al., 2009) did not reveal any evidence 
of ZEB1 binding (data not shown). This result was further confirmed by ChIP-PCR using 
primers that amplify these same genomic regions (Figure 2. 5 A). Not only was ZEB1 
binding absent but the expression levels of the microRNAs (Figure 2. 5 B) did not 
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increase upon shRNA mediated knock-down of ZEB1 expression. Therefore, no evidence 
was found that ZEB1 was regulating the miR200 family in our GBM CSC context. 
 
Figure 2. 5 The ZEB1-miR200 double negative feedback loop is inactive in NCH421K cells.  
A) ZEB1 ChIP-qPCR in NCH421K cells shows that ZEB1 does not bind to promoters of miR200 
microRNAs policystronic transcripts in NCH421K cells. ORFs are negative control regions 
with no E-box motif while ZEB1 is a positive control region in the Zeb promoter. Mean+SD 
of biological replicates is shown. B) miRNA levels in ZEB1 knockdown in NCH421K cells 
assessed by RT-PCR 72 hours after ZEB1 knockdown. Expression levels in control cells are 
displayed as percentage of expression in cells transfected with non-specific shRNA. *** for 
p<0.001. 
To determine the function of ZEB1 targets we performed a gene ontology (GO) analysis 
of a list of genes expected to be highly enriched for ZEB1 direct targets, comprised of 
genes that are activated (60) or repressed (42) by ZEB1 , and associated with at least 
one binding event. We observed that ZEB1 deregulated genes are associated with 
biological processes usually associated with development and deregulated in a cancer 
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context, with an association with distinct GO Biological Process terms depending on the 
effect of ZEB1 over their expression (Figure 2. 6).  
 
Figure 2. 6 ZEB1 target genes associate with distinct Gene Ontology terms depending if they 
are repressed or activated by ZEB1.  
Enrichment of GO Biological Process terms associated with ZEB1 activated and repressed 
genes (bound and deregulated by ZEB1) as determined with DAVID Bioinformatics resource. 
Numbers inside bars indicate number of genes associated to term. Modified Fisher Exact P-
value, as determined by DAVID database, for each category is indicated in the outside end 
of each bar. Fold enrichment is the proportion of genes of a term relative to the proportion 
of those genes in the microarray background. 
ZEB1 repressed genes associate with terms related with differentiation and epithelial 
phenotypes including “neuron development” and “epithelial cell differentiation”. Among 
these repressed genes were Pard6b, a gene that is a member of the Par6 family, a major 
regulator of apical-basal polarity in epithelial cells, that is present in tight junctions and 
adherens junctions in a complex with Par3, aPKC and Cdc42 (Brajenovic et al., 2004; 
Chen and Zhang, 2013; Hurd et al., 2003; Kohjima et al., 2002; Yamanaka et al., 2003). 
Shroom3, a protein which is essential for neural tube closure and which is involved in 
epithelial cell shape change (Das et al., 2014; Lee et al., 2007; McGreevy et al., 2015; 
Nishimura and Takeichi, 2008). Prox1, which during mouse embryogenesis, is 
expressed mostly in early neural precursors of the SVZ and coincides with the time of 
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neuronal differentiation. Abnormally high expression of Prox1 leads to depletion of the 
progenitor cell pool (Elsir et al., 2012).  
ZEB1 activated genes are associated with biological processes such as “regulation of 
apoptosis” and that related with cell motility and invasiveness such as “locomotory 
behavior” and “actin cytoskeleton organization”. Many of these genes have been 
implicated as promoters of cell invasiveness and stemness. Examples include ITGB1, an 
integrin characteristic of cells with a mesenchymal phenotype (Veevers-Lowe et al., 
2011; Zwolanek et al., 2015). ITGBI promotes glioma/GBM invasion by inducing the 
expression of ZEB1, via activation of the NF-B pathway, by forming a complex with 
CTGF, and TrkA (Edwards et al., 2011). ITGB1 has been shown to be critical for cartilage 
and bone formation, skeletal muscle development, epidermis formation, development 
of the cerebral cortex and angiogenesis (Lahlou and Muller, 2011). It has been mostly 
studied in breast cancer, where it is involved in therapeutic resistance and it has been 
recently described as a core regulator of Twist-induced EMT (Hassan et al., 2013; Yang 
et al., 2016; Yuan et al., 2015). Prex1 is a guanine nucleotide exchange factor (GEF) that 
activates Rho GTPases like Rac1 to promote cell migration, invasion and metastasis in 
melanoma and breast cancer cells through the MEK/ERK pathway. It creates a positive 
feedback loop with PI3K to activate RTK, PI3K/AKT and MEK/ERK signaling in breast 
cancer (Dillon et al., 2015; Ebi et al., 2013; Lucato et al., 2015). Although a putative a 
function for Prex1 in GBM has not yet been addressed, Rho GTPases are deregulated, 
often via hyperactivity or overexpression of their activators in this cancer context. 
Downstream effectors of Rho GTPases have been shown to promote invasiveness and, 
importantly, glioma cell survival (Fortin Ensign et al., 2013). Nrp2 is a neuropilin, a co-
receptor that enhance responses to several growth factors (GFs). Neuropilins were 
described as promoters of epithelial-mesenchymal transition (EMT), and the survival of 
cancer stem cells in other cancer contexts (Prud’homme and Glinka, 2012). 
The above mentioned examples of ZEB1 targets are in line with the biological processes 
regulated during EMT, and suggests that ZEB1 directly regulates various components of 
an EMT-like program in GBM CSCs through both its activity as a transcriptional 
repressor and activator.   
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4.4. Two modes of ZEB1 recruitment to gene regulatory regions  
To investigate the molecular basis for the dual activity of ZEB1 we started by 
investigating its mode of recruitment to gene regulatory regions. We performed a de 
novo search for DNA enriched motifs within 50 base pairs of peak summits. This search 
revealed that besides the expected E-box (CACCTG) motif directly bound by ZEB1, an 
hexamer sequence matching the consensus binding sequence for HMG-box 
transcription factors (herein referred to as “HMG motif”) was also strongly enriched 
(Figure 2. 7A). Strikingly, while the E-box was prevalent in ZEB1 peaks associated with 
low p-values (high peaks) (Figure 2. 7A, top), the HMG motif was mostly enriched in less 
significant peaks (small peaks) at the bottom half (Figure 2. 7A, bottom).  Moreover, a 
frequency distribution analysis of these two motifs demonstrate that both are sharply 
enriched at peaks summits compared to control neighboring regions (Figure 2. 7B), thus 





Figure 2. 7 E-box motif and HMG motif are differentially enriched at ZEB1 bound regions.  
A) Density plot of ZEB1 ChIP-seq reads mapping to the genomic regions surrounding the 
summit of ZEB1 binding events. The signal intensity represents the ZEB1 ChIP-seq 
normalized tag count in the 4Kb region surrounding the summit of ZEB1 peaks. P (ZEB1 
ChIP-seq) <10-10. B) Frequency distribution of E-box and HMG-box motifs within a 4kb 
region centered at ZEB1 peak summits or 4Kb upstream. Y axis represents the number of 
motifs present in bins of 100bp along the 4kb region. P (ZEB1 ChIP-Seq) <10-10. 
To determine how these motifs are distributed among the population of ZEB1 binding 
events we performed hierarchical clustering of the peaks based on the presence of each 
binding motif in a 100bp region centered at the peak summits. This clustering 
segregates most ZEB1 peaks in two large groups containing either motif, whereas only 
a minority of the peaks (3.8%) contains both (Figure 2. 8A). Furthermore, the 
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distribution of ZEB1 peaks relatively to the distance to transcription start sites (TSSs) 
and genomic features is very different in these two subpopulations of ZEB1 binding 
events. ZEB1 binding events associated with HMG motifs occurs mostly at regions 
distant from TSS, with only 13% of the binding occurring within 5kb of the closest TSS, 




Figure 2. 8 ZEB1 binding events are mediated either through E-box or HMG motifs. 
A) Hierarchical clustering of 100nts surrounding ZEB1 peak summits based on the presence 
(red) or absence (blue) of WRE, E-box or both. Only 3.81% of peaks have both motifs. ChIP-
seq p-value<10-10. B) Percentage of NCH421K ZEB1 ChIP-Seq HMG motif peaks at indicated 
distances from the nearest TSS. P<10-10. C) Percentage of NCH421K ZEB1 ChIP-Seq HMG 
motif peaks overlapping gene features. P<10-10. D) Percentage of NCH421K ZEB1 ChIP-Seq 
E-box peaks at indicated distances from the nearest TSS. P<10-10. E) Percentage of NCH421K 
ZEB1 ChIP-Seq HMG-box peaks overlapping gene features. P<10-10. 
By contrast, the population of E-box containing binding events exhibited a distinct 
binding profile, with a higher percentage occurring at close distance to TSSs - 28% of 
the binding events occur within 5kb of a TSS and a much higher proportion occurs in 
promoters, 5’UTR and exons (Figure 2. 8D, E). Thus, results show the presence of the 
two motifs is mutually exclusive, with peaks associated with each motif falling within 
regions with distinct genomic features. Importantly, our observations are consistent 
with ZEB1 being recruited via two distinct modes (direct or indirectly by an as yet 
identified transcription factor) via the E-box or HMG motif sequences, respectively.  
We then performed a frequency distribution analysis of the two DNA motifs in the 4kb 
regions surrounding ZEB1 peak summits associated with direct target genes to 
determine if the E-box and HMG motif were differentially over-represented in the 
regulatory regions of ZEB1 activated or repressed genes. Notably, the two motifs are 
differentially associated with changes in gene expression. Whereas the E-box motif is 
associated with peaks near both activated and repressed genes, the HMG motif is 
exclusively associated with peaks near ZEB1 activated genes (Figure 2. 9A).  
Since the HMG motif and the E-box motif are over-represented in peaks associated with 
gene activation we characterized the distribution of these motifs in the regulatory 
regions near activated genes. To do this we performed hierarchical clustering of the 
peaks based on the presence of each binding motif in the 200bp region surrounding the 
peak summits (Figure 2. 9B). 62% of the peaks are clustered in a group containing the 
HMG motif while 43% contain the E-box motif. Only 4.5% of the peaks contained both 
motifs therefore the recruitment of ZEB1 to peaks associated with activated genes is 




Figure 2. 9 The HMG motif is exclusively enriched at peaks associated with ZEB1 activated 
genes.  
A) Frequency distribution of E-box and HMG-box motifs within a 4kb region centered at 
ZEB1 peak summits associated with repressed or activated genes or 5Kb upstream. Y axis 
represents the number of motifs present in bins of 50bp along the 4kb region. ChIP-Seq p-
value<10-10. B) Hierarchical clustering of 200nts surrounding ZEB1 peak summits associated 
with ZEB1 activated genes based on the presence (red) or absence (blue) of HMG-box, E-
box or both. Negative control is region 4kb upstream of peak summits. ChIP-seq p-
value<10-10. 
The control represents the 200bp region 5kb upstream of the peak summits and depicts 
the presence of these motifs in regions that are not bound by ZEB1. 
In conclusion, our analysis suggests a surprising novel paradigm whereby ZEB1 is being 
indirectly recruited via a HMG transcription factor to activate gene expression.  
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4.5. LEF1 mediates ZEB1 binding to regulatory regions of Nrp2 and Prex1 
genes 
 
Figure 2. 10 ZEB1 binds to regulatory regions exclusively associated with HMG motifs. 
A) ChIP-seq enrichment profile of active regulatory regions bound by ZEB1 associated with 
the NRP2 and Prex1 genes. Binding to these regions is mediated exclusively through HMG-
boxes binding motifs. B) RT-PCR 72 hours after ZEB1 knockdown of genes directly repressed 
(Myo6 and Pard6b) or activated by ZEB1 (NRP2, Prex1, ITGB1). Relative expression values 
normalized to reference genes IPO8 and TBP. Mean and SEM of biological replicates is 
shown. ** for p<0.01, * for p<0.05. 
For the remainder of this study, we focused on the transcriptional activator function of 
ZEB1 associated with the HMG motif, as it is likely to cast light into a less studied 
molecular mechanism for ZEB1 activation of gene expression. To further investigate this 
we focused our subsequent studies on the regulation of two genes down-regulated upon 
Zeb1 knock-down: Prex1 and Nrp2. Of the eight ZEB1 peaks associated with the Prex1 
gene, five seem to have binding mostly mediated by the HMG motif whereas E-box motifs 
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are present in the proximity of three of those peaks. In the ZEB1 peaks associated with 
the Nrp2 gene, the E-box motif is absent and binding seems to be mediated exclusively 
by the HMG motif (Figure 2. 10A). 
We started by validating by real-time PCR the deregulation of the ZEB1 target genes 
Nrp2 and Prex1 as well as of other deregulated genes with associated ZEB1 peaks such 
as Pard6b (repressed) and ITGB1 (activated).  While binding of ZEB1 to ITGB1 occurs in 
a region encompassing both ZEB1 binding motifs, only E-box motifs are found at the 
ZEB1 bound regions associated with Pard6b (data not shown). Nrp2, Prex1 and ITGB1 
expression decreased after ZEB1 knockdown while, by contrast Pard6b expression 
increased, as expected (Figure 2. 10B). 
We then defined putative regulatory regions bound by ZEB1 to be used in 
transcriptional assays (see below) that contained HMG motifs but were devoid of E-
boxes associated with Prex1 and Nrp2 Both regions are located within introns, 
contained two HMG motifs each and are enriched for chromatin marks characteristic of 
active enhancers (H3k4me1 and H3K27ac), as determined by chromatin landscape 
profiling of GBM CSCs in a previous study (Figure 2. 10A). 
Due to their expression in NCH421K cells (Figure 2. 11), LEF1/TCF factors are HMG-box 
containing factors that are good candidates to mediate indirect recruitment of ZEB1 to 
its target regions via HMG motifs. LEF1 has been described as one of the main 
downstream effectors of the canonical Wnt signaling in GBM CSCs (Gao et al., 2014) and 
therefore a prime candidate to mediate ZEB1 recruitment to these motifs. In support of 
this hypothesis we were able to recover ZEB1-V5 upon immunoprecipitation of LEF1-
Flag (Figure 2. 12) from protein extracts produced from 293T cells co-transfected with 
expression vectors for both factors, indicating that ZEB1 and LEF1 can physically 




Figure 2. 11 Expression levels of LEF/TCF factors in NCH421K cells.  
Relative expression levels of TCF factors and reference genes GAPDH and TBP in NCH421K 
CS cells. Mean and SEM of biological replicates is shown. 
Due to the degeneracy of the HMG-box binding motif we wanted to assess if LEF1 could 
bind to the specific HMG motif predominantly enriched at ZEB1 peak summits. To that 
end we performed an electromobility shift-assay (EMSA) using oligonucleotide probes 
with each of the four HMG motifs identified in the Nrp2 and Prex1 regulatory regions 
and in vitro transcribed and translated LEF1 protein. While LEF1 could bind to all tested 
oligonucleotide probes, mutations of the HMG consensus motifs disrupted binding 
(Figure 2. 13A). Importantly, ZEB1 did not bind to probes solely containing the HMG 
motif (Figure 2. 13C) while it was capable of binding to control probes containing the E-
box motif (Figure 2. 13B). However, co-incubation with ZEB1 decreased LEF1 binding 
to probes containing the HMG-box binding sequence again suggesting that both factors 
can physically interact (Figure 2. 13C).  
Afterwards, we investigated LEF1 binding to the selected regulatory regions in the 
NCH421K cellular context by performing ChIP-PCR with chromatin extracted from 
NCH421K cells, using a LEF1 antibody (Figure 2. 14A). We observed that LEF1 binds 
strongly to the Prex1 region and reproducibly albeit less efficiently to a region 
containing one of the described Nrp2 HMG motifs when compared to a negative control 





Figure 2. 12 ZEB1 co-immunoprecipitates interacts with LEF1.  
Co-precipitation of ZEB1-V5 by LEF1-Flag immunoprecipitation in 293T cells transfected 
with expression vectors according to diagram. Protein levels measured by Western Blot. 
To determine if LEF1 binding directly affects the expression levels of the selected ZEB1 
activated genes we performed RT-PCR 72 hours after a shRNA-induced knockdown of 
LEF1, resulting in a 77% decrease of LEF1 transcript levels (Figure 2. 14B).  The 
knockdown of LEF1 affected negatively its own expression and that of the Wnt-signaling 
targets, Axin2 and NKD1, while having no effect in the levels of -catenin or ZEB1. 
Interestingly, it also led to decreased expression of Prex1 while Nrp2 levels were 
unchanged. While these observations support the previous LEF1 binding results and 
further implicate LEF1 in Prex1 regulation, it is possible that other ZEB1 activated 
targets bound by LEF1 such as Nrp2 may have a different threshold of sensitivity to LEF1 
levels or are co-regulated by other TCF factors in a redundant manner. 
To investigate if the ZEB1-LEF1 interaction could be mediating gene activation of Nrp2 
and Prex1, we performed transcriptional assays using reporter constructs bearing the 
luciferase gene and a minimal promoter under the regulation of the selected regulatory 
regions of the Nrp2 and Prex1 genes (Figure 2. 15A and B). Because transcriptional 
assays are highly cell context dependent, experiments were performed in both mouse 
p19 teratocarcinoma cells and human Cb192 neural stem cells. LEF1 by itself was 




Figure 2. 13 LEF1 binds to HMG motifs present in NRP2 and Prex1 enhancers and ZEB1 
interacts with LEF1.  
A) Electrophoretic mobility shift assays for 32P-labelled NRP2 HMG2 (1), NRP2 HMG2 mut 
(2), NRP2 HMG1 (3), Prex1 HMG1 (4), Prex1 HMG1 mut (5), Prex1 HMG2 (6) oligonucleotides 
incubated with in vitro transcribed/translated LEF1. B) EMSAs for 32P-labelled ZEB1 E-box 
(1) and ZEB1 E-box_Mut (2) oligonucleotides incubated with in vitro transcribed/translated 
ZEB1. C) EMSAs for 32P-labelled NRP2 HMG2 (1) and NRP2 HMG2 mut (2) oligonucleotides 
incubated with in vitro transcribed/translated factors. Filled arrowheads mark the binding 





Figure 2. 14 LEF1 binds Prex1 and Nrp2 regulatory regions, and regulates Prex1 expression.  
A) LEF1 ChIP-qPCR in NCH421K cells shows that LEF1 binds to HMG motifs in Nrp2 and Prex1 
regulatory regions in NCH421K cells. ORF1 is a negative control region with no HMG motif. 
Mean+SEM of biological replicates is shown. **** for p<0.0001, * for p<0.05. B) RT-PCR 72 
hours after LEF1 knockdown of genes directly regulated by LEF1, of genes activated by ZEB1 
(Nrp2, Prex1, ITGB1), of ZEB1 and ZEB2. Relative expression values normalized to reference 
genes GAPDH and TBP. Mean and SEM of biological replicates is shown. ** for p<0.01 and * 
for p<0.05. 
Strikingly, while LEF1 expression resulted in transactivation, ZEB1 was only able to 
activate the selected enhancers in the presence of LEF1 in p19 cells, with co-expression 
of the two factors leading to transcriptional synergy. In Cb192 cells, transcriptional 
synergy between both factors was also observed, although ZEB1 alone (but not LEF1) 
could transactivate the reporter constructs. The importance of the HMG motifs to the 
activity of the Nrp2 and Prex1 regulatory regions was analyzed by performing 
mutations previously shown to abrogate binding to these motifs. These mutations 
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abolished the synergistic effect of both TFs in transcriptional assays performed in the 
human neural stem cell line Cb192 (Figure 2. 16A and B).  
 
Figure 2. 15 ZEB1 synergizes with LEF1 in activating NRP2 and Prex1 expression.  
Reporter gene assays in p19 cells of NRP2-enhancer (A) or Prex1-enhancer (B) -globin 
reporter constructs cotransfected with expression vectors for LEF1, ZEB1 or both. Mean ± CI 
of quadruplicate assays. **** for p<0.0001. 
Finally, and in order to further investigate the importance of the HMG-box binding 
motifs outside their native contexts, we generated a vector containing 7 copies of one of 
the HMG motif present in the Nrp2 enhancer. We again observed synergy between ZEB1 
and LEF1 in transcriptional assays with this reporter construct (Figure 2. 17). 
Altogether, these observations support the view that the HMG motif is necessary and 
sufficient for the synergistic activity of ZEB1 with LEF1 and that the functional 





Figure 2. 16 HMG motif mutations abolish ZEB1/LEF1 synergy. 
Reporter gene assays in Cb192 cells of NRP2-enhancer (A) or Prex1 enhancer (B) and 
corresponding mutated versions reporter constructs cotransfected with expression vectors 
for LEF1,  Zeb1 or both. Mean ± CI of quadruplicate assays. **** for p<0.0001 and *** for 
p<0.001. 
4.6. Target gene activation by ZEB1-LEF1/TCF factors does not require 
active Wnt pathway 
Given the role of Lef1 as a downstream mediator of Wnt signaling, and since this 
pathway has been reported as promoting ZEB1 expression in NCH421K cells (Kahlert et 
al., 2012), we decided to investigate if Wnt signaling is required for the activation of gene 
expression through the novel mechanism involving a LEF1/ZEB1 synergy. With that 
aim, we started by generating a Lef1 mutant that is not expected to interact with -
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catenin, by performing mutations in two residues - D21A and E29K – of LEF1 that are 
conserved across the LEF/TCF family and are known to be required, based on structural 
and functional data, for the interaction of these transcription factors with -catenin 
(Graham et al., 2000; Grumolato et al., 2013). We also tested a mutated version of TCF7 
(TCF7mut) in those same two residues, that was shown to be incapable of physically 
interacting with -catenin. TCF7 has been described as similar to LEF1 in its ability to 
promote -catenin independent gene activation through interaction with ATF2 factors 
(Grumolato et al., 2013). TCF7L2 is also highly expressed in NCH421K cells and was 
therefore also tested in parallel with other factors.  
 
Figure 2. 17 ZEB1/LEF1 synergize in the activation of HMG motif multimere. 
Reporter gene assays in p19 cells of oligomer of 7 NRP2 HMG-box binding motif (NH7x) b-
Globin reporter constructs cotransfected with control, LEF1, ZEB1. Mean ± CI of 
quadruplicate assays. **** for p<0.0001, *** for p<0.001. 
As expected, expression of stabilized -catenin promoted the ability of TCF7, but not 
TCF7mut, to activate the Wnt-responsive TOP-Flash reporter plasmid (Figure 2. 18A). 
TCF7 synergized with ZEB1 and TCF7mut retains the capacity to function in synergy 
with ZEB1 in the activation of the Nrp2 regulatory region, suggesting that ZEB1 can 
function in synergy with other TCF factors, and this activity can occur independently of 
canonical Wnt signaling (Figure 2. 18B). Importantly, the mutated version of LEF1 also 
retains its ability to synergize with ZEB1 (Figure 2. 18C). TCF7L2 was also capable of 
activating the Nrp2 regulatory region and of synergizing with ZEB1 (Figure 2. 18D) 




Figure 2. 18 Synergy between Zeb1 and LEF1/TCF factors does not require interaction with 
-catenin.  
Reporter gene assays in p19 cells of TOP-Flash constructs (A) or Nrp2 enhancer constructs 
(B-D) cotransfected with expression vectors for TCF7 or TCF7mut, LEF1 or LEF1mut, TCF7L2, 
-catenin S33Y and ZEB1. B) Reporter gene assays in p19 cells of Nrp2-enhancer constructs 
cotransfected with TCF7 or TCF7mut, ZEB1 and S33Y. **** for p<0.0001, ** for p<0.01. 
We then tested if the HMG-box domain of the LEF/TCF factors was sufficient for the 
synergistic activity with ZEB1 independently of -catenin. We performed 
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transcriptional assays of ZEB1 with a fusion protein of the LEF1 HMG-box domain (aa 
265-384) with the VP16 transactivation domain of herpes simplex virus (Aoki et al., 
2002) (Figure 2. 19A). This fusion protein lack the LEF1 N-terminus catenin binding 
domain and the LEF1 Groucho interaction domain (Arce et al., 2009). Strikingly, the 
fusion protein retained the capacity of synergizing with ZEB1 in the activation of the 
TOP-Flash reporter plasmid (Figure 2. 19B) even though it lacked any domain capable 
of interacting with catenin and contains a transactivation domain unrelated with 
Wnt/-catenin signaling.  
 
Figure 2. 19 The N-terminal domain of ZEB1 is required for synergy with LEF/bCTAD fusion 
protein. 
A) LN/VP16 fusion protein. B) Reporter gene assays in Cb192 cells of TOP-Flash reporter 
cotransfected with LN/VP16 and expression vector for ZEB1. Mean+CI of quadruplicate 
biological replicates is shown. * for p<0.05 and **** for p<0.0001.  
These results determine that -catenin is not required for the cooperative 
transactivation of target genes by ZEB1 and LEF1/TCF factors and the HMG-box domain 
of LEF1 is sufficient for the synergistic interaction between these factors. 
163 
 
4.7. No evidence of Wnt signaling activity in NCH421K cells 
 
Figure 2. 20 Wnt signaling is inactive in NCH421K in normal culture conditions.  
A) Validation of absence of Wnt signaling activity by expression RT-PCR after a 24 hour 
incubation with 5uM of Wnt inhibitor IWP-2 with or without 100ng/uL of Wnt3a. Relative 
expression values normalized to reference genes GAPDH and TBP. B) Expression RT-PCR 
after 48 hour incubation with 40uM of Wnt inhibitor XAV939. Relative expression values 
normalized to reference genes IPO8 and TBP. C) Expression levels of Wnt signaling target 
Axin2 compared with reference genes GAPDH and TBP. Mean and SEM of biological 
replicates is shown. ** for p<0.01 and * for p<0.05. 
In order to further investigate the importance of canonical Wnt signaling to gene 
activation by the ZEB1/Lef1 synergy, we next exposed the NCH421K cells to Wnt 
antagonist (porcupine inhibitor) IWP-2 and/or Wnt3a for 24 hours and quantified the 
gene expression changes of the classical Wnt signaling activated genes Axin2, NKD1 and 
LEF1 by RT-PCR. Interestingly, the porcupine inhibitor IWP-2 failed to repress 
expression of canonical Wnt signaling target genes in control conditions while being 
able to partially block their activation when cells were incubated with Wnt3a for 24 
hours (Figure 2. 20A). Significantly, no variation in expression levels was observed for 
the ZEB1 target genes (Nrp2, Prex1 and ITGB1). Similar results were obtained upon 
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incubation of cells in control conditions with Wnt antagonist (tankyrase inhibitor) 
XAV939 (Figure 2. 20B). The residual level of Axin2 expression (a gene considered a 
read-out of Wnt signaling) (Figure 2. 20C), together with the absence of repression of 
Wnt target genes with either antagonist suggests that Wnt signaling is inactive (or 
present at very low levels) in NCH421K cells growing in control condition.  
We next assessed recruitment of -catenin and LEF1 to previously characterized 
regulatory regions of Wnt target genes in NCH421K cells grown in control conditions or 
upon 24 hour incubation with Wnt agonist (GSK3/-inhibitor) CHIR99021. As 
expected, increased expression levels of Wnt signaling target genes Axin2, LEF1 and 
TCF7 were observed upon incubation with this Wnt signaling agonist (Figure 2. 21A). In 
line with the gene expression findings, no recruitment of -catenin to Axin2 and 
Tnfrsf19 regulatory regions (Jho et al., 2002; Lukas et al., 2009) was detected after (but 
not prior) to incubation with Wnt signaling agonist CHIR99021 (Figure 2. 21B). 
Importantly, no -catenin enrichment was detected at the Nrp2 and Prex1 regulatory 
regions in any of the tested conditions. Moreover, no recruitment of LEF1 to NKD1 and 
Tnfrsf19 regulatory regions was observed prior to Wnt signaling activation (Figure 2. 
22).  
Finally, to investigate the cellular localization of endogenous -catenin, since this would 
provide further evidence of the Wnt signaling status in NCH421K cells, we performed 
immunocytochemistry of cells grown either in normal culture conditions or upon 
incubation with CHIR99021. In normal culture conditions we observed that -catenin is 
associated with the plasma membrane and excluded from cell nuclei, whereas it is very 





Figure 2. 21 -catenin does not bind to the Nrp2 and Prex1 regulatory regions before or 
after incubation with Wnt agonist.  
A) RT-PCR for expression of Wnt signaling target genes after a 24 hour incubation with 5uM 
of Wnt agonist CHIR99021. Mean and SEM of biological replicates is shown. ** for p<0.01 
and * for p<0.05. B) ChIP-qPCR to assess binding of-catenin to Wnt targets and Zeb1 
activated genes, in NCH421K cells incubated with 5uM of CHIR99021for 24. ORF1 and ORF2 





Figure 2. 22 LEF1 binding to HMG motifs of Wnt responsive genes is absent in normal 
growing conditions in NCH421K cells.  
LEF1 ChIP-qPCR in NCH421K cells shows absence of LEF1 binding in the proximity of Wnt 
responsive regions. Binding is observed after incubation with 5uM of CHIR99021 for 24 
hours. ORF1 is a negative control region. Mean+SD of triplicate assays are shown. **** for 
p<0.0001 and ** for p<0.01. 
 
Figure 2. 23 -catenin is not present in the nucleus of NCH421K cells in normal culture 
conditions.  
Immunocytochemistry analysis of nuclear -catenin levels after a 24 hour incubation with or 
without 5uM of Wnt agonist CHIR99021. DAPI was used as a nuclear marker. 
Overall, we found no evidence of active Wnt signaling in NCH421K cells grown in control 
conditions based on immunocytochemistry of -catenin, binding of -catenin and LEF1 
to target genes and gene expression of Wnt canonical targets. This leads to the 
conclusion that transcriptional activation via LEF1-mediated recruitment of ZEB1 to 
HMG motifs does not require active Wnt signaling, further supported by absence of 
detectable levels of -catenin at the Nrp2 and Prex1 regulatory regions after incubation 




Figure 2. 24 Wnt signaling activation in NCH421K cells decreases ZEB1 mRNA levels. 
RT-PCR of Wnt signaling targets (Axin2 and NKD1), of genes activated by ZEB1 through 
HMG box binding motif (NRP2, Prex1, ITGB1) and of ZEB1 and ZEB2 after a 24 hour 
incubation with 100ng/uL of Wnt3a (A), 48 hour incubation with 1uM of Wnt agonist 6-BIO 
(B) and with 5uM of Wnt agonist CHIR99021 (C) Relative expression values normalized to 
reference genes GAPDH and TBP. Mean and SEM of biological replicates is shown. **** for 
p<0.0001, *** for p<0.001, ** for p<0.01 and * for p<0.05. 
4.8. Canonical Wnt signaling pathway down-regulates ZEB1 expression 
in GBM CSCs  
Although previous results indicated Wnt signaling was not required for activation of 
ZEB1/Lef1 target genes, it could still be the case that Wnt signaling activation could 
promote the expression of such targets.  Unexpectedly, incubation of NCH421K cells 
with Wnt3a led to a decrease in the expression levels of ZEB1 (Figure 2. 24A, Figure 2.S 
1).  A reduction in the expression levels of ZEB1 was also observed with the two Wnt 
agonists, CHIR99021 and 6-BIO (Figure 2. 24B, C) while increased ZEB2 expression 
levels were also observed after incubation with CHIR9921. Concomitant with decreased 
168 
 
ZEB1 expression levels, exposure to Wnt3a and 6-BIO led to a decrease of Nrp2 and 
Prex1 expression levels whereas exposure to CHIR99021 resulted in reduced Prex1 
levels while Nrp2 expression remained unchanged. This decrease in expression levels 
of ZEB1 transcript correspond to a mild but reproducible decrease in Zeb1 protein 
expression (Figure 2.S 1). 
While the decrease in ZEB1 expression was moderate and was still associated with 
decreased expression of Prex1 and Nrp2, we assessed ZEB1 recruitment to the 
regulatory regions of its target genes upon Wnt signaling activation. Strikingly, the 
observed decrease in ZEB1 transcript level upon Wnt signaling activation resulted in a 
strong reduction of ZEB1 recruitment to HMG motif target sites (Nrp2, Prex1) to below 
detectable levels by ChIP-qPCR (Figure 2. 25C), while binding of ZEB1 to E-box 
containing regions in Pard6b and ZEB1 promoters severely decreased but was still 
detected (Figure 2. 25B). By contrast, exposure to CHIR99021 led to increased LEF1 
expression levels (Figure 2. 21A) and ChIP-PCR performed using the same chromatin 
preparations, revealed an increased binding of LEF1 to regulatory regions of classical 
Wnt target genes (Figure 2. 22).  
In conclusion, activation of Wnt pathway in NCH421K cells does not further potentiate 
the expression of ZEB1/Lef1 target genes such as Prex1 and Nrp2.  Instead, activation 
of Wnt signaling in NCH421K cells reduces ZEB1 expression, with a severe decrease in 
its indirect recruitment to HMG motif target sites, and does not further potentiate the 




Figure 2. 25 Wnt signaling activation inhibits ZEB1 binding to Nrp2 and Prex1 regulatory 
regions in NCH421K cells.  
A) Positive control regions for ZEB1 binding mediated by E-box motifs. B) Validation of ZEB1 
binding through ChIP-qPCR to positive control regions in NCH421K cells incubated with or 
without 5uM CHIR99021 for 24 hours. B) ZEB1 ChIP-qPCR shows that binding to HMG motifs 
in regulatory regions near Nrp2 and Prex1 decreases below detectable levels after incubation 
with 5uM CHIR99021for 24 hours. ORF1 and ORF2 are negative control regions with no E-
box binding motif while Pard6b and ZEB1 are positive control regions. Mean+SD of triplicate 




4.9. Correlation analysis of expression of ZEB1 and its target genes in 
GBM tumors 
Given the wide expression of Zeb1 observed in glioma and GBM tumor samples (Kahlert 
et al., 2015) (Figure 2.S 2) and having established a novel mechanism for ZEB1 activation 
of gene expression in GBM CSCs and its relevance in promoting expression of genes with 
a described function in invasion/migration and stemness we sought to confirm the 
relevance of this mechanism in a wider GBM context by comparing the transcript levels 
of ZEB1, its target genes and the LEF/TCF factors in transcriptomic data from G-CIMP 
negative IDH1-wt GBM samples (n=465) of the TCGA database.   
Table 2. 16 Correlation between mRNA expression of ZEB1 and LEF1/TCF factors in G-CIMP 
negative IDH1-wt GBM samples from the TCGA database (n=465). 
 
Both ZEB1 and LEF/TCF factors have been previously described as regulators of cell 
migration, invasion, and proliferation in the glioma/GBM (Gao et al., 2014; Kang, 2011; 
Li et al., 2016; Pećina-Šlaus et al., 2014; Rheinbay et al., 2013; Siebzehnrubl et al., 2013; 
Zhang et al., 2011) therefore we checked if ZEB1 expression correlates with expression 
of LEF/TCF factors across the TCGA dataset. Interestingly, ZEB1 expression is positively 
correlated with TCF7L2 and TCFL1, no correlation was observed with LEF1 while a 
negative correlation was found with TCF7 (Table 2. 16).  
From the 60 activated ZEB1 targets, 26 genes were positively correlated with ZEB1 
(Table 2. 17), 15 of which have expected roles in cell adhesion/migration and/or 
proliferation based on available literature, and are therefore candidate mediators of 
tumor invasion and tumorigenicity downstream of ZEB1.  Notably, the second highest 
correlation was found between ZEB1 and Prex1 (Pearson correlation=0.442) (Figure 2. 
26B), with both genes displaying a similar expression profile across different GBM 
subtypes (Figure 2. 26A). When performing linear regression ZEB1 expression 
significantly explains (p-value<0.0001) 20% of the variability of Prex1 expression. 
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Moreover, Prex1 expression correlated positively with LEF1, TCF7L1 and TCF7L2 
across the TCGA dataset (Table 2. 18).  
Table 2. 17 Significant correlation between mRNA expression of ZEB1 and ZEB1 activated 
target genes in NCH421K cells in G-CIMP negative IDH1-wt GBM samples from the TCGA 
database (n=465). Putative roles in cell adhesion/migration and proliferation based on 
literature search are indicated. 
 
Table 2. 18 Correlation between mRNA expression of Prex1 and LEF1/TCF factors in G-CIMP 
negative IDH1-wt GBM samples from the TCGA database (n=465).  
 
Considering the potential confounding effects of an analysis performed at a cell 
population level, we compared the expression of ZEB1 and Prex1 by 
immunohistochemistry in sectioned GBM tumor samples.  ZEB1 and Prex1 expression 
were strongly overlapping, across the whole tumor area when comparing alternating 
serial sections from multiple glioblastoma cases (n=6) (Figure 2. 26C). We could confirm 
this finding on the cellular level by fluorescence immunohistochemistry. Most cells that 
were Prex1-positive also showed nuclear immunoreactivity for ZEB1 and vice versa, 
although in some cases we also observed cells that were positive only for ZEB1 (Figure 
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2. 26D). In conclusion, these results are in line with Prex1 being positively regulated by 
ZEB1 in GBM tumors. 
 
Figure 2. 26 Correlative expression of Zeb1 and Prex1 in GBM samples. 
A) ZEB1 and Prex1 mRNA levels in the distinct molecular subtypes of GBM. B) Prex1 mRNA 
levels correlated to ZEB1 mRNA levels using a linear regression model. C) Representative 
alternating serial sections of GBM samples stained for ZEB1 and Prex1 demonstrating 
correlated expression. D) Co-immunostaining of ZEB1 and Prex1 showing co-expression at 
the cellular level in GBM samples 
Considering the inverse correlation between ZEB1 levels and life expectancy of GBM 
patients (Siebzehnrubl et al., 2013), as well as the importance of Prex1 in promoting 
migration and invasion of melanoma and breast cancer cells (Lindsay et al., 2011; Qin et 
al., 2009; Sosa et al., 2010), we investigated if the expression of Prex1 could be used as 
a prognostic factor in GBM samples. We divided the 159 glioblastoma samples of the 
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Gravendeel glioma dataset (Gravendeel et al., 2009) by the most significant survival 
Prex1 expression level cut-off established with the log-rank test (smallest log rank p-
value) and found that high Prex1 expression indeed correlated with reduced survival of 
glioblastoma patients (median survival of 7.7 months against 11.2 months of patients 
with low Prex1 expression) with this difference increasing to 5.2 months when 
considering only the quartile population with highest and lowest Prex1 expression 
(Figure 2. 27A and B). These observations suggest the level of Prex1 expression can be 
used as a prognostic factor in GBM, and support an important role for Prex1 as a 
downstream effector of ZEB1 in this cancer context. 
 
Figure 2. 27 Prex1 expression levels are associated with decreased survival.  
A) Kaplan-Meyer plots of survival of GBM patients with high or low Prex1 mRNA levels. B) 
Comparison of the survival curves of the 25% GBM patients with the highest Prex1 
expression level and of the 25% with the lowest expression levels. Underlying data publicly 






In this chapter we provide the first genome-wide characterization of ZEB1 target genes 
in a malignant context. This uncovered a novel mechanism whereby ZEB1 activates gene 
expression by indirect recruitment via LEF1 to the regulatory regions of a large number 
of target genes. These include previously undescribed transcriptional targets with a 
putative function in cell invasion in GBM, most notably Prex1. Genome-wide mapping of 
ZEB1 binding sites revealed a large scale use of this previously undescribed mechanism, 
a surprising finding considering the prevalent focus on ZEB1 activity as a transcriptional 
repressor in a cancer context.  
How the functional interaction between ZEB1 and LEF1 results in gene activation, and 
in particular what protein cofactors mediate this ZEB1 function, remains to be 
elucidated.  ZEB1 was recently shown to physically interact with TCF7L2 to activate 
LAMC2 and uPA genes in colorectal cancer cells, via a mechanism that involves the 
recruitment of p300.  In sharp contrast with our findings however, this activity requires 
direct binding of ZEB1 to E-box sequences, and is strictly dependent on active Wnt 
signaling.  Nevertheless, the physical interaction with both TCF7L2 in this case and LEF1 
occur through the HMG-box containing C-terminus fragment (aa252 to 619) (Sánchez-
Tilló et al., 2015). This raises the possibility that ZEB1 may interact with other HMG-box 
containing transcription factors to regulate gene transcription. Another family of 
transcription factors which are likely candidates for this interaction are the Sox 
transcription factors. Indeed, ZEB1 was identified as a Sox2 interacting protein in mouse 
NSCs (Engelen et al., 2011). However, we could not validate such interaction with human 
homologues, and co-transfection of ZEB1 with Sox2 did not promote gene expression in 
transcriptional assays as shown for Lef1 (data not shown). 
 Surprisingly when considering results in other cell types, Wnt activation reduced ZEB1 
expression in our cellular model.  This is particularly at odds with a recent study 
showing decreased ZEB1 expression upon -catenin knock-down in NCH421K cells 
(Kahlert et al., 2012).  We attribute this observation, which we can also reproduce, to a 
role of non-nuclear -catenin (Figure 2.S 3).  
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Overall, no evidence for active Wnt signaling in NCH421K cells grown in control 
conditions was found. This leads to the conclusion that transcriptional activation via 
LEF1-mediated recruitment of ZEB1 to HMG motifs does not require nuclear -catenin 
(i.e. active Wnt signaling). This is unexpected since LEF/TCF factors are mostly 
described as acting as transcriptional repressors by forming complexes with 
Groucho/TLE corepressors in the absence of Wnt signaling (Kléber and Sommer, 2004; 
Michaelidis and Lie, 2007) although a few cases of Wnt independent LEF1/TCF7 
functions have been reported - namely in association with ATF2 transcription factors 
(Grumolato et al., 2013). Otherwise, it is also possible that in other cellular contexts the 
synergistic activity of ZEB1 and LEF/TCF factors may be further enhanced by canonical 
Wnt signaling, defining a cross-talk with this important pathway. 
Recently there has been an increasing focus on the role played by LEF/TCF factors in 
GBM. LEF1, TCF7, TCF7L1 and TCFL2 were reported as being overexpressed in gliomas 
compared with normal brain tissue with their expression increasing with tumor grade. 
All LEF/TCF factors have been described as regulators of cell migration, invasion, and 
proliferation in the glioma/GBM (Gao et al., 2014; Kang, 2011; Li et al., 2016; Pećina-
Šlaus et al., 2014; Rheinbay et al., 2013; Zhang et al., 2011). Given the expected 
redundancy observed between members of the LEF/TCF family, supported also by our 
transcriptional assays, and the high correlation between ZEB1 expression levels and 
TCF7L1/TCF7L2 in the GBM context, it will be important to fully investigate to which 
extent other TCF factors may also interact with and influence ZEB1 transcriptional 
activity in the GBM context. Our work raises the possibility that the interaction of LEF1 
and other TCF factors with ZEB1 may play a role in the regulation of cell migration, 
invasion and proliferation in a Wnt-independent manner. It will be important to 
understand if this interaction could also lead to the recruitment of LEF/TCF factors to 
gene regulatory regions through E-box motifs in a genome-wide manner and if it plays 
a significant role in the transcriptional activity of the LEF/TCF factors. Furthermore, it 
will be important to understand if our paradigm is applicable in different cancer 
contexts besides GBM and more generally in a developmental context. 
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Overall, our findings provide a model whereby ZEB1 can simultaneously activate and 
repress gene expression in the same cellular context, and in this way coordinate the 
implementation of complex genetic programs such as EMT. Targets activated by 
ZEB1/Lef1 include genes with expected functions in cell invasion in GBM, most notably 
Prex1. The Prex1 gene encodes a guanine nucleotide exchange factor (GEF) that 
activates Rho family GTPases (RACs), promoting cell migration, invasion and metastatic 
growth in melanoma, prostate and breast cancer by a Rac1 dependent mechanism. The 
amplification of the region where the Prex1 gene is located is associated with poor 
patient outcomes of breast cancer, hereditary prostate cancer, pancreatic endocrine 
tumors, and ovarian cancers (Lucato et al., 2015). Prex1 mediates the activation of Rac1 
by ErbB tyrosine kinase receptors in breast cancer. It activates PI3K/AKT, MEK/ERK 
and IGF1/InsR signaling in a Rac-dependent manner in the breast cancer context, thus 
driving oncogenic signaling in a PTEN independent manner (Dillon et al., 2015; Ebi et 
al., 2013; Lindsay et al., 2011; Lucato et al., 2015; Sosa et al., 2010). In GBM, Rho 
GTPases are deregulated, often via hyperactivity or overexpression of their activators. 
Downstream effectors of Rho GTPases have been shown to promote invasiveness and, 
importantly, glioma cell survival (Fortin Ensign et al., 2013). Even if Prex1 importance 
in GBM has yet to be addressed, the finding that high Prex1 expression associates with 
poor patient survival suggests an important role in malignancy in this context much like 
in other cancer contexts.  Although Rho GTPases and their associated proteins are 
known mediators of cell motility in EMT programs, this is to our knowledge the first 
direct link between a classical EMT inducer and Prex1.  It will be important to 
understand if ZEB1 also activates Prex1 in other types of cancer, and to which extend 
Rho/Rac pathway components are under the direct control of classical EMT activators. 
We also found that ZEB1 promotes ITGB1 expression, raising the possibility that these 
factors may be involved in a feedback loop in the GBM context, since ITGB1 has been 
described as an inducer of ZEB1 expression through the NF-B pathway leading to 
increased glioma/GBM invasion (Edwards et al., 2011) Moreover, the expression of both 
these factors is significantly correlated across the TCGA dataset. Concurrently, we also 
observed the expected repressive function of ZEB1, mediated by binding to E-box 
177 
 
sequences.  Amongst the repressed genes was Pard6b, a member of the Par6 family and 
a major regulator of apical-basal polarity in epithelial cells (Brajenovic et al., 2004; Chen 
and Zhang, 2013; Hurd et al., 2003; Kohjima et al., 2002; Yamanaka et al., 2003), a gene 
that we helped identify as being repressed by ZEB1 in a cerebellar context (Singh et al., 
2016). 
Surprisingly, we could not find any evidence for the expression and/or regulation of the 
miR-200 microRNAs that is central for ZEB1 regulatory role in peripheral tumors. This 
is surprising, considering that the ZEB1/miR-200 feedback loop had been described as 
exerting simultaneous influence over invasion, chemoresistance and tumourigenesis in 
GBM through the downstream effectors ROBO1, c-MYB and MGMT (Siebzehnrubl et al., 
2013).  
In conclusion, we discovered that ZEB1 plays not only a role as a transcriptional 
repressor but also as an activator, through a novel mechanism for activation of gene 
expression through physical interaction with LEF1, in the same GBM CSC context. It 
regulates the expression of genes with expected functions in the regulation of cell shape, 
motility and proliferation and in this way coordinating the implementation of a complex 





Figure 2. 28 Working model of ZEB1 transcriptional activity in GBM CSCs 
ZEB1 plays a dual role as transcriptional activator and repressor in GBM CSCs. Important for 
this dual role is a novel mechanism for activation of gene expression through physical 
interaction with LEF1. Through this mechanism ZEB1 promotes expression of Prex1. 
Activation of Wnt/-catenin signaling decreases ZEB1 expression levels and leads to 




6. Supplemental Figures 
 
 
Figure 2.S 1 Wnt signaling activation in NCH421K decreases ZEB1 protein levels.  
ZEB1 protein levels in NCH421K cells after a 24 hour incubation with 5uM of Wnt agonist 
CHIR99021 detected by Western Blot with rabbit anti-ZEB1 antibody  
 
 
Figure 2.S 2 ZEB1 expression in glioma tumor samples.  
Immunohistochemical staining for ZEB1 protein on patient tumor samples of gliomas of 
various grades.  One representative image per tumor entity is shown.  Red=Zeb1; blue= 
nuclear counterstain with hematoxylin; pa: pilocytic astrocytoma; 5: astrocytoma; gbm: 






Figure 2.S 3 -catenin knockdown led to a decrease in ZEB1 and LEF1 levels.  
RT-PCR 72 hours after -catenin knockdown of genes directly regulated by Wnt signaling, 
of genes activated by ZEB1 through HMG box binding motif (NRP2, Prex1, ITGB1), ZEB1 and 
ZEB2. Relative expression values normalized to reference genes GAPDH and TBP. Mean and 
SEM of biological replicates is shown. *** for p-value<0.001, ** for p-value<0.01, * for p-
value<0.05. 
 
Table 2.S 1 List of ZEB1 deregulated genes with associated ZEB1 bound regions 
ZEB1 KD  
Downregulated 
genes p-value Log2 (Fold Change) 
ZEB1 KD  
Upregulated 
genes p-value Log2(Fold Change) 
ITGB1 0.00016 -1.38 DENND1B 0.047017 0.21 
TENC1 0.000759 -0.94 PRKCI 0.04278 0.23 
TSPAN3 0.000376 -0.89 ADCK2 0.049357 0.24 
A2M 0.000229 -0.89 PPM1H 0.042814 0.26 
RMI2 0.0007 -0.82 HRK 0.035658 0.26 
GPNMB 0.006637 -0.66 CSRP2 0.039165 0.27 
B3GALT2 0.020397 -0.65 SIX1 0.026801 0.28 
PACSIN2 0.000977 -0.61 SHROOM3 0.027577 0.29 
FRZB 0.024786 -0.58 KCNK1 0.033413 0.29 
SYNPO2L 0.003203 -0.57 PCNXL2 0.042543 0.29 
HAPLN1 0.002454 -0.51 FA2H 0.043124 0.29 
MGAT4A 0.002885 -0.51 CAST 0.043875 0.29 
IRAK1 0.009245 -0.49 ARHGEF16 0.036694 0.30 
ANKH 0.007329 -0.48 PALLD 0.030298 0.30 
COL20A1 0.008023 -0.48 C4orf29 0.040403 0.31 
ADAMTS17 0.007246 -0.47 MYO6 0.04278 0.31 
PACRG 0.011237 -0.45 SBK1 0.017119 0.32 
LRRC17 0.01785 -0.44 CMTM4 0.023651 0.32 
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SOBP 0.007329 -0.42 PDP2 0.038528 0.33 
GIPC1 0.006031 -0.42 SVIP 0.017119 0.34 
FAM127A 0.006912 -0.42 PIK3AP1 0.013976 0.34 
COL9A1 0.009245 -0.41 AGL 0.040455 0.34 
PHLDA1 0.007145 -0.38 NRXN3 0.037301 0.35 
HEY2 0.029014 -0.38 GUCY1A3 0.012339 0.36 
CXCL11 0.017119 -0.37 MYO5C 0.007145 0.38 
EPB41L4B 0.019501 -0.37 MANSC1 0.038329 0.40 
MANBAL 0.017789 -0.37 ZBTB8B 0.031514 0.40 
GSN 0.033323 -0.36 PROX1 0.029023 0.40 
ACSBG1 0.043467 -0.34 PDXDC1 0.007145 0.42 
PITRM1 0.026264 -0.34 SNX10 0.039006 0.43 
PTAR1 0.034906 -0.33 COMTD1 0.049357 0.43 
NCALD 0.022333 -0.33 RAB11FIP4 0.007145 0.44 
NRP2 0.033323 -0.33 FAM134B 0.005571 0.45 
LITAF 0.018074 -0.31 TPD52L1 0.049494 0.46 
HMGB1 0.029014 -0.31 PCLO 0.012339 0.48 
LGALS1 0.047017 -0.29 PARD6B 0.017119 0.49 
SOD3 0.023968 -0.29 PLA2G12A 0.00148 0.53 
PID1 0.04923 -0.29 VAMP3 0.002224 0.56 
FAM179B 0.021095 -0.29 ARG2 0.002885 0.59 
FAM129B 0.040708 -0.29 CXADR 0.007189 0.60 
BNIP1 0.034906 -0.28 IFIH1 0.017119 0.62 
DEPDC1B 0.028052 -0.28 FUCA1 0.014505 0.67 
CMTM5 0.049494 -0.28    
PLEKHM1 0.030428 -0.28    
PITPNC1 0.038507 -0.28    
MYLIP 0.041348 -0.28    
TP53I3 0.038507 -0.27    
S100B 0.031514 -0.26    
USP54 0.035686 -0.26    
PREX1 0.036449 -0.26    
SPRY4 0.036611 -0.26    
GET4 0.035686 -0.26    
RGS3 0.049494 -0.25    
ERCC1 0.049925 -0.25    
RBPJ 0.047479 -0.24    
182 
 
CSGALNACT1 0.047774 -0.24    
CORO1C 0.043645 -0.23    
SULF2 0.049357 -0.23    
NUP93 0.04278 -0.22    
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Transcriptional characterization of ZEB1 in a 








ZEB1 is highly expressed in the neural stem/progenitor cell population in the germinal 
layers of the developing brain and spinal cord, a pattern that suggests a role in 
maintaining a progenitor state, which is also supported by functional evidence in ZEB1 
null embryos. Here we performed a genome-wide analysis of ZEB1 binding profile in 
two distinct NSC lines, of human and mouse origin. Results indicate many ZEB1 binding 
events in human Cb192 cells result from indirect recruitment via an HMG-box 
transcription factor, suggesting the novel ZEB1/LEF1 paradigm is at play and extending 
previous observations to a non-malignant cell context. Strikingly, the same was not 
observed in mouse NS5 cells, which could be explained by either species differences or 
the different dorsal/ventral character displayed by the two cell lines. 
ZEB1 binding profile in NS5 cells was further combined with expression profiling after 
ZEB1 gain-of-function in granule neuron progenitors (GNPs) of the mouse cerebellum, 
to identify ZEB1 target genes in this cellular context. We found that ZEB1 acts mostly as 
a transcriptional repressor in GNPs, and identify many key apical-basal polarity genes, 
including members of the Par complex, as direct ZEB1 targets. Subsequent functional 
studies showed that by repressing these genes in GNPs, ZEB1 controls germinal layer 





During the development of the CNS there are several distinct types of neural 
stem/progenitor cells. In the primordium of the CNS, the neural plate, originates from a 
specialized region of the ectoderm made of a single sheet of neuroepithelial cells (NECs) 
which form the neuoepithelium. These cells undergo rapid symmetric divisions that 
result in planar expansion of the neural plate and generation of the neural tube. With 
the switch to neurogenesis the progenitor cells, located in the layer that lines the 
ventricle (VZ), shift their identity from NE cells to radial glial cells (RGCs). RGCs are 
capable of originating neurons, astrocytes and oligodendrocytes (Götz and Huttner, 
2005; Martynoga et al., 2012). In addition to RGCs populating the VZ, another population 
of neural progenitors arise in the secondary germinal layer basal to the VZ, named the 
SVZ: basal progenitors, also known as intermediate neural progenitors (INPs). These 
progenitor cells are also capable of self-renewal and of originating neurons and 
originate from RGCs (Borrell and Götz, 2014).  
The expression pattern of ZEB1 suggests that it may play a role as a maintainer of the 
progenitor state in a NSC context during telencephalic development. Expression of ZEB1 
is found in progenitor cells of the VZ and SVZ of the telencephalon around the lateral 
ventricles of rat, mice and human. During rat forebrain embryonic and postnatal 
development, it is expressed in this area of the VZ during E14-E16, a stage wherein 
proliferation is undergoing. During this developmental period, the ventricular zone 
expands followed by contraction by day E18 as proliferating cells differentiate and little 
expression is found in these cells that migrate to form the developing cortex. ZEB1 co-
expresses with Proliferating Cell Nuclear Antigen (PCNA) a marker expressed in the 
proliferating progenitors of the outer margins of VZ  and SVZ (Takahashi and Caviness). 
ZEB1 expression decreased during late development, along with the decrease of the 
progenitor population (Yen et al., 2001). The correlation of ZEB1 with maintenance of a 
progenitor state in the developing rat CNS is corroborated in mice where it is also highly 
expressed in proliferating neural progenitor cells in PCNA-positive areas at the outer 
margin of the VZ and SVZ. Thus ZEB1 expression overlaps with Ngn1 and Ngn2 on the 
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dorsal VZ and Ascl1 and Dlx in the ventral VZ (Darling et al., 2003; Funahashi et al., 
1993). Similarly in human embryos, ZEB1 is strongly expressed in the VZ and also in 
neural progenitors of the SVZ, with mRNA expression analyses of human brains 
revealing its highest expression in very young fetal samples (weeks 8–9) (Kahlert et al., 
2015). 
An additional  correlation between a proliferative state and ZEB1 expression was also 
observed when induction of neurodifferentiation of p19 cells led to a decrease of ZEB1 
expression (Yen et al., 2001). Importantly, analysis of ZEB1 null embryos revealed 
decreased proliferation in telencephalic progenitors, associated with ectopic expression 
of the cell-cycle inhibitory CDK inhibitors p15 and p21, whose promoters were shown 
to be directly bound by ZEB1 (Liu et al., 2008).  
Moreover, ZEB1 may play a role as a promoter of migration of NSCs in the developing 
human embryo since inhibition of ZEB1 expression in hNSCs isolated from the brain of 
first trimester fetuses and grown as neurospheres significantly decreased their 
invasiveness in in vitro assays (Kahlert et al., 2015).  
2.1. NS cell lines 
The main aim of the experiments described in this chapter was to determine if the 
previously characterized ZEB1/LEF1 paradigm is at play in non-malignant cells, by 
extending the genome-wide location analysis of ZEB1 to additional cellular contexts. 
GBM CSCs share several similarities with NSCs such as the capability to proliferate as 
neurospheres in non-adherent conditions, expression of high-levels of NSC markers 
such as Nestin, CD133 or Sox2 (Campos et al. 2010; Lee et al. 2006; Pollard et al. 2009) 
and the capacity to differentiate into cells that express neuronal, glial and 
oligodendroglial markers. Furthermore, adult NSCs in the SVZ of the adult mammalian 
brain have been extensively studied as potential candidates for the glioma cell of origin, 
alongside with astrocyte dedifferentiation and malignant transformation of 
oligodendrocyte progenitors (OPCs) (Chen et al., 2012; Goffart et al., 2013; Stiles and 
Rowitch, 2008) with a recent study even reporting the first direct observation of the 
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malignant transformation of adult NSCs from the SVZ into malignant brain tumor CSCs 
(Siebzehnrubl et al., 2009). 
Therefore, we performed the ZEB1 characterization in a neural stem/progenitor cell 
context using two distinct NSC lines:  the human Cb192 NSC line and the mouse NS5 NSC 
line. The human Cb192 cell line was derived from human fetal neural tissue at stage 19-
20 while the mouse NS5 line was derived from mouse embryonic stem cells (ESCs) 
(Conti et al., 2005; Sun et al., 2008). Despite being from different model organisms these 
NSC lines share several similarities. They both express similar forebrain radial glia 
markers such as BLBP, 3CB2 or Pax6 and are capable of differentiation into astrocytes, 
oligodendrocytes and neurons when exposed to appropriate differentiation factors. 
They both expand through symmetrical divisions and grow as homogeneous 




3. Materials and Methods 
3.1. Lentiviral vectors 
The lentiviral vectors used are listed on table 3.5. 
Table 3. 1 Lentiviral vectors 
Vector Company / Reference 
pLKO.1 (Moffat et al., 2006) (Addgene #10878) 
pLKO.1-shLuc (Sarbassov et al., 2005) (Addgene #1864) 
pLKO.1-shZEB1 Sigma Aldrich TRCN0000235853 (Singh et al., 2016) 
3.2. Transformation into chemically competent E.coli 
100μL of chemically competent E.coli DH5α were incubated with approximately 500ng 
of vector DNA for 15min on ice. After a 60sec heat shock at 37ºC the bacteria were chilled 
on ice for at least 2min, 250μL LB was added. The bacteria were incubated for 
approximately 1h at 37ºC on a shaker incubator, subsequently plated on LB-Amp plates 
and placed overnight at 37ºC. 
3.3. DNA purification 
Plasmids were isolated from E.coli DH5α using Qiagen Mini, Midi or Maxi-Prep Kits. PCR-
Products were purified with the Qiagen PCR Purification Kit, DNA bands from agarose 
gels were purified with the Qiagen Gel Extraction Kit. All steps were performed as 
recommended by the supplier. 
Alternatively, DNA was separated by phenol-chloroform extraction. For that, one 
volume (relative to the sample volume) of phenol:chloroform:isoamyl alcohol 25:24:1 
(Sigma-Aldrich) was added. The mixture was vortexed shortly and centrifuged for 5min 
at maximum speed in a tabletop microcentrifuge. The upper phase was recovered and 
1/10 volume of 3M sodium acetate and 0.7 volumes of 100% ethanol (RNase free) were 
added to precipitate DNA. The sample was incubated for 30-60min at RT and 
centrifuged (10min at RT, 13000rpm). The supernatant was discarded and the pellet 
was washed with 70% ethanol. After air drying, the pellet was resuspended in an 
appropriate volume of RNAse and DNase free water (Sigma-Aldrich). 
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3.4. DNA restriction digestion 
Analytical digestions were performed in 50μL total volume with 1-2μg DNA and ∼2units 
enzyme overnight at 37ºC. 
3.5. Cell culture 
Cb192 cells 
Cb192 cells (Sun et al., 2008) were cultured in DMEM-F12 GlutaMAX medium (GIBCO) 
supplemented with 1x N-2 Supplement (GIBCO), 0.05x B-27 supplement (GIBCO), 
Penicillin-Streptomycin (100U/mL) (Gibco), EGF (10ng/mL) (Peprotech), bFGF 
(10ng/mL) (Peprotech) and Laminin (1μg/mL) (Sigma-Aldrich) in T-flasks, plates or 
well plates (Corning) pre-coated with sterile-filtered Poly-L-Lysine (Sigma-Aldrich). 
NS5 cells 
NS-5 cells (Conti et al., 2005) were cultured in mouse Neurocult NSC basal medium 
supplemented with mouse Neurocult NSC proliferation supplement (Stem Cell 
Technologies), Penicillin-Streptomycin (100U/mL) (Gibco) EGF (10ng/mL) 
(Peprotech), bFGF (10ng/mL) (Peprotech) and Laminin (1μg/mL) (Sigma-Aldrich) in T-
flasks, plates or well plates (Corning). 
3.6. Chromatin isolation 
Cells were washed with PBS and fixed in PBS-Mg (1 mM MgCl2 PBS) containing Di-
succinimidyl-glutarate (DSG) (Sigma-Aldrich) for 45min at RT on a rocking platform. 
Cells were washed with PBS and fixed in PBS-Mg with 1% formaldehyde (Sigma-
Aldrich) for 10min at RT on a rocking platform. Crosslinking was quenched by addition 
of glycine to a final concentration of 125mM for 5min at RT. Subsequently, cells were 
washed twice in PBS and harvested by scraping in 1mg/mL BSA PBS (with proteinase 
inhibitors (Roche)). After a low speed centrifugation, cell pellets were resuspended in 
SDS lysis buffer (1% SDS, 10mM EDTA, 50mM Tris pH 8.0, Proteinase inhibitors 
(Roche)) and incubated for, at least, 10min at 4ºC. 5-7.5μL of lysis buffer/μL of pellet 
were added.  Chromatin was transferred to non-sticky eppendorfs (Ambion) and 
sheared by sonication using a Bioruptor sonicator (Diagenode) at high power settings 
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for 14min in 30s ON/OFF cycles at 4ºC. Centrifugation at 14 000rpm for 10min at 4ºC 
allowed the precipitation of cell debris and the soluble chromatin fraction on the 
supernatant was collected. DNA concentrations were typically 0.7-3μg/uL. Chromatins 
were snap-frozen in liquid nitrogen and stored at -80ºC. To verify the efficiency of the 
sonication, one aliquot of the chromatin was subjected to crosslinking reversal and 
Proteinase K (0.1mg/mL) (Roche) digestion followed by DNA purification by phenol-
chloroform extraction. Fragment size was determined by agarose gel electrophoresis. 
Typical chromatin fragment size was 300-500bp. 
The above described protocol for chromatin isolation was performed prior to all ChIPs. 
3.7. Chromatin immunoprecipitation  
Reactions were performed in non-sticky eppendorfs (Ambion) using approximately 
70μg of chromatin and 50μL of magnetic beads and ZEB1 antibody (Sigma Aldrich, 
#HPA027524) in each ChIP reaction (Table 3.14). As a negative control, an IP without 
antibody (Mock) was run in parallel. Bound chromatin was eluted by incubation of the 
beads with elution buffer (50mM Tris-HCl pH 8.0, 10mM EDTA, 1% SDS) for 15 minutes 
at 65ºC. Proteins were digested by Proteinase K (0.1mg/mL) (Roche) for 2h at 42ºC and 
crosslinking was reverted overnight at 65ºC. The DNA was purified performing one 
phenol/chloroform extraction and one chloroform:isoamyl alcohol 25:24:1 extraction 
followed by isopropanol precipitation and centrifugation for 20min at 14 000rpm, +4ºC. 
Glycogen (40μg) (Sigma-Aldrich) was added on the isopropanol precipitation step to 
facilitate the visualization of the pellet after centrifugation. 
Protein G Dynabeads (Invitrogen), high salt IP buffer (20mM HEPES pH 8.0, 200mM 
NaCl, 2mM EDTA, 0.1% Na-DOC, 1% Triton X-100, 1mg/mL BSA, Proteinase inhibitors 
(Roche)) were used and 5 washes with LiCl buffer (50mM HEPES pH 7.6, 20mM EDTA, 
1% NP-40, 0.7% NaDOC, 0.5M LiCl) were performed followed by a final wash with TE 
buffer pH 8.0 (10mM Tris-HCl, 1mM EDTA).  
3.8. ChIP-Seq  
For Sequencing, DNA purified from 8 anti-ZEB1 ChIPs of Cb192 or NS5 cells were 
merged. Libraries were prepared from 10ng of input and immunoprecipitated DNA 
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according to the standard Illumina ChIP-Seq protocol and sequenced with Illumina 
GAIIx.  
Raw reads were mapped to the human genome (GRCh37/hg19) for Cb192 cells and to 
the mouse genome (NCBI37/mm9) with Bowtie 0.12.7 (Langmead et al., 2009). 
Sequenced reads were processed after mapping with SAMTools for format conversion 
and removal of PCR duplicates (Li et al., 2009a). Peaks for each sample were called 
against the input using MACS 1.4.1 (default parameters). 
3.9. ChIP-Seq peak visualization   
To visualize the ChIP-Seq peaks, the bigwig files from each ChIP-Seq dataset were loaded 
onto the UCSC genome browser (http://genome.ucsc.edu/). 
3.10. Density plots 
ChIP-seq normalized tag signals were calculated using a 10bp sliding window over the 
± 2kb region around each peak summit to generate the occupancy profiles (in-house 
developed algorithm). These were plotted as heat maps of signal density using 
R/Bioconductor packages (http://www.Rproject.org/ and http://CRAN.R-
project.org/package=gplots).  
3.11. In silico TF motif identification  
We have used CisFinder (Sharov and Ko, 2009) in order to identify motifs enriched in 
the vicinity of ChIP-Seq peak summits. Searches were run against a control dataset with 
the same number and the same length of the test dataset peaks located 5 Kb upstream. 
FDR<0.05%. The motifs shown are the result of “Identify motifs” tool, in the 100bp 
region surrounding the peak summits with the default settings. 
Frequency distributions were plotted using the frequency tables obtained with the 
Cisfinder Search tool upon search of the motifs in the 4000bp regions centered on the 
ChIP-Seq peak summit.  Number of false positives per 10 Kb, 1. Interval for frequency 
distribution, 100bp. Control dataset with the same number of peaks and the same length 
of the test dataset but located 5 Kb upstream. E-box and HMG motif were searched as 
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consensus motifs. ChIP-Seq dataset cutoffs and intersection between ChIP-seq and 
expression profiling as previously mentioned mentioned on the figures legend.  
Clustering of ChIP-Seq peaks based on the presence or absence of the represented 
motifs. E-box and HMG motif were searched as consensus motifs. Abundance tables 
obtained with the Cisfinder Search tool were converted to binary (1-presence, 0-
absence) CSV files. Only the peaks that have at least one of the motifs searched are 
represented. These CSV files were then converted into matrixes and plotted as heatmaps 
with RStudio using the “gplots” packages, resorting to heatmaps.2. ChIP-Seq dataset 
cutoffs and fragment size are mentioned on the figures legend. 
3.12. Peak annotation  
Annotation of ChIP-Seq peaks was done with GREAT (McLean et al., 2010) using single 
nearest TSS annotation. Maximal distance, 100 Kb. The percentage of peaks at a certain 
distance from the nearest TSS was plotted using GREAT and the overlap with gene 
feature was plotted using PAVIS (Huang et al., 2013) with default settings. 
3.13. Binding and expression data integration 
Calculation of p-values for the association between binding events and up- or down-
regulated genes was performed by sampling the total number of genes represented in 
the microarray 1000 times and assuming a normal distribution. ZEB1 ChIP-Seq peak 
overlap with expression data from ZEB1 GoF microarray in GNP calculated and plotted 
as heat maps with R/Bioconductor packages “genomeIntervals”, “gplots”, and in-house 





4.1. Indirect recruitment of ZEB1 via HMG motifs in a human neural stem 
cell context 
We first performed genome-wide mapping of the genomic regions bound by ZEB1 by 
ChIP-seq in the Cb192 human neural stem cell line and identified 7,874 high-confidence 
ZEB1 binding events (p-value<10-5) associated with 4788 genes following a nearest 
gene annotation. By performing a de novo search for DNA motifs enriched within 100 
base pairs of peak summits we observed that ZEB1 binding in the most significantly 
bound regions events (p-value<10-10) was mediated exclusively by the E-box motif 
(Figure 3. 1A). However, when a similar search was performed extending the list of 
genomic regions so as to include “smaller” peaks (p-value<10-5) additional motifs were 
found to be enriched. These included the HMG motif previously identified in NCH421K 
cells but also the TRE motif (TGASTCA) preferentially bound by AP-1 Jun/Jun or Jun/Fos 
dimers (Gustems et al., 2014) and the NFI half site (TTGGC) (Gronostajski, 2000). AP-1 
complex members and NF-I were identified as ZEB1 interaction partners though mass 
spectrometry, and both AP-1 and NFI binding motifs are enriched in a ZEB1 ChIP-seq 
list from murine pre-adipocyte cell line 3T3-L1 (Gubelmann et al., 2014). We next 
extended our location analysis of ZEB1 to the NS5 mouse NSC line. ZEB1 ChIP-seq in NS5 
cells identified 11,846 ZEB1 binding events (p-value<10-5) associated with 7732 genes 
following a nearest gene annotation (Figure 3. 1B). As in Cb192 cells, ZEB1 binding in 
the most significantly bound regions (p-value<10-10) was mediated exclusively by the E-
box motif. However, when the list of ZEB1 bound regions was extended to include less 





Figure 3. 1 E-box motif and HMG motif are enriched at ZEB1 bound regions in Cb192 NSCs. 
A) Density plot of ZEB1 ChIP-seq reads mapping to the genomic regions surrounding the 
summit of ZEB1 binding events in Cb192 cells. The signal intensity represents the ZEB1 ChIP-
seq normalized tag count in the 4Kb region surrounding the summit of ZEB1 peaks. ZEB1 
ChIP-seq p<10-5. B) Density plot of ZEB1 ChIP-seq reads mapping to the genomic regions 
surrounding the summit of ZEB1 binding events in NS5 cells. The signal intensity represents 
the ZEB1 ChIP-seq normalized tag count in the 4Kb region surrounding the summit of ZEB1 





Figure 3. 2 Only the E-box motif is enriched at ZEB1 bound regions in Cb192 NSCs.  
A) Frequency distribution of E-box and HMG motifs within a 4kb region centered at ZEB1 
peak summits or 5Kb upstream in Cb192 cells. Y axis represents the number of motifs present 
in bins of 100bp along the 4kb region. ZEB1 ChIP-Seq p<10-5. B) Frequency distribution of 
E-box and HMG-box motifs within a 4kb region centered at ZEB1 peak summits or 5Kb 
upstream. Y axis represents the number of motifs present in bins of 100bp along the 4kb 
region. ZEB1 ChIP-Seq p<10-5. 
To further analyze the enrichment of the HMG motif at ZEB1 bound regions in both 
Cb192 and NS5 cell lines, we compared the frequency distribution of the E-box and HMG 
motifs in genomic regions centered at the ZEB1 peak summits, using a list of genomic 
regions of identical size, located 5Kb upstream as control regions. This analysis show 
that while the E-box motif is enriched at ZEB1 peak-summits in both Cb192 and NS5 cell 
lines, the HMG motif is strongly over-represented at the ZEB1 peak summits in Cb192 




Figure 3. 3 ZEB1 binds preferentially to promoters in NS5 cells and distal regions in Cb192 
cells. 
A) Percentage of NS5 ZEB1 ChIP-Seq peaks at indicated distances from the nearest TSS, 
p<10-5. B) Percentage of NS5 ZEB1 ChIP-Seq peaks overlapping gene features, p<10-5. C) 
Percentage of Cb192 ZEB1 ChIP-Seq peaks at indicated distances from the nearest TSS, 
p<10-5. D) Percentage of Cb192 ZEB1 ChIP-Seq peaks overlapping gene features p<10-5. 
Strikingly, this difference is associated with a distinct profile of distribution of ZEB1 
binding events relatively to genomic features in these two similar NSC lines. In NS5 cells, 
ZEB1 binds predominantly within 5kb of the TSS (44%) (Figure 3. 3A) and a big 
percentage (32%) of binding regions is associated with genomic features in the 
proximity of TSSs (promoter, 5’ UTR and exon) (Figure 3. 3B). In sharp contrast, in 
Cb192 only 15% of ZEB1 binding regions located within 5kb of the TSS (Figure 3. 3C) 
with less than 10% being associated with features near TSS (promoter, 5’ UTR and exon) 
(Figure 3. 3D). Instead, ZEB1 binding occurs mostly distally from the TSS, in genomic 
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features related to distal binding such as intergenic, intron and 3’ UTR. The above 
observations indicate that the binding profile of Cb192 cells is similar to the ZEB1 
binding profile in NCH421K cells, concerning to the proximity for certain genomic 
features and overrepresented DNA motifs. Moreover, hierarchical clustering of ZEB1 
Cb192 peaks (Fig.27A) based on the presence of each binding motif in a 100bp region 
surrounding the peak summits yielded results similar to the one observed in the GBM 
CSC line with segregation of the ZEB1 binding events in two large groups containing 
either motif (only 2.7% of the peaks contained both). Furthermore, these two 
subpopulations of ZEB1 binding events are very distinct when analyzing their 
association with distinct genomic features. ZEB1 binding events associated with the 
HMG motif occur almost exclusively in regions distant from TSS (88%), with only 12% 
occurring within 5kb of the closest TSS, and only 8.2% occurring in regions with 
genomic features near the TSS (promoters, 5’UTR or exon) (Fig.27B, C). However, the 
subpopulation of E-box containing binding events exhibited a binding profile similar to 
the one observed in NS5 cells, where ZEB1 binds exclusively through E-boxes (29% of 
the binding events occur within 5kb of a TSS) (Fig.27D, E).  
In conclusion, genome-wide location analysis of ZEB1 in the two cell lines revealed 
distinct binding profiles.  In human Cb192 cells, and similar to NCH421K cells, results 
suggest ZEB1 is recruited to regulatory regions both directly (via E-box) or indirectly 
(via HMG motif), with direct binding taking place in proximal promoter regions and 
indirect binding in distal enhancers.  Quite differently, in mouse NS5 cells no evidence 
of indirect recruitment of ZEB1 via HMG boxes was found, with ZEB1 binding occurring 




Figure 3. 4 ZEB1 bind through E-boxes is strongly associated with proximal promoter regions 
and in NS5 cells and distal regions in Cb192 cells. 
A) Hierarchical clustering of 100nts surrounding ZEB1 peak summits based on the presence 
(red) or absence (blue) of HMG motif, E-box or both. Only 2.67% of peaks have both motifs. 
ChIP-seq p<10-5. B) Percentage of HMG motif peaks at indicated distances from the nearest 
TSS, p<10-5 And overlapping gene features(C), p<10-5. D) Percentage of E-box peaks at 




4.2. Characterization of ZEB1 target genes in Granular Neuron 
Progenitors  
In a separate study conducted by the laboratory of David Solecki (St. Jude Children´s 
Research Hospital, Memphis, USA), functional experiments aimed at unraveling the 
function of ZEB1 in the developing mouse cerebellum revealed that ZEB1 gain-of-
function decreases GNP differentiation, with a concomitant increase in proliferation and 
decreased migration from the external granule layer (EGL) to the internal granule layer 
(IGL). By contrast, loss-of-function through ZEB1 knock-down results using a sequence-
specific shRNA resulted in the opposite phenotype. Overall, these experiments led to the 
conclusion that ZEB1 inhibits differentiation of GNPs to cerebellar granular neurons 
(GCNs) and is necessary and sufficient to restrict GNPs to the EGL (Singh et al., 2016).  
With the aim of understanding the transcriptional response triggered by ZEB1 and how 
it contributes to the maintenance of the GNP state, we combined the ChIP-seq list of 
ZEB1 binding sites in the mouse NS cell line NS5 with the list of deregulated genes 
obtained by expression profiling upon ZEB1 gain-of-function in mouse P7 GNPs grown 
for 24 hours in single cell suspension. We found ZEB1 binding events to be statistically 
significantly associated with downregulated genes (p=1.8E-6) when compared to the 
association of one thousand similarly sized randomized sets of genes (Fig.28A), whereas 
association with up-regulated genes was not observed. Furthermore, we determined the 
fraction of up- and downregulated genes associated with ZEB1 binding events grouped 
in cumulative bins of increasing p-value, and assessed the significance of this association 
by comparing with control data sets comprised of one hundred randomized sets of 
binding events of equal size. Again, results indicate that ZEB1 binding is only associated 
with gene repression genome-wide (Fig.28B), thus suggesting that ZEB1 functions 




Figure 3. 5 ZEB1 binding in mouse NS cells is significantly associated with gene repression 
in a GNP context 
A) Number of ZEB1 binding events associated with up or down-regulated genes in ZEB1 GoF 
microarrays from P7 GNPs grown for 24 hours in single cell suspension. Test data 
represented as box with median of test and first and third quantiles; whiskers, ±1.5 x 
interquartile range (IQR). P (ZEB1 ChIP-Seq) <10-15. P (ZEB1 GoF microarrays) <0.05, 
FC>|1.2|. B) Heatmap displaying the cumulative fraction of deregulated genes in ZEB1 GoF 
that are directly regulated by ZEB1 (activated by ZEB1, top left panel; repressed by ZEB1, 
bottom left panel). Number of transcripts with expression fold change >1.2 are plotted 
against ZEB1 BEs with increasing p-value. Control: 100 sets of random BEs (right, mean value 
shown). 
The intersection of the ZEB1 ChIP-seq list with expression profiling after ZEB1 gain-of-
function in P7 GNPs led to the identification of ZEB1 repressed genes involved in cell 
adhesion, cell motion, epithelial development and morphogenesis (Fig.29A). ZEB1 
directly bound proximal promoters of key apical-basal polarity genes such as Pard6a, 





Figure 3. 6 ZEB1 directly represses genes involved in cell adhesion, cell motion and 
differentiation 
A) Enrichment of GO Biological Process terms associated with ZEB1 directly targeted genes 
(bound and deregulated by ZEB1). Parentheses show number of genes associated with 
each term. B) ZEB1 ChIP-seq enrichment profile in the vicinity of putative ZEB1 target 





The difference in over-represented motifs and distribution of ZEB1 peaks relative to 
genomic features suggests different modes of recruitment of ZEB1 to its target sites in 
the two cell lines analyzed. Indeed, our results suggest that the ZEB1/LEF1 paradigm 
described in NCH421K cells is at play in Cb192 cells, while no such evidence was found 
in the NS5 cell context. Considering the similarities between the mouse and human NSC 
lines (Conti et al., 2005; Sun et al., 2008) we expected that ZEB1 would have a similar 
recruitment profile in both these cell lines. However, these different results may be 
explained when considering that these cells are of different origins. Although both cell 
lines express the same set of radial glial cell markers when growing in basal media, 
neurons derived from NS5 NSCs express GABAergic markers while neurons derived 
from Cb192 NSCs do not. This may be due to differences in the phenotype of human NSC 
lines and mouse NSC lines since it has been described that human telecenphalic 
progenitors, as the Cb192 cell line, derived from human ESCs adopt a predominantly 
dorsal identity and differentiate into glutamatergic neurons in a chemically defined 
medium without known morphogens, with the dorsal phenotype dependent on Wnt 
(Martynoga et al., 2012). Specification of NSCs representative of ventral telencephalic 
progenitors from hESCs is promoted by the activation of Shh and/or inhibition of Wnt. 
On the other hand, the mouse NS5 cell line was established from mESCs in conditions 
that result in a ventral identity, the inhibition of Shh signalling is required for the 
generation of dorsal progenitors (Li et al., 2009b; Nicoleau et al., 2013). Specification of 
NSCs representative of dorsal telencephalic progenitors from mESCs is promoted by the 
inhibition of Shh.  
Thus, NS5 NSCs are representative of RGCs from the ventral telencephalon which 
differentiate into GABAergic neurons, while Cb192 NSCs are representative of RGCs of 
the dorsal telencephalon since they were not derived in media with active Shh or 
inhibition of Wnt. The different ventral/dorsal character of both cell lines provides an 
explanation for the presence of the HMG motif solely in the ZEB1 ChIP-seq list of the 
human NSCs since LEF1 is predominantly expressed in the dorsal telencephalon since 
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day E11.5 in mouse embryos and is required for the development of the hippocampus 
(Galceran et al., 2000; Oosterwegel et al., 1993).Overall, it would be important to 
understand if the interaction with LEF1 could modulate ZEB1 function differently in 
distinct domains along the dorsal-ventral axis and if it could be playing any regulatory 
role in neocortex development.  
The combination of the ZEB1 ChIP-seq list with the list of deregulated genes obtained 
upon ZEB1 gain-of-function in mouse P7 GNPs demonstrated that ZEB1 acts as a 
transcriptional repressor in the GNP context. It also led to the identification of several 
ZEB1 bound and deregulated target genes, including Pard6a, Pard6b, Pard3a or Pard6g, 
which are present in tight junctions in a complex with aPKC and Cdc42 and are major 
regulators of apical-basal polarity in epithelial cells (Brajenovic et al., 2004; Chen and 
Zhang, 2013; Hurd et al., 2003; Kohjima et al., 2002; Yamanaka et al., 2003). 
Interestingly, the Pard6b gene is also repressed by ZEB1 in the GBM CSC context, thus it 
is probably one of the main targets of ZEB1 independently of cellular context. Additional 
evidence for the importance of several targets in mediating ZEB1 function in GNPs was 
obtained by our collaborators by performing rescuing experiments expression of 
Pard6a, Pard3a, Lin7a, Chl1, among others, in GNPs of P7 cerebella over-expressing 
ZEB1. This resulted in a rescue of GNP proliferation rates, GZ exit and IGL directed 
migration. Therefore, through its activity as a transcriptional repressor, ZEB1 inhibits 
polarization and detains proliferating progenitors in the cerebellar germinal zone 
(Suppl. Fig.2). 
Neural progenitor cells have been studied with growing emphasis on their mode of cell 
division and how it is influenced by cell polarity. NECs and RGCs are bipolar progenitors 
at M-phase. They have apical-basal polarity, with an apical plasma membrane attached 
to the ventricular surface through adherens junctions. NECs divide symmetrically in 
proliferative divisions and possess tight junctions. On the other hand, RGCs divide 
asymmetrically in neurogenic divisions into another RGC and a more differentiated 
daughter cell - either a neuron or a basal progenitor (BP). BPs are progenitor cells with 
nonpolar morphology at M-phase. They originate from the apical RGCs, but are not 
attached to the apical ventricular surface or to the basal surface and migrate into the 
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SVZ. These progenitors are a major source of cortical neurons (Borrell and Götz, 2014; 
Fietz and Huttner, 2011; Martynoga et al., 2012; Nonaka-Kinoshita et al., 2013). For 
RGCs to maintain their self-renewing asymmetric divisions, the cell polarity 
determinants of the Par family (Par3 and Par6) and their regulator, the small Rho 
GTPase Cdc42 are required and must be localized to their apical membrane (Bultje et 
al., 2009; Cappello et al., 2006; Costa et al., 2008). As opposed to GNPs, RGCs are highly 
polarized cells, and loss of adherens junctions and delamination is usually associated 
with the generation of more differentiated daughter cells, either neurons or basal 
progenitors. Thus the ZEB1 activity as a transcriptional repressor of Pard3 and Pard6 
genes in a GNP context may not operate in neurogenesis in other regions, such as the 
developing telencephalon. Identifying ZEB1 target genes that may regulate apical-basal 
polarity in a NSC context would allow us to understand how it could affect the 
maintenance of the neural progenitor cell state and the effect it could have in the 
generation of specific neural progenitor cell populations such as BPs, and neurons. 
Differences in apical-basal polarity, across the distinct neural progenitor identities along 
neural development, are closely linked to neural progenitor proliferation, to daughter 
cell identity and consequently to brain development. The control of polarity transitions 
in neural progenitors assumes particular importance and conceptual parallels have 
been established between polarity transitions and those displayed in developing 
epithelia. In this context, it is important to understand the role played by EMT-inducing 
factors and the parallels of the delamination of neural progenitors with an EMT 
program. In previous studies, Foxp and Snail superfamily member Scratch were shown 
to inhibit cadherins, promote transition away from radial glial polarity and neuronal 
delamination from the VZs of the spinal cord and neocortex, respectively (Itoh et al., 
2013; Rousso et al., 2012). Thus, distinct EMT factors may be expressed at distinct stages 
of the neuronal lineage, at which points distinct components of an EMT-like program 
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GBM CSCs have emerged as one of the main contributors to GBM malignancy, 
heterogeneity and therapy resistance (Sottoriva et al., 2013; Stieber et al., 2013). These 
cells can be classified into two mutually exclusive subtypes, Proneural and Mesenchymal 
(Mao et al., 2013; Ricci-Vitiani et al., 2008), with Proneural CSCs shifting to a 
Mesenchymal phenotype after radiation treatment. The Mesenchymal CSCs are more 
aggressive, invasive and angiogenic than Proneural cells. In a live tumor environment, 
these cells have different characteristics depending of the microenvironmental niche in 
which they are residing: a vascular niche and a hypoxic niche. GBM CSCs residing in the 
vascular niche have enhanced self-renewal due to interaction with endothelial cells 
(Calabrese et al., 2007) while the infiltrative phenotype is strongly promoted by the 
hypoxic microenvironmental niche with a vast majority of the cells in this hypoxic niche 
being CSCs (Christensen et al., 2008). Anti-angiogenic therapy (Groot et al., 2010; 
Tomaso et al., 2011) leads to a significant improvement in progression-free survival 
rate, although not in overall survival duration since it also leads to a shift in the tumor 
phenotype to a predominantly infiltrative phenotype. Therefore, there has been an 
increased interest in studying factors that regulate proliferation and invasion of GBM 
CSCs which efforts focused on understanding the role that EMT inducing factors 
overexpressed in GBMs may be playing in this context.  
This thesis aimed to gather insights into the function of ZEB1 in GBM, by characterizing 
the transcriptional network regulated by this classical EMT inducer in a GBM CSC 
context. ZEB1, which is highly expressed in GBM tumors and whose expression is 
associated with increasing tumor grade (Kahlert et al., 2015), has recently emerged as a 
pivotal regulator of invasiveness, chemoresistance and tumorigenesis in GBM 
(Siebzehnrubl et al., 2013). Moreover, its expression is regulated by several oncogenic 
pathways and microenvironmental cues with relevance for the biology of GBM CSCs 
(Edwards et al., 2011; Joseph et al., 2014; Kahlert et al., 2012, 2015).  
In chapter 2, we performed the first genome-wide characterization of the 
transcriptional activity of ZEB1 in a malignant context. This resulted in a model whereby 
ZEB1 simultaneously activates and represses gene transcription depending on how it is 
recruited to the regulatory regions of target genes. Importantly, this work led to the 
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identification of a novel interaction with LEF/TCF factors and to the identification of 
several novel ZEB1 target genes including Prex1, a candidate mediator of GBM tumor 
invasion downstream of ZEB1 associated with poor patient survival.   
In chapter 3, we performed genome-wide mapping of the ZEB1 binding sites in two 
distinct NSC contexts - mouse NS5 cell line and human Cb192 cell line - and combining 
the genome-wide mapping obtained in mouse with expression profiling after ZEB1 gain-
of-function in a GNP context. Most importantly, we found evidence that the ZEB1/LEF1 
interaction also takes place in Cb192 cells, thus extending the importance of this 
paradigm to a non-malignant cell context.    
Another similarity found between the ZEB1 activity in NSCs and GBM CSCs was the 
repression of genes involved in apical-basal polarity. Specifically, we found that ZEB1 
directly repressed Pard6b expression in the GBM CSC and GNP cell contexts, along with 
other Par family members (Pard6a, Pard3a, Pard6g) in the GNP context. These proteins 
are present in tight junctions in a complex with Cdc42 and aPKC in epithelial cells. In the 
developing telencephalon, these proteins are required for adherens junction formation 
and must be localized to the apical membrane of RGCs for these to maintain their self-
renewing asymmetric divisions (Bultje et al., 2009; Cappello et al., 2006; Costa et al., 
2008). 
Future perspectives 
Our results allowed us to characterize the molecular basis for ZEB1 function in a GBM 
CSC context and establish several parallels between its activity and regulated genes in 
this context and in the NSC context.  
However, important questions remain about the relevance of this mechanism for 
activation of gene expression in the activity of LEF1 and other TCF factors. All LEF/TCF 
factors have been described as regulators of cell migration, invasion, and proliferation 
in glioma/GBM (Gao et al., 2014; Kang, 2011; Li et al., 2016; Pećina-Šlaus et al., 2014; 
Rheinbay et al., 2013; Zhang et al., 2011) and there is high correlation between ZEB1 
transcript levels and TCF7L1/TCF7L2 transcript levels in the TCGA database. It will be 
important to investigate to which extent other TCF factors may function interchangeably 
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with LEF1 in the LEF1/ZEB1 interaction in a GBM context. Moreover, genome-wide 
location analysis of LEF/TCF factors should indicate whether they are indirectly 
recruited by ZEB1 to E-box mediated gene regulatory regions, leading to a regulatory 
program independent of their ability to bind to HMG motifs. Additionally, it will be 
important to understand if our paradigm is also applicable in different cancer contexts 
besides GBM.   
During development, ZEB1 is expressed in progenitor cells of the VZ and SVZ of both the 
ventral and dorsal telencephalon in mouse, rat and human. A full characterization of the 
function of ZEB1 in the neural developmental context would be important to understand 
the relevance of the ZEB1/LEF1 interaction in neocortex development and if it leads to 
significant differences in the transcriptional network regulated by ZEB1 along the 
dorso-ventral axis. Simultaneously, it would allow us to study how ZEB1 may be 
regulating the maintenance of the neural progenitor cell population and how it affects 
the population of distinct progenitor cells in the developing telencephalon. 
EMT is a cellular process that plays a crucial role during several steps of embryonic 
development and also in controlling the shift between proliferation to metastization for 
carcinomas and that confers a stem cell phenotype (Micalizzi et al., 2010). In certain 
non-epithelial cellular contexts, the transcriptional activity of these EMT-inducing 
factors may control the same cellular properties required for triggering EMT, thus 
promoting cellular transitions that may share some generic traits with the EMT. For 
example, in GBM, CSCs reside and show distinct characteristics in two 
microenvironmental niches: in hypoxic conditions they have a more invasive and 
angiogenic phenotype while those in a vascular niche are more proliferative. This 
transition of GBM CSCs from a proliferative phenotype in the vascular niche to a more 
invasive and angiogenic phenotype in the hypoxic niche shares many similarities with 
the EMT.  
Otherwise, EMT inducing factors may regulate yet undescribed target genes that could 
lead to differences with EMT in specific cellular traits. In a neural developmental 
context, differences in apical-basal polarity, across the distinct neural progenitor 
identities are closely linked to neural progenitor proliferation, to daughter cell identity 
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and consequently to brain development. The control of polarity transitions in neural 
progenitors assumes particular importance and conceptual parallels have been 
established between polarity transitions and those displayed in developing epithelia. In 
this context, it is important to understand the role played by EMT-inducing factors and 
the parallels of the delamination of neural progenitors with the EMT.  
There are several transcription factors capable of inducing EMT by repressing the 
expression of a few epithelial and apico-basal polarity genes (Micalizzi et al., 2010), and 
several of these factors are expressed and have already been described as playing roles 
not related with EMT in non-epithelial cells. As an example, ZEB1 acts as a 
transcriptional repressor in the GNP context, repressing genes that regulate apical-basal 
polarity. Through this basic mechanism, ZEB1 inhibits polarization and detains 
proliferating progenitors in the cerebellar germinal zone (Singh et al., 2016). In previous 
studies, Foxp and Snail superfamily member Scratch were also shown to inhibit 
cadherins, and regulate distinct processes promote transition away from radial glial 
polarity and neuronal delamination from the VZs of the spinal cord and neocortex, 
respectively (Itoh et al., 2013; Rousso et al., 2012). Thus, distinct EMT factors may be 
expressed at distinct stages of the neuronal lineage, at which points distinct components 
of an EMT-like program may be deployed. 
Furthermore, we and others demonstrate that one of these EMT-inducing factors, ZEB1, 
regulates extensive transcriptional networks and establish interactions with other 
transcription factors and signaling pathways depending of the epigenetic context and 
cellular type (Gubelmann et al., 2014; Lehmann et al., 2016; Postigo et al., 2003). Thus, 
extending our approach of combining genome-wide location analysis with expression 
profiling upon loss-of-function to other EMT inducing factors could clarify their 
mechanism of action, identify interactions with other factors/pathways, allow us to 
understand if there is a minimal common transcriptional program that triggers EMT 
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